Financings, debt, distress, legal cases, listing changes and mergers at public pharmaceutical companies, small caps first in our coverage, newest first. Every story links its primary source.
Company Updates ·
Sephience revenue reached $182 million in the quarter, the company acquired ST-920 for $111.0 million upfront, and it now expects total revenue of $1.29 to $1.32 billion for 2026.
PTCTReading a sequencing gel, 1980. Photo: Linda Bartlett, public domain, via Wikimedia Commons
Company Updates
Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029.
PCSA
Company Updates
Kiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027.
KPRX
Company Updates
Protocol amendments add patients with rash from KRAS and MEK inhibitors, including people with neurofibromatosis type 1, and shorten some washout periods.
AZTR
Company Updates
Dermata Therapeutics enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch its second commercial product in the first half of 2027.
DRMAAlnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open.
ALNYLigand sued Viking on May 19, 2026 after purporting to end the TR-Beta license. Viking cross-sued Ligand and Metabasis. A hearing on Ligand's demurrer is set for February 26, 2027.
VKTXLGNDThe ITC affirmed sanctions against Ascletis Bioscience, Gannex, Ascletis Pharmaceuticals, Ascletis Pharma and Jinzi Jason Wu in May 2025. Both sides appealed, and argument is expected in Q4 2027.
VKTXA Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits.
VNDAIndivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc.
INDVAltimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.
ALTThe Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded.
ENTAA termination agreement ends the license and assigns the patents and know-how to Mineralys. Up to $255.0 million in commercial milestones still applies.
MLYSNasdaq gave Propanc no 180-day compliance period because it reverse split within the past year. The company says it will appeal by October 30, 2026. Its fiscal 2026 net loss was $18.9 million.
PPCBBristol Myers Squibb will end its PRX019 license on January 28, 2027, dropping up to $617.5 million in milestones it could have owed. The 8-K cites an internal strategic review and gives no further reason.
PRTAThe proposal goes to a virtual annual meeting on December 18, 2026. The board would pick the ratio and could decide not to split at all.
RVPHAn abstract on the Phase 1 trial of DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver on November 4, 2026.
MTVAA proxy supplement filed after a stock dividend explains a six-fold increase in shares available under the 2014 Stock Incentive Plan, which stockholders vote on November 6, 2026.
JAGXA poster from the company's Meharry Medical College collaboration is scheduled for the Gerontological Society of America meeting in National Harbor, Maryland, in November 2026.
GNPXStout v. Skye Bioscience alleges misleading statements about nimacimab from November 4, 2024 to October 3, 2025. Two derivative suits captioned against Dhillon are stayed, and consolidation was sought on August 11.
SKYEA jury found for former employee Wendy Cunning in 2023. The Ninth Circuit vacated the judgment in 2024. Skye now estimates the legal contingency at $5,417,250 and cites settlement talks.
SKYEThe 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey.
AMRNActuate Therapeutics priced 30,985,900 shares and warrants for 15,492,950 more shares at $0.71 per set, for about $11.0 million before costs. The stock last sold at $0.40, and the company reported $4.4 million of cash at June 30, 2026.
ACTUAdial Pharmaceuticals becomes Azora Therapeutics and is expected to trade as AZR from October 29, 2026, after stockholders approved converting the preferred stock issued in its June 2026 acquisition of Azora. The October release does not mention AD04, the drug the company's March 2026 annual report called its lead asset.
ADILMilestone has until April 21, 2027 to close at $1.00 or more for 10 consecutive business days, after 30 consecutive business days below that level.
MISTAll five patients who finished the expanded access study reported improved outcomes and negative conventional PCR tests, and four of five were also negative on a highly sensitive test.
SXTPAclaris priced 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 more shares, $49,999,934 before costs, on the day it announced small Phase 1b results for its antibody ATI-052. The prospectus puts cash at approximately $204.6 million on September 30, 2026.
ACRSThe November 12, 2026 meeting will vote on issuing stock under the Astor notes and warrants, and on reverse splits of up to 1-for-1,000. There were 9,322,805 shares outstanding on the October 23, 2026 record date.
CDTGeoVax can borrow up to $1,000,000 at 12% interest from Bowery Consulting Group, and it agreed to pursue a public offering of at least $5,000,000. The lender designated the new directors.
GOVXThe board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026, against 9,093,871 shares outstanding at the record date.
GOVXImunon's preliminary prospectus covers up to 20,000,000 shares, sold with warrants that could cover up to 70,000,000 more. The auditor's opinion on 2025 results includes substantial doubt about the company's ability to continue as a going concern.
IMNNHolders of record on November 5, 2026 would get one CVR per share, but only if shareholders approve a return of capital proposal on November 4. The company had $2.2 million in cash at June 30, 2026.
INMPulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted.
PULMRapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary.
RAPPValion Bio sold 4,717.73 Series C preferred shares for $4,717,717.61, but $3,217,717.61 of that stays with the buyers to cover overdue cash true-up payments. The company receives $1,500,000 in cash.
VBIOTen patients with newly diagnosed AML advanced to transplant after treatment with mipletamig, venetoclax and azacitidine, according to Aptevo's October 26, 2026 release.
APVORallybio's board declared an estimated $13.56 per share special cash distribution on October 25, 2026. Payment is conditioned on stockholder approval at a November 4, 2026 meeting, with closing expected November 6, 2026.
RLYBAEON Biopharma asked stockholders to approve a reverse stock split of between 1-for-2 and 1-for-100, to be voted on December 15, 2026. The stock last sold at $0.24 on October 23, and NYSE American's cumulative ratio limit counts the company's 1-for-72 split of February 2025.
AEONEquillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029.
EQThe split cuts the share count to about 588,677 from roughly 5,886,774. The stock keeps trading on Nasdaq as ONCO under a new CUSIP.
ONCORedx holders would own about 59.74% of the combined company and Skye holders about 5.38%, at an assumed exchange ratio of 0.0892. Skye also plans a reverse stock split, and its proxy warns that stockholders will vote without certainty about the combined company's Nasdaq listing.
SKYESupernus ended its UBS credit line on October 20, 2026, with nothing drawn and no penalty. The filing says the combined company is to enter a new senior secured facility at closing, but it gives no closing date and no terms.
SUPNThe board approved Amendment No. 1 to the rights agreement with Computershare, moving the final expiration date to the close of business on October 27, 2027.
NEUPNasdaq says the stock closed below $1.00 for 30 consecutive business days. Cash fell from $184.8 million at year-end 2025 to $155.5 million at June 30, 2026, and the company says it could seek a reverse stock split.
AKBABolt Biotherapeutics has agreed to acquire Prana Therapies in a stock-for-stock reverse merger and raise $120 million in a concurrent private placement. After the deal, Bolt's own holders are expected to own about 6.9% of the common stock, and the company says the cash lasts into 2028.
BOLTCitius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million.
CTORCTXRLunai Bioworks will not appeal a Nasdaq staff decision to delist its stock and plans to deregister with the SEC. Trading on Nasdaq is expected to be suspended on October 30, 2026.
LNAINasdaq closed Medicus Pharma's bid price case on October 23, 2026, three days after a delisting letter. The 8-K does not say whether the company now meets the $5 million stockholders' equity standard Nasdaq cited.
MDCXTraws can sell up to $50,000,000 of new stock to Roth over 36 months, but no shares can be sold until the SEC declares a resale registration effective. Cash was $5.0 million on June 30, 2026, and cash used in operations was $18.2 million in 2025.
TRAWThe new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30.
UTHREvery 10 shares of common stock will combine into one share on NYSE American, with the stock trading on a split-adjusted basis from market open on October 26, 2026.
AZTRSagimet's investor presentation says $257.6 million in cash, cash equivalents and marketable securities at June 30, 2026, plus a $115 million underwritten offering completed in September, should fund operations to mid-2029. The presentation does not name the underwriters.
SGMTThe offering priced below the $19.10 last reported sale price. Arcus says the money goes mainly to casdatifan, its HIF-2 alpha inhibitor now in two phase 3 programs.
RCUSA peer-reviewed mouse study tied the TUSC2 gene, used in Genprex's REQORSA program, to protein balance and synaptic function in the hippocampus.
GNPXA Delaware suit naming Casdin Capital and SomaLogic directors is set for a March 2027 bench trial. SRS had claimed up to $17.5 million in Palamedrix milestones; that matter is resolved and the company paid Illumina $7.5 million on its indemnity.
LABChina SXT and the purchasers in its October 8, 2026 registered direct offering agreed to cancel, in full, a right to buy up to $12 million more shares. The company says the offering's securities already issued are not affected.
SXTCAlaunos told the SEC on October 21, 2026 that it believes its $350.0 million financing restored compliance with Nasdaq's $2,500,000 equity rule. The same filing says Nasdaq may not agree, and a November 10 hearing was still set.
TCRTThe upsized offering funds a planned bitopertin launch. Disc says cash plus proceeds lasts into 2030 and had an estimated $682.8 million before the deal.
IRONThe paper, published online on October 13, 2026, includes a pediatric compassionate-use case report. Quoin also described interim results from its Phase 2/3 study.
QNRXCarew v. Lifecore Biomedical names the company and unnamed executive officers. The final approval hearing was held on July 28, 2026. A separate New York suit by 22NW Fund continues against the company.
LFCRThe appeals court sent the Texas case back for new class certification proceedings. A $31.25 million settlement was filed in June, and Remi Barbier and Lindsay Burns, named in the 10-Q, are not parties to it.
FLNAIndaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million.
INDPThe all-cash deal values Silence at about $1.1 billion in enterprise value, an 82% premium to its 30-day average price. Closing is expected in the first quarter of 2027.
SLNAlexandra Peterson and Gabrielle Toledano resigned effective October 14, 2026, and the board reduced its size from five to three. The board has not decided whether to fill the vacancies.
PMHSCuranex Pharmaceuticals is a defendant, with underwriters Dominari Securities LLC, Pacific Century Securities, LLC and Revere Securities LLC, in two New York class actions over its August 2025 IPO. Both suits allege Securities Act violations in the offering documents.
CURXThe drugmaker ends its Nucynta license and royalties with Grünenthal and gets certain patents assigned to it. Grünenthal has filed a motion to dismiss the New Jersey case.
COLLThe 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue.
RARECollegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company.
COLLDogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026.
DWTXOS Therapies raised $7.2 million gross in the first closing of a warrant inducement, but the holders who exercised received new warrants for the same number of shares at $1.40, and the company reported only $205,035 in cash at June 30, 2026.
OSTXThe Cambridge RNAi developer sold 11.1 million shares at the midpoint of its range. Its lead drug, a Factor XI siRNA for blood clots, has more phase 1 data due in late 2026.
CTYSLNThe sale draws on an agreement allowing up to $10,000,000 of convertible promissory notes. The company expects it to close on or before October 19, 2026.
CMNDAdial reconvened its 2026 Annual Meeting on October 15, 2026 for four proposals and adjourned it a second time to October 26, 2026, while its Nasdaq listing application remains without approval.
ADILValion's CDMO unit finished an initial evaluation of LarmorBio's BioScan-NMR platform for continuous bioprocess monitoring.
VBIORallybio's holders would keep 2.8% of the merged company, while Avenzo's holders would own 56.6% and investors in a $215.0 million financing 40.6%. Rallybio stockholders vote on the deal on November 4.
RLYBSupernus (Nasdaq: SUPN) took on Sage's New York class action naming Barry Greene and Kimi Iguchi, three derivative suits against sixteen unnamed insiders, and an SEC subpoena. Supernus faces two merger suits of its own.
SUPNThe case names Actinium and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala and Sergio Giralt. Four derivative suits against directors and officers follow the same allegations.
ATNMAditxt's subsidiary Ignite Proteomics and the blank-check company Copley Acquisition Corp ended their June 2026 business combination agreement on October 9, 2026. Each side bears its own expenses, and the 8-K gives no reason for the termination.
ADTXALX Oncology's exchange trades 13,353,384 common shares for pre-funded warrants with a $0.001 exercise price, and the 8-K describes no cash payment to the company.
ALXOEvofem moved the maturity of convertible notes held by Adjuvant to December 1, 2026, and removed some affirmative covenants. The 8-K gives no repayment plan, and the company's year-end cash was $578,000.
EVFMNasdaq gave Mustang Bio until April 12, 2027 to lift its bid price to $1.00. The company has said it intends to do a reverse stock split if necessary.
MBIOThe company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026.
TRAXThe company will receive $210 million and $203 million in cash, subject to antitrust clearance. The NIH is owed 20% of the first sale.
RAREAibotics signed an asset purchase agreement with PlayJamaica Limited on October 12, 2026, and completed the acquisition on October 14, issuing 22,500 shares of Series B Preferred Stock.
AIBTThe designation is the eighth regulatory milestone for QRX003, according to the company. If QRX003 is approved in the EU, it would receive 10 years of market exclusivity.
QNRXAptevo will present its CD40-directed multispecific portfolio at the Society for Immunotherapy of Cancer annual meeting in Phoenix, November 4 to 8, 2026.
APVOMannatech said a Swiss holding company transaction and a pro forma tax adjustment put it back above Nasdaq's stockholders' equity minimum, subject to review and to Nasdaq's view.
MTEXThe 8-K lists a net $175.0 million payment to UTC, a further $145.4 million in installments, and a YUTREPIA label change removing PH-ILD. Three parties are also paid to end the RareGen case, and one of them is a related party.
LQDAUTHRXeris Biopharma's subsidiary filed two patent infringement suits on October 13 after a new Keveyis patent was granted. The 8-K names seven defendants.
XERSMilestones could add up to $47.5 million, plus royalties at a mid-teens percentage of net sales. The product has tentative FDA approval only, and Aquestive will be its exclusive manufacturer under a 20-year supply agreement.
ETONThe deal ends six lawsuits. Liquidia also owes $145.4 million in two installments due in 2027 and $60.3 million to other parties this month.
LQDAUTHRSilo Pharma agreed on October 13, 2026 to buy certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock. The shares are locked up for up to twelve months, and the 8-K names no underwriter or placement agent.
SILOSarah Browne, M.D., joins MetaVia as Chief Medical Officer effective October 12, 2026, ahead of the fourth quarter 2026 topline readout from Part 3 of the DA-1726 Phase 1 trial.
MTVAThe batch is a manufacturing milestone that supports the planned start of a Phase 2b trial in the first quarter of 2027. The company issued a press release announcing it on October 13, 2026.
PHIOPreliminary revenue rose 256% from the second quarter after the REZENOPY launch and higher Arbli wholesale unit sales. The figures are unaudited.
SCNXLunai's 10-K says the Oct 7 demand covers all pending litigation. The Chancery case alleges breach of a 2018 investor rights agreement, and mediation has not been scheduled.
LNAIADC Therapeutics agreed to an $86.6 million private placement and to cut its senior loan to $50.0 million, and its royalty holder gave up a $150 million change-of-control payment. The changes depend on the placement closing, and expected cash at September 30, 2026 was $189.2 million, against $219.1 million at June 30.
ADCTThe first tranche brought in $3,000,000, with net proceeds of $2,869,850 after closing fees. The lender can convert at 70% of the lowest recent close, with a floor of $0.18354, and the company reported $747,000 of cash at June 30, 2026.
CDTNasdaq said the ordinary shares closed below US$1.00 for 30 consecutive business days. The letter has no current effect on the listing or trading.
GDTCPulmatrix stockholders are due to vote October 26, 2026 on a merger with Eos SENOLYTIX, Inc., whose lead data so far are mouse studies. The filing gives no amount for the merger-associated financings it expects, and the company's cash was $2.2 million at June 30, 2026.
PULMAlaunos bought Velaris in a stock deal and closed a $350 million private placement led by Fairmount. Velaris has no product candidate tested in humans, and Alaunos had $124,000 in cash at June 30, 2026, according to its quarterly report.
TCRTTuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million.
HURANasdaq staff told Alaunos on October 5, 2026 that its securities are subject to delisting under Listing Rule 5550(b)(1). The company plans to request a hearing and says it is working with a financial advisor on potential transactions.
TCRTLunai's 8-K asks Nasdaq to suspend trading, citing records from its Delaware suit. A later 8-K says trading will be suspended on October 30 unless the company asks for a hearing, and it does not plan to ask.
LNAIArtelo was among about 180 Nasdaq companies first identified as below the new threshold. The company gives no market value figure, and the rule is on a temporary stay.
ARTLThe offering totals $45,000,000 before fees. The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt.
RTSNThe exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change.
BDRXBoundless Bio filed a Form S-4 on October 8, 2026 for its merger with private Serapha Bio. The filing estimates about 8.6737 Boundless shares for each Serapha share before a planned reverse split, and expects existing Boundless holders to own about 3.8% of the combined company.
BOLDViatris agreed to buy Pacira for $36.50 a share in cash, an equity value of $1.65 billion, through a tender offer and a second-step merger. The release states no premium to the recent share price.
PCRXVTRSThe deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate.
RNAValion Bio filed a $100,000,000 shelf registration on October 7, 2026, and the same day agreed to sell 3i $50,000 of Series B preferred and warrants. The public float used for the shelf was based on a $7.75 price, while the last reported sale on October 5 was $2.48.
VBIOFibroBiologics sold a $1,200,000 convertible debenture to Peak One Opportunity Fund, L.P. for $1,020,000, an original issue discount of 15%. The debenture matures October 8, 2027 and converts only after a default, at $0.78 per share.
FBLGThe Nasdaq Stock Market has filed a Form 25 to remove Aditxt's common stock from listing, dated October 7, 2026. The form does not say why Nasdaq acted, and the company reported $268,852 of cash at March 31, 2026.
ADTXNasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025.
RDHLAt an October 6, 2026 webinar, the company said 30 patients were enrolled in its hospital study and that it plans to complete the current dataset and move to unblinding.
SXTPKairos Pharma says median progression-free survival was 17.7 months with ENV-105 plus apalutamide, compared with 2 months on apalutamide alone, and has changed the trial to enroll patients earlier.
KAPANOMAD Power Solutions began a tour of its Voyager battery systems on October 6, 2026. Three regional roadshows run through November 16, with stops in the Mountain West, Northeast and Southwest.
NMADThe purchase closed October 6, 2026 for $2,000,000 in cash and 25,000,000 shares, and four directors have ties to the seller's group.
HEPAThe buyer, run by David Konn, pays $1,000,000 in cash and signs a $500,000 note at 7% interest, secured by a pledge of the units.
ADIAHercules Capital is the lender. Rocket received $35 million at closing, reported no revenue in 2025 or 2024, and held $283.7 million in cash and investments at June 30, 2026.
RCKTHTGCBeyondSpring closed the sale of the holding company for its China unit, Bulin, on September 30, 2026. The buyer paid no cash at closing. It took on the China portion of the DUBLIN-4 Phase 3 trial in exchange, and BeyondSpring will receive the clinical data from that work.
BYSIInovio, CEO Jacqueline Shea and CFO Peter Kies are defendants in a Pennsylvania class action. Shea, Kies and seven directors are named in derivative suits. A lead plaintiff was appointed July 27, 2026.
INOBeyondSpring Inc. completed the sale of BeyondSpring Ltd. to Biolin Investment Limited on September 30, 2026. No cash changed hands. The company received a license to China trial data, a funding commitment from the buyer, and a clawback, and it gave up control of SEED Therapeutics.
BYSINasdaq staff said Kyntra Bio had not shown compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. A hearing request keeps the stock trading for now.
KYNBRocket Pharmaceuticals received $35 million at closing under a credit facility of up to $150 million with Hercules Capital. The company expects its cash, with that first draw, to fund operations into the third quarter of 2028, and it says more borrowing could extend that into 2029.
RCKTHTGCTelomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million.
TELOA 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice.
UPCImmunome paid Bristol-Myers Squibb $20.0 million and 4,425,487 shares under Amendment No. 4, which ends its milestone and royalty obligations. The 8-K names no underwriter or placement agent; at June 30, 2026 the company held $217.7 million in cash and equivalents plus $302.3 million in short-term investments.
IMNMMindWave will build, run and host an insurance network for BlockAssure and receive development fees plus 20% of the AssureCoin supply.
APUSThe October 2, 2026 exchange agreement would give Aibotics all membership interests in Empulser Enterprises LLC in return for Series C Preferred Stock with a stated value of up to $22,000,000.
AIBTSilo Pharma agreed on October 1, 2026, to acquire software, technology and intellectual property from Norsight Consulting in exchange for a warrant to buy 300,000 shares.
SILODr. Reddy's told Tonix on October 1, 2026 that it filed an ANDA for a generic version of TONMYA 2.8 mg sublingual tablets and certified that four Orange Book patents are invalid, unenforceable or not infringed. No lawsuit has been filed, and Tonix says it intends to enforce its rights.
TNXPBeyondSpring Inc. received a Nasdaq letter on September 29, 2026 saying its market value of listed securities has been below $35 million for 30 consecutive business days. It has until March 29, 2027 to regain compliance, and its shares keep trading in the meantime.
BYSIDaré Bioscience has until March 29, 2027 to show a $1.00 closing bid price for 10 consecutive business days. A second 180-day period is possible only if it meets the other listing standards and says it will cure the shortfall, by a reverse split if needed. Its cash fell to $12.6 million by June 30, 2026.
DAREA preliminary prospectus dated October 2, 2026 set out a best efforts offering of units with Series D warrants. The deal was later priced to raise about $6.0 million before fees.
SBFMThe safety review committee recommended moving to Cohort 2 after reviewing safety data from Cohort 1. About 24 patients are expected to enroll in the second cohort.
AZTRLantern has until March 24, 2027 to restore the $35,000,000 market value minimum after a Nasdaq notice dated September 25, 2026. Its 2025 net loss was $17.1 million.
LTRNBempikibart showed a 35.3% mean reduction in SALT score at Week 36 in alopecia areata. The company intends to start a registration-directed program in the first half of 2027.
QTTBErick Frim resigned as interim chief financial officer on September 29, 2026, and the board appointed Eric Sherb effective October 1, 2026, at a base salary of $60,000 a year.
APUSNOMAD Power Solutions agreed to a secured note with a $6.57 million principal amount, for $6.0 million in gross proceeds. The note matures 12 months after its purchase price date and carries a 9% interest rate.
NMADValion and Shear Kershman Laboratories finished formulation work on a needle-free Entolimod, with systemic exposure testing next.
VBIOAEON Biopharma received official minutes from a Type 2b meeting with the FDA on its BOTOX biosimilar. It plans to file an IND for a comparative pharmacodynamic study in the fourth quarter of 2026.
AEONLantern sold 1,469,725 shares at $1.09 each plus pre-funded warrants for up to 2,200,000 shares. A concurrent private placement of warrants for up to 3,669,725 shares needs stockholder approval before exercise.
LTRNCalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first.
CALCA technical amendment sets a formula-based exchange ratio for a combined company of 10,000,000 shares. A later amendment cut that number to 5,000,000.
CMMBIssued common shares will fall from 4,059,227 to 507,404, subject to fractional-share adjustments.
CMNDPetros Pharmaceuticals assigned all of its assets to PT Liquidation, LLC for the benefit of creditors on September 30, 2026, and says it has ceased substantially all operations. The executive chairman and two directors resigned the same day, and the Series A preferred stock must be redeemed immediately.
PTPISciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern.
SPRCSlides filed with the SEC say the differences between AL001 and lithium carbonate were not statistically significant in the healthy cohort.
ALZNThe company reports 89 subjects enrolled, with two more in screening, and says it remains on track for a Part A readout in the first quarter of 2027.
MBRXBeyondSpring has set up an at-the-market program through Citizens for up to 9,200,000 ordinary shares, capped at $11,942,800 by its public float limit. The prospectus supplement is dated September 29, 2026, and the same day the company agreed to sell its Chinese subsidiary to Biolin Investment Limited.
BYSIThe company is selling 11,363,637 shares through J.P. Morgan. Proceeds will fund development of its CAR-T candidate NXC-201.
IMMXImunon will exchange $1,200,000 of a Streeterville note for 120 Series B preferred shares that cannot convert into common stock but carry an 8% return. Cash and cash equivalents were $6.9 million at June 30, 2026.
IMNNStockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty.
LABTThe company, formerly Renovaro Inc., expects to file its Form 10-K for the year ended June 30, 2026 within the 15-day grace period. Its net loss for the prior year was about $178.0 million.
LNAIPyxis Oncology is selling 36,047,919 shares at $2.900 and pre-funded warrants, with common warrants at $3.50 that cannot be exercised until stockholders approve more authorized shares. Its auditor's report on the 2025 financial statements carries a going-concern warning.
PYXSUnicycive disclosed in an 8-K dated September 28, 2026 that a second securities class action was filed on September 3, 2026 against the company and certain of its officers over its oxylanthanum carbonate application. An earlier class action and two derivative suits are pending in the same federal court.
UNCYADARx Pharmaceuticals sold 26,250,000 shares at $17.00 in its IPO for about $446.3 million gross, and AbbVie bought 5,255,542 shares in a concurrent private placement worth about $89.3 million. The company had net losses of $46.4 million in 2024 and $73.1 million in 2025.
ADRXCelularity sold about $11.01 million of notes that convert at $1.50 a share, with warrants for about 4,037,000 shares. A second tranche of up to $10.0 million is available at the buyers' election through September 30, 2027.
CELUNasdaq closed the bid price matter on September 25, 2026, after an April notice. The 1-for-80 reverse split took effect on September 10, 2026, and the 2025 net loss was $170.4 million.
GOSSJaguar issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 cut to a note first sold in 2021. The company reported about 1,945,542 shares outstanding as of September 25, 2026.
JAGXThe deal is valued at up to $663.7 million if performance milestones are met. Contingent value rights could lift total payout to $9.67 per share.
LFCRThe split takes effect September 28, 2026, to keep the company in compliance with the Nasdaq bid-price rule, and trading on the split-adjusted basis starts September 29.
CDTThe reverse split of Matinas BioPharma Holdings took effect at 12:01 a.m. Eastern Time on September 28, 2026. Every 15 shares of common stock became one share.
MTNBA federal jury found that Eli Lilly breached the implied covenant of good faith in a rezpegaldesleukin license with Nektar and awarded $90 million, according to an 8-K filed September 25, 2026. Nektar is also a defendant in a securities class action, Schramke v. Nektar Therapeutics, filed in March 2026.
NKTRThe company filed a late-filing notice for the year ended June 30, 2026. It says it has not been able to compile the financial data for its Form 10-K.
AAGHViking sold shares at $35 and 2% notes due 2032 that convert at about $50.75. Both deals were upsized from $200 million each, and full exercise of the underwriters' options lifted gross proceeds to $575 million.
VKTXAptevo is optimizing several trispecific candidates for scalable manufacturing and expects IND-enabling studies for its lead candidate, APVO451, in the first half of 2027.
APVOClass A shares outstanding will fall from 380,623,358 to 12,687,445 when the 30-for-1 consolidation takes effect on October 1, 2026. Shareholders approved it on September 5, 2026, and authorised share capital rises to US$15,090,000.
BGMThe sales raised $0.48 million, and anti-dilution terms cut the exercise price of the August 2026 Series I Warrants to $0.51.
MBRXSubject to regulatory approval, the new source is expected to reduce unit costs by 40% or more. Evofem expects to submit a supplemental NDA in mid-2027.
EVFMBoard member Dean Zikria becomes interim chief executive officer, Thomas Jensen takes the board chair, and Lisa Wolf keeps her roles.
VBIOBank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier.
JAZZMorgan Stanley & Co. LLC and J.P. Morgan Securities LLC are the underwriters' representatives. The initial conversion price is about $50.75 a share, and the company sold 7,857,143 common shares at $35.00 in a separate offering the same day.
VKTXMapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales.
MPLTZymeworks subsidiaries sold $350,000,000 of 8.25% senior secured notes due December 31, 2036 to an OMERS Private Capital affiliate, and former Theravance holders received contingent value rights that the filing calls highly speculative.
ZYMEThe class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026.
SRPTThe September 2026 deck's risk list includes a possible reverse stock split to meet Nasdaq listing requirements.
XBIOThe designation is the second Fast Track for QRX003, after Netherton Syndrome in March 2026. It follows an IND that the FDA cleared in July 2026.
QNRXAytu (Nasdaq: AYTU) is the plaintiff against Granules Pharmaceuticals in Delaware, with trial moved to January 12, 2027. It is also a nominal plaintiff in a Section 16(b) suit against Armistice, now on appeal.
AYTUPTC says the rolling BLA for ST-920 is expected to be completed in the fourth quarter of 2026, with the goal of accelerated approval.
PTCTThe company effected the reverse split on September 17, 2026, and filed a certificate removing the terms of fourteen older preferred stock series from its charter, leaving about 520,088 common shares outstanding.
JAGXParkview Holdings One LLC is the lender. The $650,000 draw is small against $27.6 million of cash used in operations in 2025, and TuHURA reported $995,977 in cash and cash equivalents at June 30, 2026.
HURAAnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24.
ANABThe company stopped enrolling in its phase 3 MDD and bipolar studies of azetukalner. Fierce Biotech reported the shares fell 26% pre-market the next day.
XENEDawson James Securities is sole placement agent for the offering, priced at $1.46 per share under Nasdaq at-the-market rules.
TCRTShareholders' equity of $1,075,007 in the 10-K for the year ended June 30, 2026 fell below the $2,500,000 Nasdaq minimum. The company has 45 calendar days to submit a plan.
INMPorfirio Sanchez Talavera resigned as chief executive officer on September 18, 2026, and Carlos Septién, previously chief operating officer, took the post.
GCANDNasdaq staff says Moleculin is not eligible for a compliance period because it effected a 1-for-25 reverse stock split on December 1, 2025. The company plans to request a hearing, which stays any delisting action while it is pending.
MBRXNasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180 calendar day compliance period that ends March 16, 2027.
BYSINasdaq gives Filana until March 16, 2027 to regain compliance. Cash and equivalents fell to $86.6 million at March 31, 2026, from $128.6 million at the end of 2024.
FLNANasus Pharma can sell up to $8,500,000 of shares through BTIG but is not obliged to. Its June 30, 2026 balance sheet held $11,904 thousand in cash, restricted cash and short-term deposits, and its prospectus supplement lists substantial doubt about going concern among its risks.
NSRXRetension Pharmaceuticals, a Falls Church, Virginia developer of a hypertension drug, filed a Form S-1 on September 18, 2026. The preliminary prospectus leaves the share count and price blank, and its 2025 financial statements have been restated.
RTSNAt its September 17, 2026 annual meeting, stockholders approved a reverse split at a ratio of 1-for-2 to 1-for-20 and raised authorized common shares from 75,000,000 to 125,000,000.
SNGXStockholders approved a 2017 plan amendment, a 2026 equity plan, a 2026 employee stock purchase plan and an increase in authorized shares to 500,000,000 at the September 17, 2026 meeting.
ADILThe Nasdaq Stock Market said on September 17, 2026 that it will delist the common stock of Aditxt, Inc. The stock was suspended on June 25, 2026 and has not traded on Nasdaq since then.
ADTXZoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited.
IBOPRPHModica v. Aquestive names the company and chief executive Daniel Barber in New Jersey federal court. A derivative suit, Wilson v. Brown, is stayed behind it.
AQSTA news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures.
QNTMThe board adopted Second Amended and Restated By-Laws on September 16, 2026, effective immediately.
TCRTPasithea Therapeutics said its KTTAW warrants will expire on September 17, 2026 and stop trading on Nasdaq, while its common stock keeps trading as KTTA.
KTTAThe board approved a one-for-fifteen reverse split of the common stock, effective 12:01 a.m. Eastern Time on September 28, 2026, under the existing MTNB symbol.
MTNBThe deal needs Xenetic stockholder approval. Pro forma, current Xenetic holders would own approximately 15.0% and Santersus holders approximately 85.0%.
XBIOJaguar Health exchanged a convertible note and Series Q preferred shares for common stock in September 2026, and issued 535,000 common shares plus a pre-funded warrant to acquire the Napo Therapeutics shares of a minority holder.
JAGXTyra Biosciences priced 9,079,000 common shares and pre-funded warrants for 9,078,529 more, expecting about $400.0 million gross at $22.03 a share. The company had $73.8 million of cash at June 30, 2026, and a 2025 net loss of $119.9 million.
TYRAAll TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations.
ASNDNOVO BBoth hires come as Q32 Bio prepares a registration-directed program for bempikibart in alopecia areata. The company plans to start it in the first half of 2027.
QTTBThe bridge facility provides up to $5,000,000 to Realbotix LLC, the target of a pending all-stock share exchange, with an initial advance of $2,500,000.
ONCOPhio Pharmaceuticals said on September 14, 2026 that it reached a development milestone for PH-762, including the submission of materials to the FDA and a planned Phase 2b neoadjuvant study.
PHIOThe company says Ameluz with the RhodoLED lamp is the first and only photodynamic therapy approved in the United States to treat a skin cancer. It plans a launch from late fourth quarter 2026 through first quarter 2027.
BFRIMindWalk Holdings signed a binding term sheet with Sanabil (Cayman) for a revolving credit facility of up to $30 million at a fixed 7.00% annual rate. The definitive agreement is not yet signed.
HYFTTuHURA reported the draw in an 8-K dated September 17, 2026. Parkview Holdings One LLC is the lender, and cash and cash equivalents were $995,977 at June 30, 2026.
HURAThe note matures March 1, 2027 and is payable in 24 weekly installments of $88,593.75. The lender can convert at the greater of 70% of the lowest volume-weighted average price or a $0.05 floor.
CDTSionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial.
SIONA September 12, 2026 submission asks FDA for a Commissioner's National Priority Voucher for an efficacy supplement to ARAKODA in babesiosis.
SXTPBioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commission on gross proceeds.
BIVINine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers.
ACADThe appointment on September 10, 2026 followed a First Amendment to a settlement agreement that sets the board's interim makeup. Chae has been Co-Chief Executive Officer since May 4, 2026.
APUSLenders and noteholders agreed to forbear from enforcing remedies for a limited period. The forbearance period is set to end October 15, 2026 unless extended, and can end sooner on several triggers.
KPTIA preclinical study found DA-1726-derived radioactivity concentrated in adipose tissue and retained over time, which MetaVia says supports the waist circumference reduction seen in clinical studies.
MTVARallybio said Jonathan Lieber will move to part-time employment on September 15, 2026 and remain Chief Financial Officer. His employment ends at the closing of the pending Avenzo Therapeutics merger.
RLYBCocrystal Pharma said on September 9, 2026 that it dosed the last subject in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected in late 2026 or early 2027.
COCPLexaria Bioscience cut the exercise price on 453,969 existing warrants to $12.92 a share, for about $5.9 million in gross proceeds. In return it issued two new warrant series, each for the same number of shares, at $12.67.
LEXXThe warrants will be exercised at $12.92 per share for gross proceeds of about $5.9 million, with H.C. Wainwright & Co. as exclusive placement agent. Holders receive new Series A and Series B warrants at $12.67.
LEXXThe peptide drug developer will fund repurchases from cash and royalty income. It held $849.5 million at June 30, before $275 million in Takeda payments due in the fourth quarter.
PTGXThe designation is the second Rare Pediatric Disease Designation for QRX003. Quoin said an approved application could qualify it for a priority review voucher.
QNRXA September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early October 2026.
SXTPKiora named Keith J. Lane, previously Chief Scientific Officer at Ora, Inc., to lead clinical development and regulatory affairs. The appointment supports the KIO-301 retinitis pigmentosa program.
KPRXGRI Bio said new whole-blood, serum and flow cytometry data from its 35-patient Phase 2a study support nine mechanistic pillars for GRI-0621 in idiopathic pulmonary fibrosis.
GRIThe 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans.
EVMNA September 2026 report sets out a 1-for-3,000 reverse split of Can-Fite's ordinary shares in January 2026, and a change that cut each ADS from 300 ordinary shares to two. The company also lists the risk of failing NYSE American continued listing standards.
CANFThe board approved the program after Keros received a development milestone payment under its elritercept license with Takeda. The program does not oblige Keros to buy any shares.
KROSThe exchange says stockholders' equity was $1.8 million at June 30, 2026, below the $2.0 million standard, and the listing continues under an accepted plan through October 2, 2027.
MTNBADARx Pharmaceuticals filed an S-1 for a Nasdaq IPO under ADRX, with five banks on the cover and the share count and price range left blank. Its net loss was $73,088 thousand in 2025, and it holds a $335.0 million upfront payment from AbbVie.
ADRXClearmind will also lend Charging Robotics $1.5 million at 4% as a condition of closing, which is expected the week of September 7, 2026.
CMNDThe consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are promotional.
XRTXThirteen of 14 evaluable TP53-mutated frontline AML patients treated with mipletamig, venetoclax and azacitidine had clinical benefit, according to Aptevo's September 3, 2026 release.
APVOThe note bears 8% interest payable in kind and matures September 3, 2027. It converts at $0.04 per share after stockholders approve more authorized shares.
HEPACash rose to $8,526 thousand at June 30, 2026, from $3,125 thousand at year end, while the six-month loss was $2,942 thousand. Most of the cash came from a $10.0 million equity line that has since ended.
PRFXThe company borrowed $1,500,000 on September 2, 2026 under a loan agreement with Parkview Holdings One LLC. The facility allows up to $50 million and matures on April 21, 2031.
HURAQuantum BioPharma has applied to delist its Class B shares from the Canadian Securities Exchange, with September 4, 2026 expected as the last trading day, subject to approval. The company's own release does not give the trading volumes behind the decision.
QNTMThe sale closed September 1, 2026 at an adjusted price of $25,250,000, and the company filed unaudited pro forma statements showing its effect.
ISCOShareholders approved authority for a reverse split tied to an uplisting, and a special committee to negotiate retiring the Series B preferred stock. The company's release reports no vote counts.
ETSTPDS Biotechnology amended a $6,000,000 note with YA II PN, Ltd. to require weekly remittances from at-the-market sales and to apply other equity proceeds to a mandatory redemption payment.
PDSBKyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., lowering the maximum payments and making a $42.6 million upfront payment.
KYNBThe note was issued on August 31, 2026 and repaid in full on September 4, 2026. It came with warrants for 237,000 shares.
CDTTeva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer.
TEVAAprea said it holds 28 issued and 30 pending patents for its precision oncology programs, with the WEE1 family of applications expiring in 2047 if granted.
APREThe board appointed Jerry Leonard as chief financial officer on August 27, 2026, effective September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, after interim CFO Robert Dickey gave notice of his resignation.
HINDNYSE American notified Oragenics on August 26, 2026 that it is not in compliance with two continued listing standards on stockholders' equity. The company has 45 days to submit a compliance plan and says it intends to do so.
OGENBioLineRx sold 1,348,921 ADSs at $2.78 each and issued warrants on 2,023,382 more ADSs. It also amended older warrants on 277,273 ADSs and cut its at-the-market facility to zero.
BLRXQuoin agreed to sell 6,305,300 ADSs or pre-funded warrants at $4.88 and warrants for up to 3,152,650 ADSs, for about $30.8 million at closing. The same day it reported interim results from six patients, and its 10-K carries a going-concern warning.
QNRXNasdaq says Shuttle no longer meets Listing Rule 5250(c)(1) because its quarterly report for the period ended June 30, 2026 is late. A plan to regain compliance is due October 27, 2026.
SHPHCan-Fite BioPharma's shelf sets a ceiling of $100,000,000, but the at-the-market sales agreement with H.C. Wainwright & Co., LLC covers only $1,065,000, a limit set by its public float.
CANFThe July 3, 2026 agreement allows pre-paid purchases of up to $31,500,000 before an original issue discount. The August 27 amendment restores the $0.20 floor after a 1-for-80 share consolidation had raised it to $16.00.
SXTCThe 1.875% notes due 2032 carry an exchange price of about $355.24, a 42.5% premium to the Aug. 26 close. The offering was upsized from $1.0 billion.
JAZZArtelo will combine every nine shares of common stock into one, with split-adjusted trading beginning August 31, 2026, and about 547,774 shares outstanding afterward.
ARTLThe split takes effect August 31, 2026 under the same VBIO symbol, and the company says it aims to meet the Nasdaq minimum bid price rule.
VBIOBioXcel filed Chapter 11 on Aug 27 with Teva's $57.5 million upfront bid as the floor for a court auction. That upfront sum is below the company's $107,152 thousand of total debt at June 30.
BTAITEVAShareholders backed the Korsana merger share issuance and change of control on August 26, 2026. The combined company expects to trade on Nasdaq as KRSA from September 9, 2026; a Cayman redomestication failed.
KRSAJazz Investments I Limited plans to sell $1.0 billion of exchangeable notes due 2032. Jazz also expects to buy back up to $225.0 million of its ordinary shares from note purchasers.
JAZZA Form D filed August 26, 2026 reports $1,650,000 sold to eight investors, while the August 14 agreements covered $1.35 million. The shares carry registration rights.
TTRXPTC Therapeutics will pay $111 million upfront and up to $100 million more in milestones for ST-920, subject to approval by the bankruptcy court.
PTCTNasdaq extended the Ensysce Biosciences bid price deadline to February 22, 2027, and said the company must meet initial listing criteria after its Cy Biopharma acquisition.
ENSCThe agreements are dated August 25, 2026, and priced at $0.05 per share. The filing names no underwriter or placement agent.
HEPAPDS Biotechnology approved a reduction in force on August 6, 2026 and estimates a one-time charge of approximately $842,000. It also ended Stephan Toutain's role as Chief Operating Officer.
PDSBThe split took effect Aug. 26 and cut Class A shares to about 3.04 million. Three weeks later the company reported that its HLHS trial missed its primary endpoint.
LGVNArbutus filed a Schedule TO on August 24, 2026 to start an issuer tender offer for up to US$230 million of its common shares, paid in cash. The filing points to an Offer to Purchase dated the same day, and it does not state the start or expiry dates in its own text.
ABUSSkye Bioscience's equity line with a Redmile affiliate covers up to $22,000,000 and requires purchases of up to $2,000,000 a month once it starts. The line is reduced if the PIPE exceeds $103,000,000 and falls away at $125,000,000.
SKYENasdaq granted Pasithea Therapeutics 180 more days, to February 16, 2027, to regain the $1.00 minimum closing bid price required for continued listing.
KTTANYSE Regulation's August 19, 2026 letter says the company resolved deficiencies under two continued listing standards. A new lapse within 12 months could bring faster action.
AZTRSplit-adjusted shares will trade under the existing KAPA symbol at market open on September 1, 2026, and the company says the split is meant to help it keep its NYSE American listing.
KAPAMoleculin can now sell up to $19,700,000 under its at-the-market program, weeks after a July deal with warrants on 37,130,001 shares. The trial figures it cited are blinded and preliminary, drawn from 62 patients.
MBRXInsiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales.
MANENasdaq told Adial on August 18, 2026 that it no longer meets the $2,500,000 stockholders' equity requirement. The company says it anticipates regaining compliance once holders approve conversion of its Series A Non-Voting Convertible Preferred Stock.
ADILGossamer Bio's private placement of up to $250 million opens with $25.0 million at a first closing. A $125.0 million second closing depends on FDA acceptance of its seralutinib filing, and warrants that could add about $100.0 million depend on FDA approval.
GOSSArbutus said on August 21, 2026 that it plans a modified Dutch auction tender offer for up to US$230 million of its common shares at US$5.00 to US$5.75 each, funded from cash on hand. The offer has not started, and the company says it needs exemptive relief in Canada and the United States first.
ABUSNasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance.
CTXRCTORTD Cowen is the sales agent for up to $500,000,000 of common stock under a sales agreement that sits inside a $1,000,000,000 shelf. The filing puts the outstanding count at 61,069,887 shares on June 30, 2026.
ORKAThe FDA raised no objection to the planned Phase 1 design and identified no clinical hold issues. Protagenic plans to submit the IND before the end of 2026.
PTIXCuranex's 1-for-20 reverse split took effect on August 20, 2026. Nasdaq closed its bid-price matter on September 3, after the stock traded at or above $1.00 for ten consecutive business days.
CURXAbbott Laboratories, a defendant in numerous NEC lawsuits, agreed to resolve the Gill case, where a jury awarded $495 million, and claims for about 2,000 other infants. About 1,700 lawsuits remain pending.
ABTUroGen gets an option on IntraGel's TumoCure for advanced head and neck cancer and agrees to invest up to $7,000,000 in IntraGel's equity. The 8-K gives no clinical data, no option fee and no exercise deadline.
URGNNet loss attributable to common stockholders was $12.7 million for the quarter ended June 30, 2026, as U.S. revenue from its two main prescription products now flows to licensee Future Pak under a January 2026 agreement.
JAGXUnder an agreement dated August 19, 2026, FreeT Inc. assigned to Apimeds Pharmaceuticals a set of Apitox rights, including 100% of the Korean medicine clinic market and a 25% royalty entitlement on U.S. proceeds.
APUSKiora will receive a $1 million upfront payment from Chong Kun Dang for KIO-301 rights in South Korea. Kiora says its partners will coordinate a single global Phase 3 trial in retinitis pigmentosa.
KPRXThe board approved the appointment on August 19, 2026, effective immediately. The filing says no arrangements tie his selection to any other person.
HEPATuHURA Biosciences' stockholders approved on August 18, 2026 the issue of 1,878,287 shares to its lender, Parkview Holdings One LLC, as a fee for a $50 million revolving credit facility. The company's cash stood at $995,977 on June 30, 2026, according to its quarterly report.
HURADodge v. Mereo Biopharma Group PLC (1:26-cv-988) was filed Feb. 4, 2026 in the Southern District of New York. The lead plaintiff filed an amended complaint on July 13, 2026.
MREONasdaq said on August 18, 2026 that the ADSs are still below $1.00 but the company is eligible for 180 more calendar days.
MREONasdaq said on August 18, 2026 that Skye Bioscience's stockholders' equity was a deficit of $497,307 at June 30, 2026, below the $2,500,000 minimum. The company has until October 2, 2026 to submit a plan to regain compliance.
SKYESilo agreed on August 18, 2026 to buy software, technology and domain names from Parkview Consulting LLC, paying with shares subject to a lock-up of up to twelve months.
SILOThe contract manufacturer will make drug product for IND-enabling preclinical studies and future clinical trials of the company's AAV-based diabetes gene therapy.
GNPXCocrystal Pharma's board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately, according to a Form 8-K filed August 18, 2026.
COCPNasdaq gave BullFrog AI until February 8, 2027 to regain the $1.00 minimum bid price. Stockholders approved a reverse stock split at a ratio of not less than 1-to-2 and not more than 1-to-15.
BFRGAmylyx's final supplement prices 14,090,000 shares at $35.500 for $500,195,000 before costs, above the $350,000,000 in the first filing. The company announced Phase 3 topline results the same day.
AMLXSciSparc put in C$2.7 million, half the total, and says it will hold approximately 44.6% of NeuroThera afterward. NeuroThera plans to use the money for general working capital.
SPRCNTLXJames Rolke and Chester Zygmont each received restricted stock awards that vest in four tranches tied to market capitalization milestones of $30 million to $120 million.
REVBDermata Therapeutics agreed to sell 2,293,608 shares, or pre-funded warrants, at $1.46 per share, with Series E and Series F warrants attached. Gross proceeds are expected to be about $3.4 million before offering expenses.
DRMACash and cash equivalents reached CAD 307,828,515 at June 30, 2026, after a January 2026 public offering at US$90 a share. Over the nine months the company used CAD 23,402,489 in operations and reported no revenue.
DRUGFulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers.
FULCThe Hearings Advisor told the company on August 17, 2026 that staff confirmed compliance with Listing Rule 5550(a)(2), and the requested hearing was cancelled.
LEXXXORTX ended June 30, 2026 with $994,045 in cash after a $5,000,000 public offering, and the going-concern note stays. Operations used $3,768,993 in the six months.
XRTXQuoin said it had about $10.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, and that it expects that position to fund operations into 2027.
QNRXTraws reports $5.0 million in cash at June 30, 2026, and says existing cash plus expected at-the-market proceeds fund planned operations into the first quarter of 2027.
TRAWThe company reported cash-on-hand of $8.3 million as of June 30, 2026, and an update on its lead candidate EB-003 ahead of an IND submission.
ENVBRevenue rose from $56,325 in the first quarter, gross margin was approximately 97.7% and the net loss narrowed to about $2.8 million. The company began commercial launch of REZENOPY during the quarter.
SCNXDaré Bioscience sold 4.38M shares at $1.37 and gave buyers two warrant series covering 8.76M more, while Nasdaq reviews its listing and cash runs into Q4.
DARECuranex says its cash will not last twelve months, a reversal of the no-doubt finding in its first-quarter report. Prepaid research payments have so far held cash use well below its losses.
CURXExicure's securities class action and its shareholder derivative suits are over, according to a quarterly report filed August 14, 2026. The class action settled for $5.625 million, funded by insurers, and the derivative suits were dismissed in June 2026 after court approval.
XCURGT Biopharma is the only defendant named in New York suits by Z-One, Silberfein, DiPietro and the Werthman Trust. Z-One's claims were dismissed and appealed. The other three are in settlement talks.
GTBPA Northern District of California class action names Vistagen, CEO Shawn Singh and COO Joshua Prince. Two derivative suits are stayed behind it, and a separate pro se case was dismissed with prejudice on August 12.
VTGNBE&K Building Group sued HCW Biologics, Cogent Bank and subcontractors in Broward County over unpaid renovation invoices. Fisk Electric's suit was consolidated, and Cogent Bank has demanded the liens be cleared.
HCWBDefendants: Capricor and unnamed officers in the new July 30 class action, and Capricor and CEO Linda Marbán in the 2025 one. The FDA also moved the deramiocel date to November 22, 2026.
CAPRAdlai Nortye reports $231.9 million in cash and short-term investments at June 30, 2026, up from $8.1 million six months earlier, after two private placements of $140 million and $150 million before fees, and it has de-prioritized AN4005 as a monotherapy.
ANLCASI Pharmaceuticals had $3.8 million of cash at June 30, 2026, after its ordinary shares left Nasdaq and began quoting on the OTCQB. Its first-half release says recurring operating losses have raised substantial doubt about its ability to continue as a going concern.
CASIFSales run through Leerink Partners under an agreement dated June 28, 2024. The commission is up to 3.0% of gross proceeds.
IFRXNutra Pharma filed a Form 12b-25 notice on August 14, 2026, saying its quarterly report for the period ended June 30, 2026 would be late. Its cash at December 31, 2025 was $12,181.
NPHCThe notice also says its 2025 Form 10-K and its March 31, 2026 Form 10-Q have not been filed. The company cites delays in finishing its financial statements and an auditor review.
PKTXSkye Bioscience's investor deck describes a U.K. scheme of arrangement to combine with Redx Pharma, a concurrent financing totaling $125 million, and a contingent value right for former Skye holders. The deck says Skye is discontinuing its CBeyond trial of nimacimab.
SKYEDogwood reported a second quarter net loss of $11.5 million, including a $6.7 million non-cash impairment, and $9.6 million in cash that it says funds operations through the Phase 2b readout.
DWTXEquillium reported a second-quarter net loss of $4.7 million and cash and cash equivalents of $57.2 million at June 30, 2026, which it says can fund planned operations into 2029.
EQNet product revenue rose 32.9% from a year earlier, and gross margin reached 80%. The net loss was $0.6 million, compared with $5.3 million in the prior-year quarter.
BFRIEnsysce Biosciences said the Cy Biopharma acquisition closed on August 6, 2026, with private placement financings of $38.6 million and cash runway into late 2027.
ENSCThe notes mature in July 2044 and are secured by royalty payments that EirGen Pharma Limited receives on mazdutide. HCR Injection SPV, LLC serves as agent.
OPKWinning bids yield about $163.55 million in cash at closing and up to $100 million in milestones. Every sale still needs court approval, and the company is still selling other assets.
SGMOQLLYMapLight agreed to sell 9,197,887 voting shares at $11.38 and pre-funded warrants for 3,983,168 more shares, for about $150.0 million gross before fees.
MPLTMapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $150.0 million at $11.38 a share. Six-month operating cash use was $96.0 million.
MPLTThe company says its cash lasts through the first quarter of 2027 and it will need more capital after that. SOTERIA is due to start in the second half of 2026.
PLYXThe warrant covered 1,192,207 shares at $5.03. Because GEM used the cashless option, Turn received no cash and issued fewer shares than the warrant allowed it to buy.
TTRXCytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia.
CYTKAptevo Therapeutics (Nasdaq: APVO) closed deals that cut warrant exercise prices to $4.03 per share and sold shares or pre-funded warrants in a private placement. Roth Capital Partners was placement agent.
APVOKyntra Bio, formerly FibroGen, says it must advance legal costs for an SEC case against its former chief medical officer and may have to cover some costs and judgments. It had accrued about $7.0 million for those obligations at June 30, 2026, up from an amount it called not material three months earlier.
KYNBThe class action names CorMedix and six officers, including Khoso Baluch. A settlement of derivative suits naming 12 individuals had a final approval hearing set for September 23, 2026.
CRMDAlumis (Nasdaq: ALMS) inherited Boukadoum v. Acelyrin in its May 2025 merger. The filing names ACELYRIN and unnamed officers and directors; ACELYRIN's 2024 signers are listed.
ALMSAptarGroup and Aptar France sued ARS Pharmaceuticals and ARS Pharmaceuticals Operations in March 2025. The company's separate antitrust suit against AptarGroup was moved to New York in July 2026.
SPRYA stockholder sued the company and unnamed current and former officers in the Southern District of California on August 5, 2026. A pharmacy filed a separate fax-advertising class action in July.
SPRYThe 10-K says the court certified the class on June 18, 2026 in In re BioVie Inc. Securities Litigation. BioVie and unnamed officers are defendants; insurance carries a $2 million deductible.
BIVIKinnamon v. Gossamer Bio names the company and unnamed executive officers and directors over a June 16, 2025 to February 20, 2026 class period. The 10-Q gives no loss estimate.
GOSSNervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units.
NGENProQR raised about $59.2 million in June, through a $50.0 million underwritten registered direct offering and a $9.2 million private placement to Eli Lilly and Company. The release names no underwriter, and says cash of €117.1 million covers runway into mid-2028.
PRQRRegen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date.
RGBPAprea Therapeutics reported a net loss of $3.6 million for the quarter ended June 30, 2026, and said its cash should last into the first quarter of 2028. The company is also expanding enrollment in its lead WEE1 inhibitor trial.
APREPTC says the ST-920 rolling BLA will be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 if the acquisition closes.
PTCTAditxt, Inc. said that on August 12, 2026 MDNA Holdings Inc. acquired substantially all of the outstanding shares of its majority-owned subsidiary, Pearsanta, Inc. Pearsanta agreed to pay Aditxt royalties on Net Revenue and two milestone payments of $250,000 each.
ADTXNet sales rose to $26.7 million for the quarter ended June 30, 2026, and the company reported net income after a net loss a year earlier.
MTEXAEON Biopharma reported $3.4 million in cash at June 30, 2026, and said upfront proceeds from its July offering extend its runway into the first quarter of 2027. The company also regained NYSE American compliance on August 3, 2026.
AEONJPMorgan Chase Bank, N.A. is administrative agent. The amendment cuts the spread on term loan A by 0.75% and on term loan B by 0.50%.
ALKSManagement says June 30 cash covers GX-03 work in atopic dermatitis into the third quarter of 2027, but the 10-Q also raises substantial doubt that Turn can continue as a going concern.
TTRXA federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed.
ANROInovio sued VGXI, Inc. and GeneOne Life Science, Inc. in a Pennsylvania state court in 2020 over a supply agreement. The defendants counterclaimed. A seven-day trial was scheduled to begin October 13, 2026.
INOThe SEC fined former CEO Ankit Mahadevia $112,500 and former CFO Satyavrat Shukla $75,000 in a settled January 2026 order. Spero's letter of Jan 20, 2026 says the SEC does not intend to recommend action against it.
SPRORepurchases run no later than December 31, 2026. The company expects year-end 2026 cash and financial investments of EUR 1.975 billion to EUR 2.050 billion, including the buyback.
LKFTPharvaris reported €318 million of cash at June 30, 2026, after a $132.3 million underwritten offering it closed in May. The company says the money extends its runway into 2028, while its quarterly loss reached €47.8 million and its key pivotal trial has yet to report.
PHVSVogenx priced 6,250,000 shares at $13.00, for $81,250,000 before underwriting discounts. The prospectus shows $251 thousand of cash at March 31, 2026 and a going-concern warning.
VOGXThe upsized offering priced at $13.50 per ADS a day after the SANRECO results, adding to $72.1 million in cash at the end of June.
SLNThe NYSE American company reported $11.3 million of cash at June 30, 2026, after first patients were dosed in a Phase 2a trial of more frequent VCN-01 dosing in pancreatic cancer.
TOVXThe company had $18.1 million in cash, cash equivalents and marketable securities on June 30, 2026. It expects to report initial clinical data from its lead antibody conjugate, BDC-4182, with its third-quarter results.
BOLTDermata Therapeutics reported $4.4 million in cash and cash equivalents at June 30, 2026, and said it expects to launch Tome Foundational Treatment on August 25, 2026. Cash is expected to fund operations into the fourth quarter of 2026.
DRMAVeradermics reported $819.9 million in cash and securities at June 30 and says the money lasts into 2030. That runway depends on Phase 3 readouts, the first of them due in the second half of 2026.
MANETherapeuticsMD (Nasdaq: TXMD) sued Mayne Pharma LLC in Delaware over net working capital allowances and faces a countersuit. Teva and Sun Pharma are defendants in New Jersey patent cases over generic IMVEXXY.
TXMDErasca (Nasdaq: ERAS) is named in a June class action in San Diego federal court. An August derivative suit names its current directors and CFO. The 10-Q names no officers in the class action.
ERASY-Trap, Inc. sued Bicara Therapeutics and Biocon Ltd in Massachusetts federal court in October 2024. Discovery is ongoing, and a patent office review Bicara requested was instituted on July 15, 2026.
BCAXWarrant holder Andrew Schwartzberg seeks more than $3.1 million from Gain and Gene Mack for breach of contract, fraudulent inducement and promissory estoppel. Gain's 10-Q reports going concern doubt.
GANXA later announcement prices 17,435,897 common shares and pre-funded warrants for 3,076,926 shares, for expected gross proceeds of about $200.0 million. The offering is expected to close on August 14, 2026.
ABCLTango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination.
TNGXAdial anticipates that Cary Claiborne and Vinay Shah will leave after stockholders approve the proposals at the annual meeting, and that Matthew Davidson will become president and chief executive officer.
ADILThe first closing on August 10, 2026 covered $5,000,000 of units, including a bridge note conversion, and the second tranche is optional for each purchaser.
OSTXThe senior secured revolving credit facility will help fund the cash price for Dura Driver Control Systems, along with cash on hand. The release names no lender.
ASBPVeru, Chairman and CEO Mitchell Steiner and CFO Michele Greco are defendants in a Florida class action. Five derivative suits name seven officers and directors. Veru says it cannot estimate losses.
VERUClear Future, Inc. sued Veru Inc. in Delaware Superior Court after buying the FC2 female condom business for $18.0 million in cash. Veru is the defendant named in the 10-Q and says it cannot estimate losses.
VERUHo and Yankov complaints named Rocket, CEO Gaurav Shah and former CFO Aaron Ondrey. Rocket's motion to dismiss the consolidated complaint is pending, and a derivative suit is stayed.
RCKTStockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed.
AXSMAxsome's 10-Q says it has settled with every current Sunosi ANDA filer, the last being Aurobindo on June 2, 2026. Its Symbravo patent suit against Apotex Inc. is in fact discovery.
AXSMThe Peters suit names MoonLake and its chief executive, chief financial and chief scientific officers. The class period runs March 10, 2024 through September 29, 2025.
MLTXGuggenheim Securities may act as agent or principal and is entitled to a 3.0% commission. The last reported sale price on August 7, 2026 was $42.39 per share, and the supplement puts dilution to new buyers at $37.68 per share.
COGTHolders will vote on September 22, 2026 on raising authorized common stock from 12,500,000 shares and on a reverse split of up to 1-for-20.
LABTThe notice lists one holder of record of the ordinary shares and is dated August 7, 2026. Wave Life Sciences Ltd. reported a net loss of $204.4 million for 2025.
WVEMinerva reported GAAP net income of $17.5 million for the quarter, driven by a non-cash warrant gain, and cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026.
NERVKiora ended the quarter with about $16.8 million in cash and short-term investments. The company also reported a private placement for up to $24.0 million, with $5.0 million received upfront.
KPRXThe draw is part of a revolving credit facility of up to $50 million with Parkview Holdings One LLC that matures in April 2031.
HURAPaul Feller sued RestorGenex, Pro Sports & Entertainment, ProElite and Stratus Media Group, GmbH in Los Angeles. The court dismissed some claims on March 26, 2026. CervoMed says it is defending itself vigorously.
CRVOA Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25.
ANIPCGONOrphalan sued Novitium, and Xeris and Strongbridge sued Novitium and ANI. In a Harmony patent case against AET and Sandoz entities, the defendants counterclaim against Harmony and Novitium.
ANIPCronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees.
MRKBlossomHill priced 9,375,000 shares at $16.00 for $150,000,000 before costs, with delivery expected on or about August 10, 2026. The auditor's report on the 2025 financial statements includes a going-concern paragraph.
BLSMCorbus can sell up to $127,500,000 of common stock through Jefferies LLC, which earns a fixed 3% commission on each share. At the $9.40 price the filing uses, new buyers would see $2.46 a share of immediate dilution.
CRBPThe offering totals $345,600,000 before underwriting discounts, and the company's auditors have raised going-concern doubt.
LTGOThe holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end.
ROIVThe Phase 2a study will test more frequent repeated dosing of VCN-01 with standard chemotherapy in first-line metastatic pancreatic cancer.
TOVXMetaVia reported a net loss of $5.3 million for the quarter ended June 30, 2026, with cash and cash equivalents of $12.6 million, and said all active Part 3 patients reached their highest planned doses.
MTVARevelation reported a net loss of $3.3 million for the quarter and $11.5 million in cash at June 30, 2026, which it says can fund operations through the first quarter of 2027.
REVBBioVie said bezisterim met its prespecified endpoints in early-stage Parkinson's disease, with improved blood inflammatory markers and better composite clinical outcomes than placebo.
BIVIEnsysce completed its acquisition of Cy Biopharma on August 5, 2026 and agreed to a Series C private placement of about $43 million in two tranches. After the deal, Cy's former holders would own about 73.86% of Ensysce on a fully diluted basis, and the second tranche depends on a clinical milestone.
ENSCYarborough v. Ardelyx named the company and executives Michael Raab, Susan Rodriguez, Laura Williams and Elizabeth Grammer. The First Circuit appeal was dismissed on March 26, 2026.
ARDXViatris (Nasdaq: VTRS) and unnamed current and former officers are defendants in a Pennsylvania class action over Indore disclosures. Derivative suits name officers and directors in Pennsylvania and Delaware.
VTRSThe Federal Circuit affirmed on July 9, 2026 that the asserted patent claims are invalid. Wyeth, the Pfizer subsidiary and co-plaintiff, had won a $107.5 million jury award against AstraZeneca Pharmaceuticals LP and AstraZeneca AB.
PBYIPuma is suing Hedrick Gardner Kincheloe & Garofalo, L.L.P. and attorney David L. Levy over its defense in the Eshelman case. The Court of Appeals revived the claim on Sept. 3, 2025.
PBYIArcturus filed in the Southern District of California on September 23, 2025. Capstan Therapeutics answered with counterclaims against the company and two employees, and no trial date is set.
ARCTThe 10-Q says the Karam suit against PepGen, its CEO and its CFO was voluntarily dismissed on Nov. 18, 2025. The filing does not name the officers; the 2023 annual report shows McArthur and Donnelly.
PEPGDefendants: Verrica and unnamed current and former officers and directors. A July term sheet would end a case certified in March; Verrica accrued $4.0 million and needs court approval.
VRCABraveheart Bio's final prospectus, dated August 5, 2026, prices 21,250,000 shares at $18.00 each. Net proceeds are estimated at $351.2 million, and the company's accumulated deficit was $80.3 million at March 31, 2026.
BRVEThe April offering sold 6,527,779 shares at $18.00. The interim report does not name the underwriters, and the six-month loss rose to $34,113 thousand.
GHRSOculis sold 2,250,000 shares under its ATM program for CHF 47,775 thousand in the first half of 2026. Cash and cash equivalents fell to CHF 61,614 thousand at June 30, 2026.
OCSNasdaq's August 5, 2026 letter says the Class A ordinary shares closed at $1.00 or more for ten straight business days. The shares stay on the Nasdaq Capital Market.
ZYBTArcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of 2028.
RCUSGILDAZNThe company reported positive 36-week topline results for bempikibart and completed a $200.0 million public offering in July 2026.
QTTBNasdaq's Hearings Panel confirmed on August 4, 2026 that Genprex regained the $1.00 minimum bid price, but the panel keeps jurisdiction until December 7, 2026.
GNPXDermata Therapeutics expects its first commercial product, Tome Foundational Treatment, to be available for sale starting August 25, 2026. The set of four once-weekly treatments sells for $178, about $45 per treatment.
DRMAEton (Nasdaq: ETON) signed a license agreement for ASN-001, a late-stage infantile hemangioma gel. It owes milestone payments after FDA approval and tiered royalties of 10% to 15% on net sales.
ETONNasdaq gave Vistagen until February 1, 2027 to restore a $1.00 minimum bid, while its 10-K says its lead Phase 3 study missed the primary endpoint. It used $42.1 million in operations in its last fiscal year.
VTGNThe 10-Q names Perrigo, CFO Eduardo Bezerra and former CEOs Patrick Lockwood-Taylor and Murray Kessler in French v. Perrigo. A Teamsters pension fund is lead plaintiff and filed an amended complaint on May 1, 2026.
PRGOBioAge Labs' 10-Q says a federal court dismissed the IPO securities class action with prejudice on March 2, 2026, and the plaintiff has appealed to the Ninth Circuit. The defendants are BioAge, its directors and certain officers, and the filings do not name the officers.
BIOAGeron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss.
GERNThe Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000.
CNTXAcadia is the plaintiff against Aurobindo, MSN, Teva and Zydus entities. A June 2025 judgment for Acadia is on appeal, and a new Zydus case goes to trial November 2, 2026.
ACADMirum, Satiogen and Shire Human Genetic Therapies are plaintiffs in four consolidated cases. A 30-month FDA stay runs through March 29, 2029, and the Markman hearing is April 21, 2027.
MIRMA $191.3 million non-cash impairment charge drove the loss. The company expects annualized savings of approximately $40 million from the restructuring.
EBSFaeth reported a net loss of $16.0 million for the quarter ended June 30, 2026, and said topline data from its Phase 2 PIK-201 trial in endometrial cancer are expected by year-end.
FTH60 Degrees sold shares at $1.74 for approximately $1.0 million gross, with H.C. Wainwright & Co. as exclusive placement agent, after its annual report carried a going-concern warning.
SXTPCAMP4 Therapeutics sold 10,756,498 shares and pre-funded warrants for 21,925,368 shares on August 3, 2026, after the trigger for the second closing was satisfied.
CAMPNiagen and its ChromaDex subsidiary are sued in two consumer class actions and a Thorne patent case. A Federal Circuit ruling on a $9.2 million fee award to Elysium is pending.
NAGEIonis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025.
ARWRThomas and Kent v. Reneo name Reneo and unnamed individual defendants. The 10-Q says plaintiffs have not pursued the claims; the 2024 proxy lists Reneo's board.
OKURThe company says it is no longer subject to a Form S-3 sales limit. It had not sold any Class A shares under the program as of August 4, 2026.
OKURTyra Biosciences has sold the full $150,000,000 under its May 2025 at-the-market agreement and has raised the ceiling to $250,000,000. The filing also shows a 2025 net loss of $119.9 million and cash used in operations of $95.1 million.
TYRAThe agreement allows up to $25 million of Series D convertible preferred stock, and the first tranche closed July 31, 2026.
ALZNOPKO Health, a longtime shareholder, buys 5,474,053 shares at $0.9134 each in a private placement with no warrants attached.
COCPOPKNYSE Regulation confirmed that AEON resolved the stockholders' equity deficiencies it had reported, after an offering that closed on July 15, 2026. The company expects the below-compliance indicator to be removed from its trading symbol.
AEONSupernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026.
SUPNINDVAmneal's subsidiary converted $2.039 billion of term loans into new loans with a lower interest margin and added a $45.2 million term loan. The company estimates about $12 million of annual cash interest savings, and the maturity stays at August 1, 2032.
AMRXKuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders.
LSTASage Chemical and TruPharma sued Supernus, Britannia, US WorldMeds and others in Delaware. Four individuals were dismissed in 2024. Insurance coverage suits tied to an unnamed Delaware action are open.
SUPNEyePoint, Inc. sued Ocular in Massachusetts state court on March 20, 2026 over alleged false statements about DURAVYU. The court denied a restraining order on April 13 and has not ruled on a preliminary injunction.
OCULStoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million.
STOKAgreements dated July 31, 2026 cover 61,100,000 shares at $0.05 per share. The offering closed on August 3, 2026, and the filing names no underwriter.
HEPACDT Equity and J.J. Astor & Co. signed a second amendment on July 31, 2026 that raised the note's principal to $2,266,650 at 19% interest. Weekly installments of $104,187.65 start August 19, 2026, and the lender may convert part of the balance into common stock.
CDTProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027.
PRPHNasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million.
MIRANasdaq said PDS Biotechnology's common stock closed below $1.00 for 30 consecutive business days. The letter has no immediate effect on its Nasdaq Capital Market listing, and the company names a reverse stock split as one option.
PDSBTeamsters Local 710 leads a consolidated New Jersey class action against Organon and unnamed officers. Two derivative suits are stayed, and a July 6 suit against the board and Sun Pharma entities challenges the merger proxy.
OGNApnimed priced 12,000,000 shares at $16.00 for $192,000,000 before fees. The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus.
APMDNorthwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000.
NWBOPTC reported second quarter 2026 total revenue of $361 million, including $239 million of product revenue, and raised full-year product revenue guidance to $850 to $950 million.
PTCTThe panel's July 29, 2026 decision lets Genprex stay listed on the Nasdaq Capital Market while it keeps a closing bid of at least $1.00 each trading day until December 7, 2026.
GNPXAnnexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval.
ANNXThe Danish investor sold 1.6 million shares in open-market trades at $12.00 to $15.00 and reported 2,086,622 shares left, about 4.9%.
MPLTBristol Myers Squibb's 10-Q says the company and certain Sanofi entities are defendants in a Texas state suit over Plavix labeling, sales and promotion. Arkansas has sued BMS over 340B contract pharmacy policies, and a Celgene securities class action settled with final approval in May 2026.
BMYBristol Myers Squibb's 10-Q says it sued seven generic drugmakers in the U.S. District Court for the District of Delaware over Camzyos patents. The defendants are Aurobindo, Zenara, Micro Labs, Dr. Reddy's, Annora, Apotex and MSN. The filing gives no case numbers, filing dates or rulings.
BMYShares outstanding will drop from 24,787,446 to 1,652,518. The company expects to seek a Nasdaq hearing if it gets a delisting notice.
LEXXThe company sold 21,045,000 shares at $20.50 in July and expanded a loan facility to $400 million as it prepares a possible Duchenne launch.
DYNNasdaq says Traws has until January 25, 2027 to regain compliance with the minimum bid price requirement, and that its listing remains fully effective for now.
TRAWThe combined company would operate as Caldera Therapeutics. A concurrent private placement of approximately $278 million is expected to close alongside the merger, which is expected to close by early 2027.
SYBXProcessa said it acquired Vidya Therapeutics, whose lead asset is the BTK inhibitor VT-7208, alongside a concurrent private placement of approximately $200 million.
PCSAThe company agreed to sell 618,682 units at $2.585 per unit, including shares to its founder, chairman and an officer, and the common warrants need stockholder approval.
HCWBThe board of The Greater Cannabis Company, Inc. named Carlos Septién, Michelle Cervantes Vivanco and Ernesto Gómez Berjón on July 29, 2026, and they join the board after a notice period.
GCANDCelularity (Nasdaq: CELU) was told on July 23, 2026 that its Class A common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its listing, the company says.
CELUEarth Science Tech's board wants a non-binding stockholder signal on a reverse split to meet the bid price test for an uplisting. The company says it is not currently a listed issuer, and the proxy's notice gives no split ratio.
ETSTInventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months.
IVAThe company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year.
LBRXThe securities purchase agreement covers 37,812 shares of Series F convertible preferred stock with an initial conversion price of $0.9767 per share.
ONCOTuHURA Biosciences borrowed $1,500,000 more under its $50 million revolving facility with Parkview Holdings One LLC. The filing gives no interest rate for the draw and flags conflicts of interest tied to the lender.
HURATwo Alkermes subsidiaries filed Hatch-Waxman patent suits in New Jersey and Delaware against Teva Pharmaceuticals, Apotex and MSN entities. FDA approval of each generic application is stayed for up to 30 months.
ALKSValue Drug Company sued Alkermes, Inc. and Alkermes Pharma Ireland Limited in Massachusetts in October 2025. A December 2025 motion to dismiss is the latest step the 10-Q reports.
ALKSBGM Group filed the annual report for the year ended September 30, 2025 on July 21, 2026, and Nasdaq said the filing cured the lapse on July 24. The same report shows a net loss of $19.9 million, up from $1.4 million.
BGMAptevo filed a patent application covering a Nectin-4 x PD-L1 dual-targeting backbone that it says could support radiopharmaceuticals, T-cell engagers and other immune-based approaches.
APVOThe one-for-ten split took effect on July 24, 2026, and the stock trades on NYSE American under APUS on a split-adjusted basis, with par value cut to $0.001.
APUSBTIG, LLC ended the 2020 at-the-market sales agreement with Matinas BioPharma, effective July 23, 2026, and the company says it owes no termination penalties.
MTNBMannKind sold 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88. The company names a $45.0 million contingent value rights payment, triggered by an FDA approval, among the uses of the money.
MNKDNasdaq told Standard BioTools on July 22, 2026 that its shares closed below $1.00 for 30 days. The company has until January 19, 2027 to regain compliance, and its own filing says it cannot be sure it will.
LABNasdaq told Oncolytics its stock closed below $1.00 for 30 consecutive business days. The letter does not change the listing for now, but the company's annual report says its $5.2 million of cash cannot fund planned operations for 12 months, and that doubt about its ability to continue as a going concern is substantial.
ONCYNasdaq staff says the bid price closed below $1.00 for 30 consecutive business days and that FibroBiologics gets no 180-day compliance period after a reverse stock split. The company intends to request a hearing.
FBLGCash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM.
SMMTScancell will acquire Neuphoria in an all-share deal that would create a combined company listed on Nasdaq, alongside a financing of up to $89 million.
NEUPSCLPThe underwriters bought 4,696,102 additional shares on July 23, 2026, for about $1.5 million in gross proceeds. Lake Street Capital Markets, LLC acted as representative of the underwriters.
AEONRainaldi Revocable Trust sued certain current and former Summit directors in Delaware Chancery in 2025, with Summit a nominal defendant. The parties stipulated to dismissal on May 27, 2026.
SMMTChina Pharma Holdings, Inc. priced a registered direct offering of 2.5 million common shares at $2 per share, for gross proceeds of $5 million before placement agent fees and other expenses. FT Global Capital, Inc. is the exclusive placement agent.
CPHIThe collaboration will evaluate ENV-105 with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer involving bone, and the company cites a $570M to $1.3B addressable global market.
KAPAPhio Pharmaceuticals increased its board to six members and appointed R. Todd Plott, M.D., effective July 20, 2026, to serve until the 2026 annual meeting of stockholders.
PHIONasdaq staff confirmed on July 20, 2026 that XTL meets four listing rules. Another equity shortfall within the year would lead to a delist determination.
XTLBA July 2026 corporate presentation says the company targets profitability in 2028, based on malaria prevention sales and a supplemental indication for babesiosis.
SXTPSunshine Biopharma Inc. signed an at-the-market sales agreement with Aegis Capital Corp. under which it may sell up to $4,000,000 of common stock, with Aegis as exclusive sales agent.
SBFMNasdaq told Rockwell Medical on July 16, 2026 that the company had regained compliance with the $1.00 minimum bid price, and closed the matter. The 8-K does not give the closing prices behind that finding.
RMTIHealthy Extracts Inc. issued a one-year promissory note with a principal amount of $258,750 to LABRYS FUND II, L.P. under an agreement dated July 17, 2026. The company received a net amount of $225,000, minus expenses.
HYEXDamora Therapeutics completed its redomestication effective July 16, 2026. Its ordinary shares trade on Nasdaq under a new CUSIP from July 20, 2026.
DMRANasdaq told Daré Bioscience (Nasdaq: DARE) on July 13, 2026 that it no longer meets Listing Rule 5550(b). The company intends to request a hearing, which would stay delisting while the panel decides.
DAREBlossomHill's S-1 leaves the share count, the price range and the proceeds blank. The prospectus also says the auditor's report on the 2025 financial statements carries a going-concern paragraph.
BLSMLatigo Biotherapeutics, Inc. filed a Form S-1 on July 17, 2026. The filing leaves the share count and price range blank, and the auditors have raised going-concern doubt.
LTGOHolders swapped about $23 million of 8.00% notes for about 5.0 million shares and about $23 million in cash. A separate holder converted $10.5 million of notes into about 3.6 million shares.
XERSAjay Kumar Dhadha resigned as chairman effective June 30, 2026. Guy Ofir resigned as chief financial officer and general counsel effective July 16, 2026, and the company appointed Uri Tadelis as CFO.
RAPHThe split takes effect July 17, 2026 and trades on a split-adjusted basis from July 20, reducing outstanding shares to approximately 631,077.
CDTBio-Path reports two small share sales under its Regulation A offering and an advisory engagement to find a buyer, partner or licensor.
BPTHAditxt signed Amendment No. 2 to its secured note purchase agreement with Ignite Proteomics investors on July 16, 2026. The amendment adds an investor, cancels one note and issues two new notes, and leaves the total senior secured principal unchanged.
ADTXArbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026.
ABUSROIVHelus Pharma sold 10,309,280 shares at US$4.85 in an underwritten offering that closed on June 25, 2026. The proceeds are meant partly for a Phase 3 depression program whose data are not due until the fourth quarter.
HELPThe company reports no serious adverse events, defined as Grade 3 or higher, in 13 patients treated with ENV-105 and osimertinib, and says the safety profile supports progression toward an early efficacy readout.
KAPATwo ex vivo human skin studies of ATR-COSF showed deeper protein penetration and higher skin elasticity, according to a July 15, 2026 release. A human study is planned next.
AZTREnsysce Biosciences disclosed in an 8-K that Jeffrey Millard resigned as chief operating officer, effective July 10, 2026, with no reason or successor given.
ENSCDouglas Beck became chief financial officer and treasurer effective July 15, 2026, and serves as principal financial and accounting officer. He is a licensed certified public accountant.
PMHSPrestige Brands, a subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due 2034. The 8-K names no placement agent, underwriter or advisor and does not say how the proceeds will be used. The parent's annual report says Walmart and Amazon were its only customers above 10% of gross revenues during 2026.
PBHBraveheart Bio, Inc. filed a Form S-1 on July 15, 2026 for an initial public offering on The Nasdaq Global Market under the symbol BRVE. The preliminary prospectus leaves the share count and price blank, and names Goldman Sachs & Co. LLC and Jefferies as joint bookrunners.
BRVEProQR is registering 3,030,303 shares for resale by a holder the prospectus calls Ginkgo, issued in April 2026 under a share purchase agreement tied to a services contract. ProQR receives none of the proceeds, and the prospectus gives no per-share price for the shares.
PRQRVogenx filed a Form S-1 on July 15, 2026 for an initial public offering with the share count and price still blank. The filing reports $251 thousand of cash on March 31, 2026, and its financial statements carry going-concern doubt.
VOGXMorgan Stanley, Jefferies, Cantor Fitzgerald and Oppenheimer are the representatives of the underwriters. The offering is expected to close on July 16, 2026.
QTTBThe split, approved by the board on July 2, 2026, moves shares outstanding from 11,108,577 to approximately 504,936, and the company released an investor presentation the same day.
GNPXNextCure (Nasdaq: NXTC) agreed to an all-stock merger with Avere Therapeutics. The 8-K puts pre-merger Avere holders at about 98.11% of the combined company, which would take the Avere Therapeutics name.
NXTCNasdaq said on July 8, 2026 that the matter is closed. The company had been notified of the shortfall on June 18, 2026.
APLMThe company said on July 13, 2026 that its one-for-ten reverse split would take effect on July 24, after a March 2026 target passed without a filing.
APUSMatinas BioPharma agreed to combine with GH Power in a business combination expected to close in the fourth quarter of 2026, and to sell its MAT2203 and LNC business to Azurity Pharmaceuticals for $4.0 million upfront.
MTNBThe offering was priced at $0.3221 per share and accompanying warrants. Lake Street Capital Markets, LLC is sole bookrunner, and Laidlaw & Company (UK) Ltd. is lead manager.
AEONCumberland will pay a $1.50 special dividend and has authorized up to $5 million of buybacks. The board acted after the Apotex sale produced more net cash than the company had projected.
CPIXErasca's final terms are 31,428,572 shares at $17.50, a total of $550,000,010.00, above the $500,000,000 first announced. Its two clinical-stage programs are early, and the annual report shows a net loss of $124.5 million for 2025.
ERASCitizens JMP Securities, LLC may sell up to $5,575,709 of Traws common stock under a July 10, 2026 prospectus supplement, the amount the company's current baby shelf limit allows.
TRAWThe board adopted a rights plan on July 10, 2026 and declared a dividend of one right per share, payable to stockholders of record on July 21, 2026.
REVBSilo agreed to sell 619,965 shares and warrants at $6.452 per share, with H.C. Wainwright & Co. as exclusive placement agent. The company expects about $4 million upfront.
SILOThe third-generation Voyager series raises standard usable storage to 2.025 MWh on the Eagle and Falcon and to 1.0 MWh on the Hawk, with power ratings and footprint unchanged.
NMADThe buyer is American Type Culture Collection, Inc., and the company expects the sale to close in the third fiscal quarter of 2026, subject to closing conditions.
ISCOCue will sell 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for gross proceeds of about $50.0 million. Cormorant Asset Management led. The 8-K also reports RSU grants to officers and directors.
CUEApnimed, Inc. filed a Form S-1 with a preliminary prospectus dated July 10, 2026. The cover leaves the share count and price range blank, and the company has no approved drug yet.
APMDCue Biopharma is selling 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for about $50.0 million in gross proceeds. Its release says the lead candidate is advancing toward Phase 1, while its annual report calls that candidate preclinical.
CUECanaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible book value at $0.97 a share against a $3.37 reference price.
NAGEAll active patients in both Part 3 cohorts of the DA-1726 obesity study reached target doses of 48 mg and 64 mg, and topline data remains on track for the fourth quarter of 2026.
MTVAZyVersa said a director has resigned and that it is considering cost reductions, pay cuts for two officers and possible sales of its VAR 200 or IC 100 candidates while it seeks to raise capital.
ZVSAEvofem issued a $706,304 subordinated note to HUB Cyber Security, Ltd. The 12% note matures eleven months after July 8, 2026, and accrues a $2,000 weekly monitoring fee plus a one-time administration fee of $14,126.
EVFMEvommune's chief financial officer disclosed a purchase that matches a May sale under the short-swing rule, and agreed to pay the company $10,160.
EVMNSpain's AEMPS cleared the Phase 2a study of more frequent VCN-01 dosing in first-line metastatic pancreatic cancer.
TOVXSemnur, a majority-owned subsidiary of Scilex, said iHolding Group LLP would buy $100,000,000 of newly issued common stock at an expected $10.00 per share. The proposal remains subject to due diligence and definitive agreements.
SMNRBora Pharmaceuticals and Bora Biologics USA paid $122.5 million, before transaction fees and expenses, for MacroGenics' GMP manufacturing operations. The sale closed effective June 30, 2026 and is subject to post-closing adjustments.
MGNXBora Pharmaceuticals took over MacroGenics' Rockville manufacturing site and hired about 140 former employees. The $122.5 million price is before fees, and the 8-K says extra post-closing payments may not be earned or received.
MGNXThe Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date.
BTAIQOragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026. The company's June 29, 2026 annual meeting included a vote on authority for a reverse stock split of one-for-two to one-for-fifty.
OGENFour directors were elected effective July 1, 2026, George Hornig became executive chairman and Terrence M. Tierney became interim chief executive officer. The annual evergreen increase falls from 10% to 3%.
PMHSThe company's subsidiary drew $95,000,000 on July 1, 2026. The 8-K also notes a $400,000,000 private offering of senior unsecured notes due 2034 whose pricing a July 6, 2026 press release announced.
PBHNuvation Bio issued $37.5 million more of its 0.75% convertible senior notes due 2032 on July 6, 2026, after underwriters exercised their option in full. The offering now totals $287.5 million, with estimated net proceeds of about $277.6 million, and the notes can be settled in cash, shares or both at the company's choice.
NUVBShareholders approved the second tranche on June 18, 2026, and the investor now holds a $2.875 million note convertible at 93% of recent trading prices.
GELSThe index change took effect after the U.S. market close on June 26, 2026. A Form F-3 filed on July 13, 2026 replaces an older shelf and includes a $50,000,000 at-the-market program.
HYFTThe CEO and the principal financial officer paid for the shares by cancelling amounts the company owed them, including personal cash advances. IGC Pharma paid no cash.
IGCNuvation Bio's underwriters exercised in full an option for $37.5 million more of 0.75% convertible senior notes due 2032, lifting the offering to $287.5 million. Net proceeds are estimated at $277.6 million, and the capped calls bought with them cost about $2.2 million.
NUVBMetaVia filed a prospectus supplement for up to $4,000,000 of common stock under its at-the-market sales agreement with Ladenburg Thalmann & Co. Inc., dated November 6, 2025.
MTVALIXTE is issuing 2,992,041 common shares and 50,366.07 Series D preferred shares to NOMAD stockholders, and has changed its name to NOMAD Power Solutions effective July 3, 2026.
NMADThe July 2026 investor presentation describes a formal asset search after a $22.5 million financing and a leadership rebuild.
CNSPOmeros expects to close a $16.0 million principal repurchase of its 9.50% convertible notes due 2029, and agreed to buy up to $14.5 million more. The repurchases would leave about $40.3 million of notes outstanding, and the company may replace the cash with debt that is not convertible into equity.
OMERArdelyx received the funds on June 29, 2026 under its 2022 loan and security agreement. The loan bears interest of 4.55% plus the greater of 1-month SOFR or 3.5%, with interest-only payments until July 1, 2030.
ARDXPyxis Oncology agreed to sell 19,600,153 shares at $2.551 and warrants at $3.289 to investors led by BVF Partners L.P. The press release says the upfront money extends cash into the second quarter of 2027, while the company's annual report carried a going-concern warning and said cash would fund operations only into the fourth quarter of 2026.
PYXSThe company signed an Open Market Sale Agreement with Jefferies LLC on July 2, 2026. Jefferies is entitled to a commission of up to 3.0% of gross sales.
ENTAThe $4,000,000.00 PNC line now runs to April 14, 2027, and a new Convertible ELOC of up to $250,000.00 replaces a matured $500,000.00 equipment note.
INBPThe 7% preferred converts at $137.79 a share and is aimed at supporting present and upcoming launches. $933.9 million was funded at close.
BBIODanina Fisher and Gary S. Stetz, II joined the board on July 1, 2026. The filing notes that Mr. Stetz is the son of Gary Stetz, the interim chief executive.
HEPAViatris signed a ¥40,000,000,000 senior unsecured term loan with Mizuho Bank, Ltd. as administrative agent. The proceeds may repay a 2021 loan of the same size, and the company reported a net loss of $3.51 billion for 2025.
VTRSCadrenal (Nasdaq: CVKD) received gross proceeds of approximately $3.0 million from one institutional investor. Warrants could add about $5.8 million if exercised in full for cash, the company says.
CVKDCumberland sold six branded products for $100 million in cash and repaid about $5.3 million owed to Pinnacle Bank. It kept ifetroban, whose data so far come from early-stage studies, and its filings do not split out revenue for the products it sold.
CPIXApotex paid $100 million in cash to close the branded-products deal after shareholders approved it. Cumberland now says it will focus on ifetroban, but its release gives no trial figures for any of the programs.
CPIXAptevo was awarded a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, its nectin-4-targeted trispecific candidate.
APVOThe amendment moves the maturity of $410,000 in notes from June 30 to August 14, 2026, raises the rate to 17% from July 1 and requires extension shares.
BSPKThe company says both Annamycin arms showed favorable efficacy trends against the control arm in relapsed or refractory AML, on a full intent-to-treat basis.
MBRXTuHURA Biosciences drew an additional $1,900,000 under its revolving credit facility with Parkview Holdings One LLC. The facility matures April 21, 2031 and allows up to $50 million in borrowing, and the filing does not describe its interest rate or collateral.
HURAThe company calls it a line of credit backed by UK tax credits. It drew $1.6 million first, mainly for OST-HER2 manufacturing.
OSTXJ.J. Astor & Co. is the lender on a senior secured convertible note with a principal amount of $1,971,000, amended on June 30, 2026. The company receives $1,460,000 in two tranches, and repays the loan in weekly installments of $82,125 starting July 10, 2026.
CDTA Nasdaq Hearings Panel found HCW Biologics (Nasdaq: HCWB) back in compliance with the minimum bid price rule. The company faces a mandatory panel monitor and will effect a one-for-six reverse stock split on June 30, 2026.
HCWBAbivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results.
ABVXAlaunos says a body-fat-adjusted analysis of liver weight in a 48-day mouse study supports further preclinical work on ALN1003.
TCRTTrafalgar Asset Management, LLC bought all the Series A and Series B preferred stock on June 29, 2026, and certain company debts were settled and canceled the same day.
GCANDCelularity signed a $1,000,000 secured loan with the Philip & Daniele Barach Family Trust at 4.0%. The loan matures at the earlier of 30 days after closing or receipt of certain financing proceeds, and it rises to 18.0% after a default.
CELUArdelyx drew a $50.0 million Term F Loan from SLR Investment Corp. on June 29, 2026. The loan matures July 1, 2030 at 4.55% plus the greater of 1-month SOFR or 3.5%, and in a default the agent can reach the company's cash.
ARDXRockwell Medical's one-for-ten reverse split takes effect at 12:01 a.m. Eastern Time on July 1, 2026. The certificate was filed June 24, and the company says fractional shares will be paid in cash at the June 30 closing price, adjusted by the company.
RMTIZymeworks will pay $17.00 per share in cash, financed mainly by a $350 million non-recourse note from OMERS Life Sciences. The release says 75% of the YUPELRI profit-share cash flows are assigned to OMERS to service the note.
ZYMESoligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,500,000.
SNGXNYSE American says Matinas BioPharma fell short of two stockholders' equity standards and accepted its compliance plan, with a plan period through October 2, 2027.
MTNBALX Oncology borrowed $10,000,000 at closing from HSBC Ventures USA and used it to refinance its Oxford Finance and Silicon Valley Bank loan. The facility can reach $50,000,000, but $10,000,000 of that is uncommitted and the rest depends on draw dates and milestones.
ALXOA First Amendment to the Hercules loan splits the remaining $50,000,000 tranche and extends later draw deadlines into 2027 and 2028.
IRONNuvation Bio plans $200.0 million of notes due 2032 and expects to use the proceeds to repay its senior secured loan and pay for capped calls. The rate and conversion price are not set until pricing.
NUVBLigand closed $700.0 million of 0.00% convertible senior notes due 2031 after the initial purchasers exercised their option in full. Net proceeds were approximately $678.2 million, with about $72.9 million going to note hedges and approximately $60 million to a share repurchase. The initial conversion price is approximately $334.27 per share.
LGNDThe amended agreements raise change-in-control severance and set a three-year initial term, and the board amended the bylaws on proxy nominations, the definition of Cause and emergency succession.
REVBInvestors agreed to buy 18,673,429 units at $0.8033 or $0.8032. Series A and B warrants could add up to approximately $34 million if fully exercised for cash. Closing is expected on or about June 25, 2026.
CALCThe FDA conditionally accepted QYLEKI as the proposed brand name for QRX003 in Netherton Syndrome, and the company says a pivotal Phase 3 study is expected to start in the second half of 2026.
QNRXDr. Corsee Sanders, a former Genentech/Roche and Celgene executive, joined the board as an independent director effective June 17, 2026.
CLDILEGNRAREAvenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00.
CALCBoundless Bio agreed to an all-stock merger with privately held Serapha Bio and said it would cut about 75% of its workforce. After closing, Boundless holders would own about 3.69% of the combined company, and most of the early data behind the deal come from a trial in Shanghai.
BOLDTraws says MHRA feedback has led it to add preclinical safety information to the tivoxavir marboxil data package, which it expects to resubmit in the third quarter of 2026.
TRAWThe Canadian Intellectual Property Office issued a notice of allowance for a patent covering REQORSA with PD-1 or PD-L1 antibodies in lung cancer.
GNPXLigand plans a private offering of $550.0 million of notes due 2031 to fund note hedges, a repurchase of up to $75 million of stock and general purposes, including a pending deal for Xoma Royalty Corporation.
LGNDAditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The filing does not name the investors.
ADTXStockholders approved raising authorized common stock from 350,000,000 to 500,000,000 at a June 17, 2026 meeting, with 88,853,129 votes against. The 8-K does not say how many shares are outstanding or planned for issue.
AKBAStockholders voted on June 17, 2026 to raise authorized common stock from 300,000,000 to 600,000,000 shares. The 8-K does not say what the company plans to do with the extra shares.
CTMXDefinium sold 20,588,236 common shares at $34.00, or $700,000,024 before discounts, on the same day it reported that its Emerge depression trial met its primary endpoint. The prospectus supplement names eight underwriters, and its underwriting terms name no counsel.
DFTXThe annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026.
ELDNProvectus holders authorized a reverse split of between 1-for-10 and 1-for-50, with the ratio left to the board, and a matching cut in authorized shares. The company had $251,291 of cash at December 31, 2025, and its net loss widened to $5.4 million.
PVCTuniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch.
QUREPetros appointed Robert Weinstein as chief accounting officer and principal financial officer on June 18, 2026, the day it separated Mitchell Arnold from his finance roles.
PTPINasdaq told Silo it regained compliance with the minimum closing bid price requirement as of June 17, 2026, and the matter is now closed.
SILOKIO-300 significantly suppressed seizure-associated activity in an ex vivo mouse temporal lobe epilepsy model, Kiora said. The poster was presented at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026.
KPRXThe loan funds long-lead components and working capital ahead of an acquisition that the companies expect to close on or about July 1, 2026.
NMADThe FDA granted orphan drug designation to GRI-0621 for idiopathic pulmonary fibrosis, a designation that could bring seven years of U.S. market exclusivity if the drug is approved.
GRIPTC Therapeutics sold $550,000,000 of 0.0% convertible senior notes due 2031 through Morgan Stanley & Co. LLC as representative of the initial purchasers. The initial conversion price is about $107.48 a share.
PTCTViatris completed a €650,000,000 offering of 4.250% senior notes due 2033 on June 17, 2026. The proceeds first repay June revolver borrowings used to pay off $1.675 billion of 2026 notes, and the company reported a 2025 net loss of $3.51 billion. The 8-K names no underwriter.
VTRSKardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern.
KARDThe Standby Equity Purchase Agreement lets PRF sell up to $15.0 million of shares over 36 months at 97% of recent prices. Its 2026 going-concern paragraph and $3.1 million year-end cash sit beside the new line.
PRFXRedhill Biopharma agreed on June 18, 2026 to sell 8,571,429 ADSs at $0.70 each with two series of warrants. The upfront money is about $6 million, and the warrants add about $13.4 million only if they are exercised for cash, which the company says is not assured.
RDHLThe annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor.
XNCRProtoKinetix appointed Keith Brunt as a director and president and added Michael Jones and Jason Lamp to its board on June 17, 2026, after a March 31, 2026 resignation.
PKTXIn a letter to shareholders issued June 17, 2026, CEO Francisco Salva said the company will redirect funds from ATR-12 enrollment to a filaggrin cosmetic ingredient and recombinant protein work.
AZTRJaguar Health's monthly royalty minimums of $750,000.00 now start October 1, 2026 under both royalty interests, and a Streeterville note matures October 1, 2026 instead of July 1. Streeterville also received common stock for Series Q preferred shares.
JAGXOmeros agreed to repurchase up to about $16.0 million of 9.50% convertible notes due 2029 for a total of up to about $34.0 million. The final price depends on the stock's trading in an averaging period that began June 18, 2026.
OMERGossamer Bio's exchange of 2027 convertible notes drew $181,052,000 of tenders, and $18,948,000 of the old notes remain outstanding under a supplemental indenture that strips most covenants. The new notes are secured first-lien debt.
GOSSThe license for VEPPANU (vepdegestrant) became effective after the Hart-Scott-Rodino waiting period ended early. Rigel paid the licensors, Arvinas and Pfizer, a one-time upfront payment of $70.0 million.
RIGLOutstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT.
LABTThe offering totals $225,995,000 before underwriting discounts. Underwriters hold a 30-day option for 1,155,000 more ADSs, and closing was expected on June 23, 2026. The shares priced below the last sale price of $33.52.
LEGNRigel paid the licensors a one-time upfront payment of $70.0 million after the antitrust waiting period ended early. The 8-K describes no milestones, royalties or clinical details for the drug.
RIGLDyne Therapeutics' Hercules facility now totals up to $400.0 million, with $200.0 million outstanding after a $50.0 million draw on June 16, 2026. Hercules Capital, Inc. is administrative agent and collateral agent for the lenders.
DYNPrestige Consumer Healthcare (NYSE: PBH) completed the Breathe Right purchase for $1.045 billion in cash and entered a Term Loan Credit Agreement. It also raised its asset-based revolver commitments to $225 million.
PBHPolomar and Altanine terminated their merger agreement as of June 12, 2026, and ended a related patent license. Polomar has until September 7, 2026, to sell remaining inventory under that license.
PMHSPDS Biotechnology's $6,000,000 note carries a 10% rate, a warrant for 2,158,274 shares and a twelve-month term. Yorkville Securities, an affiliate of the investor, is one of two sales agents for a $50,000,000 at-the-market program.
PDSBHolders cast 16,993,038 votes for the reverse split and 6,597,036 against it at the June 12, 2026 annual meeting. The 8-K reports the result but gives no split ratio and no effective date.
RMTITraws says a negative review by the UK regulator has deferred its planned Phase 2a influenza challenge study, and that it is advancing backup influenza compounds.
TRAWA June 10, 2026 Nasdaq letter said Genprex would be delisted unless it requested a hearing, because its stock closed under $1.00 for 30 consecutive business days and it had a reverse split on October 21, 2025.
GNPXA bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026.
LIPOViatris is offering €650,000,000 of 4.250% senior notes due 2033 to repay revolving credit borrowings drawn to retire its 2026 notes. Its 2025 net loss was $3.51 billion.
VTRSClearmind Medicine will issue $1,000,000 of convertible notes for $900,000 in cash, under a one-time exception to its own $2,500,000 quarterly limit. The agreement also amends the conversion price and sets a $1.875 floor price per share.
CMNDRocket received $180.0 million in gross proceeds from a large pharmaceutical company. It says pro forma cash of approximately $322.6 million should fund operations into the second quarter of 2028.
RCKTNasdaq told Soligenix on June 10, 2026 that its stock has closed below the $1.00 minimum bid price, and the company has until December 7, 2026 to regain compliance. Its board then ended the HyBryte development program, after an interim analysis in a Phase 3 trial recommended stopping it for futility.
SNGXNasdaq told Celularity on June 9, 2026 that its market value of listed securities was below the $35 million minimum for 30 consecutive business days. The notice does not delist the stock.
CELUAnnexon's stockholders approved raising authorized common stock from 300,000,000 to 500,000,000 shares on June 11, 2026, with 8,795,454 abstentions and no reason given for the increase.
ANNXClinical Cancer Research published the Phase 1 study of VCN-01 with durvalumab in patients whose cancer was refractory to immunotherapy.
TOVXThe deal adds AT177, a colon-targeted AhR agonist for ulcerative colitis, to Adial's pipeline, with about $32 million in initial gross proceeds and up to $32 million more tied to Phase 1 initiation.
ADILCDT Equity agreed to pay off its Alliance Global Partners and Ascent Partners loans and signed a loan of up to $1,460,000 with JJ Astor & Co, which it says is now its only loan facility. Its 2025 net loss was $39.2 million.
CDTXeris will retire about $23 million of its 8.00% convertible notes due 2028 for about $23 million in cash plus common stock, with Morgan Stanley as placement agent. About $10.5 million of the notes will remain outstanding.
XERSParabilis Medicines (Nasdaq: PBLS) sold shares to Regeneron at 90% of the $20.00 IPO price under a Stock Purchase Agreement dated June 9, 2026. The placement closed June 11, 2026.
PBLSThe final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June 15, 2026.
ELVNVeraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million.
VRXAParabilis Medicines priced 33,500,000 shares at $20.00 each, and Regeneron agreed to buy $75.0 million of stock at 90% of the IPO price, as the company's net loss reached $145,889 thousand in 2025.
PBLSAditxt, Inc. signed a definitive business combination agreement for Ignite Proteomics, LLC, its 100%-owned subsidiary, at an implied equity value of approximately $150 million. Ignite would become an independent public company through a newly formed holding company.
ADTXAn 8-K filed June 9, 2026 sets out the offer letter for the new chief executive, who replaces two co-chief executives.
COCPThe prospectus supplement adds $2,425,000 of common stock to an at-the-market agreement with H.C. Wainwright & Co., LLC, following $4,483,711.04 already sold under it.
ENVBBGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000. The private placement closed on June 8, 2026.
BGMAt its June 8, 2026 annual meeting, MetaVia stockholders approved a reverse split of 5 to 22 shares into one, with the ratio left to the board, and 200,000 more shares for the equity plan.
MTVAAlethia Young resigned from the PTC Therapeutics board effective June 8, 2026, and will remain an advisor under a consulting agreement running through June 8, 2027.
PTCTSavara stockholders approved doubling authorized common stock to 600,000,000 shares. The 8-K gives no reason for the increase, and it also reports a new CFO and COO effective July 15, 2026, after the current CFO resigns for health reasons.
SVRAToo few shares were present for the June 5, 2026 special meeting on share issuance for warrants, and the company must call another meeting.
TOVXThe board approved restricted share awards on June 5, 2026, to the chairman, two directors and the president and chief commercial officer.
PTPIIGC Pharma has extended its $12,000,000 bank facility with O-Bank, and the facility fee rises from $48,000 to $60,000. The filing gives no amount drawn and no interest rate.
IGCKairos Pharma has signed a term sheet to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor, from privately held Celyn Therapeutics, Inc., and has listed the milestones it expects for the rest of 2026.
KAPAIMUNON has sold $10 million of preferred stock and two secured notes to Streeterville Capital, with half placed in a collateral account, to fund its Phase 3 OVATION 3 trial. The company used $13.9 million in operations in 2025.
IMNNSyndax Pharmaceuticals agreed on June 3, 2026 to issue $250.0 million of 2.25% convertible notes due 2031 in a private placement, with about $243 million of net proceeds expected. J. Wood Capital Advisors LLC is the sole placement agent, and the company's 2025 net loss was $285.4 million.
SNDXThe restructuring follows the discontinuation of pociredir for sickle cell disease and carries expected charges of approximately $4.2 million. Leerink Partners LLC is advising the board.
FULCThe amended 2024 plan also drops a cap on its annual share increase. The vote came at the June 3, 2026 annual meeting.
OKURSyndax estimates net proceeds of about $243 million from the notes after the placement agent's fees and expenses. The 2.25% notes mature on June 15, 2031, and the conversion price is about $24.76 per share.
SNDXTrevi stockholders voted to double authorized common stock to 400,000,000 shares and to add 8,000,000 shares to the stock incentive plan. The lead cough drug has no Phase 3 results yet, and the 2025 net loss was $42.8 million.
TRVIAt its June 3, 2026 annual meeting, Minerva's stockholders approved two charter amendments, and the board adopted amended bylaws the same day.
NERVThe antiviral developer names a former biopharma chief executive with 23 product launches to lead the company, effective immediately.
COCPAditxt has issued senior secured convertible notes that combine about $725,000 in new cash with earlier notes consolidated into them, at a 35% original issue discount. The company held $268,852 in cash at March 31, 2026.
ADTXGossamer Bio says holders of 90.526% of its 2027 convertible notes tendered early, and the company expects to issue $65,174,000 of new 7.50% secured convertible notes due 2030 at early settlement. The exchange also strips most covenants from the old indenture.
GOSSBriaCell sold 1,449,300 common shares at $3.25 in a best efforts offering for gross proceeds of $4.71 million. ThinkEquity LLC was sole placement agent, with a 7.5% cash fee and warrants for 72,465 shares, and the company's 10-K carries a going-concern warning.
BCTXMineralys sold 5,660,378 shares at $26.50, below the $28.85 last sale on June 2, 2026. The proceeds fund part of a $200.0 million upfront payment to buy back a royalty owed to Tanabe Pharma Corporation.
MLYSMineralys can draw $100.0 million at closing on a $500.0 million loan, while the next $150.0 million depends on FDA approval of lorundrostat, and it owes Tanabe a $200.0 million cash payment.
MLYSA new credit agreement refinances a 2020 facility, with BSP Agency, LLC as administrative and collateral agent.
MRVIThe court ruled June 1, 2026 in Heron's patent suit against Azurity Pharmaceuticals and Slayback Pharma entities. Heron says it will appeal to the Federal Circuit and that the ruling does not affect a prior settlement.
HRTXThe Nevada certificate took effect on June 2, 2026, and shares began trading split-adjusted on Nasdaq on June 3. The ticker stays SILO under a new CUSIP number.
SILOThe notes carry a $1,500,000 principal amount and a cash purchase price of 90% of principal. The sale falls under an investor agreement amended in April 2026.
CMNDFulcrum ends pociredir, its lead sickle cell program, after FDA concerns about malignancy risk, and sets no timeline for its strategic review. It reported $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026.
FULCThe 8-K reports the May 28, 2026 annual meeting vote counts, including a reverse split ratio of 1-for-5 to 1-for-15 set at the Board's discretion.
ENVBSoligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,956,000.
SNGXVyome reported a net loss attributable to common shareholders of approximately $963,000 for the quarter ended March 31, 2026, and cash of approximately $8.8 million, while announcing an in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise.
HINDThe company did not file its quarterly report for the period ended March 31, 2026 on time, and it has until July 20, 2026 to submit a plan to regain compliance.
CDTPrices ran from $3.70 to $4.10 a share depending on commitment size. MStone Partners, the largest holder, bought $360,000 of stock.
PLYXRoyalty Pharma signed a $1.8 billion unsecured revolving credit facility maturing May 22, 2031, and repaid its 2021 facility in full. The covenants cap funded debt at 4.00 times Adjusted EBITDA, and the exhibit names a different borrower from the 8-K.
RPRXSol-Gel's first-quarter 2026 report shows $52.8 million in cash and securities at March 31 after a March offering of about $33.1 million, with revenue of $0.1 million and a net loss of $3.7 million. The company says the funds support operations into 2028.
SLGLTraws says a proprietary combination antiviral may have activity against hantavirus, Ebola and Lassa, and that it plans to work with the U.S. CDC and regional regulators in Africa.
TRAWIn a late-breaking poster at the EASL Congress 2026, the company reported a 9.1% mean body-weight reduction at Day 54 in the 48 mg cohort, with no serious adverse events up to that dose.
MTVAAptevo and Niowave agreed to a 50/50 collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment at closing.
APVOMinerva signed a sales agreement with Leerink Partners LLC for up to $75.0 million of common stock, and its filing also says the roluperidone Phase 3 relapse phase now runs 52 weeks.
NERVAditxt, Inc. received a Nasdaq letter on May 27, 2026 citing stockholders' equity of $(35,174,386) for the period ended March 31, 2026. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 11, 2026.
ADTXAt its May 27, 2026 annual meeting, Dermata Therapeutics shareholders approved raising the share reserve of its 2021 equity plan to 402,214 shares and repricing warrants for up to 120,734 shares. Three Class II directors were elected.
DRMAThe lender paid $12 million at closing and deposited $10 million in a subsidiary's account under a deposit account control agreement. The notes carry monthly cash redemptions and trigger-based increases.
MDCXAlaunos says early, non-GLP mouse data for ALN1003 span weight, insulin resistance, adipose signaling and liver pathology.
TCRTA Genprex-supported abstract at the 2026 ASCO Annual Meeting linked Trop-2 and PTEN protein levels to progression-free survival in non-small cell lung cancer, but not in small cell lung cancer.
GNPXThe company says its novel direct-acting antivirals show pan-viral activity in early in vitro work against hantavirus, bunyavirus and influenza.
COCPEric Sherb resigned as chief financial officer on May 26, 2026. Dr. Narasimhan Mani, already a director and Co-Chief Executive Officer, took the interim role the same day.
SCNXThe company canceled a previously approved 1-30 reverse split and its board approved a digital asset treasury and a share of a court judgment held by its chief executive.
BPTHThe $50 million revolving facility from Parkview Holdings One LLC matures in April 2031. The company expects to use the first draw for general corporate purposes.
HURAKardigan filed an S-1 for an IPO that would list on the Nasdaq Global Market as KARD. The filing leaves the share count and price range blank, reports $287.1 million of cash and investments, and still says there is substantial doubt about its ability to continue as a going concern.
KARDCartesian drew $50.0 million at closing under a senior secured loan that can reach $150.0 million, with the lenders able to convert up to $15.0 million into common stock at $8.2526 a share. The loan carries a minimum cash covenant starting April 1, 2027, and the 8-K does not name the individual lenders.
RNACNasdaq said Ensysce Biosciences must submit a plan by July 6, 2026, to regain compliance with its $2.5 million stockholders' equity requirement, or face delisting.
ENSCThe loans carry a variable rate of at least 8.95% and mature on June 1, 2030. Only the first $50.0 million was funded at closing, and the two later tranches depend on milestones.
RNACNasdaq told TransCode on May 19, 2026 that its stockholders' equity of $1,251,427 is below the $2,500,000 minimum. The company has until July 3, 2026 to submit a plan to regain compliance, and its equity had been $10,335,466 at December 31, 2025.
RNAZTempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning.
TPSTThe company priced 2,846,975 units at $1.405 each to a group of healthcare investors, and the warrants are exercisable at $1.28 per share.
HCWBThe F-3 caps the Wainwright ATM at $824,331 because the public float is below $75.0 million. The filing puts the float at $4.9 million, and the ADS last traded at $3.78 on May 18, 2026.
PPBTInMed and privately held Mentari Therapeutics signed a definitive merger agreement, alongside a concurrent US$290 million private placement for the combined company.
INMThe Board fixed the ratio under a stockholder authority approved April 30, 2026, to help keep the stock above Nasdaq's $1.00 minimum bid price.
ONCOThe split is part of the company's plan to regain compliance with Nasdaq's minimum bid price rule. Issued shares fall from 10,190,337 to about 1,019,033.
CMNDAuthorized common stock rises from 115,000,000 to 215,000,000 shares, against 103,882,937 shares outstanding at the March 25, 2026 record date.
LRMRParabilis Medicines filed its IPO registration on May 19, 2026, with a $75.0 million Regeneron private placement tied to a collaboration, while its net loss grew to $145,889 thousand in 2025.
PBLSRegencell Bioscience agreed on May 19, 2026 to sell 985,222 ordinary shares at $20.30 each in a registered direct offering, about $20.0 million gross. Univest Securities, LLC is the sole placement agent and is also buying shares for its own account.
RGCThree posters, one on DA-1726 and two on vanoglipel, were accepted for the American Diabetes Association Scientific Sessions in New Orleans, June 5 to 8, 2026.
MTVAAlaunos reported non-GLP mouse data for ALN1003 on insulin resistance, adipose signaling and liver histology, and said its cash runway extends into the second quarter of 2026.
TCRTNet sales were $0.9 million, up from $0.8 million a year earlier. The CEO said the company looks forward to non-dilutive capital from ex-U.S. partnerships in 2026.
EVFMRevenue rose 449% from a year earlier on more Arbli orders. The company also reported $11.0 million of non-dilutive debt financing.
SCNXThe reasonable best efforts offering of 12,000,000 common units at $0.50 per unit is expected to close on or about May 19, 2026, with Aegis Capital Corp. as exclusive placement agent.
SBFMThe offer would swap $200 million of 2027 notes for new 7.50% secured convertible notes due 2030, plus shares or prefunded warrants.
GOSSPalatin will switch from NYSE American to the Nasdaq Capital Market, with its last NYSE American trading day on May 28, 2026. The move needs no shareholder action, but the company's annual report carries a going-concern warning.
PTNAkari Therapeutics says its quarterly report for the period ended March 31, 2026 will be late, partly because of work on an upcoming public offering. It also expects a material non-cash impairment charge, and its March 2026 annual report carried a going-concern paragraph.
AKTXNervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding.
NGENHealthy Extracts Inc. acquired 100% of Adli Gummies Inc. under an agreement dated May 15, 2026. It issued secured promissory notes of $165,000 and $629,000 and shares equal to approximately 17.76% of its outstanding common stock.
HYEXTraws reports a net loss of $7.1 million for the quarter ended March 31, 2026, and says its private financing of up to $60 million supports operations into the first quarter of 2027.
TRAWThe company said the FDA accepted its IGALMI at-home sNDA with a November 14, 2026 PDUFA date, and that it is reviewing strategic options. First quarter net loss was $12.7 million.
BTAIQNet revenues fell to $2.0 million as U.S. sales dropped 33%. The company reported a net loss of $3.3 million and cash of $1.1 million at March 31, 2026.
EMMAThe company reported cash-on-hand of $4.9 million at March 31, 2026, and a cash balance of approximately $10.3 million as of May 15, 2026.
ENVBEnsysce Biosciences reported first quarter 2026 results, said its PF614-301 Phase 3 trial reached 50% of its interim enrollment target, and began a review of strategic alternatives.
ENSCA May 11, 2026 consent and waiver letter sets aside several closing conditions and requires updated audited financial statements. A May 12 amendment cuts the chief executive's base salary to $19,000 a month.
PMHSNasdaq says Skye's stockholders' equity of $9,011,804, reported for the quarter ended March 31, 2026, is below the $10,000,000 Global Market minimum. The company has until June 29, 2026 to submit a plan.
SKYEApimeds (APUS) says it needs more time to finalize financial statements for the quarter ended March 31, 2026 and expects to file within a five-calendar-day extension. Its latest 10-K carries a going concern paragraph.
APUSExicure says it needs more time to finish its quarterly report and expects a net loss of approximately $1,827,911 for the quarter. Cash fell to about $2,504,054 by March 31, 2026, and its 10-K already carried a going-concern warning.
XCUROramed Pharmaceuticals says it needs more time to finish the financial statements for the quarter ended March 31, 2026, and expects to file within five calendar days of the due date. Its 2025 annual report showed a $7,675,000 Scilex note due March 31, 2026, and going-concern warnings at two companies it has invested in.
ORMPOS Therapies will miss the May 15, 2026 deadline for its first-quarter 10-Q and says it expects to file within the five-day extension. The filing comes from a company whose annual report, filed March 31, 2026, carries a going-concern warning and reports $269,830 of cash at year-end.
OSTXRani Therapeutics (Nasdaq: RANI) has until November 9, 2026, to regain bid price compliance. It also reported cash, cash equivalents and marketable securities of $43.4 million and a first quarter net loss of $8.0 million.
RANIABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period.
ABVCCumberland would receive $100 million in cash from Apotex and keep its ifetroban programs. Because Tennessee law may treat the sale as a sale of substantially all of its assets, shareholders are asked to approve it.
CPIXDogwood reported a first quarter net loss of $5.0 million and cash on hand of $13.2 million, which it says runs into the fourth quarter of 2026.
DWTXAditxt, Inc. said it will effect a 1-for-27 reverse split of its common stock at the opening of trading on May 18, 2026. The company says the split is primarily intended to bring it into compliance with Nasdaq's minimum bid price requirement.
ADTXResearch collaborators presented data showing the company's Pdx1 and MafA gene therapy reversed hyperglycemia in a type 2 diabetes mouse model at the 2026 ASGCT Annual Meeting in Boston.
GNPXRevenue rose about 17% to $10.1 million in the first quarter. Nasdaq confirmed on May 6, 2026 that the company had regained compliance with its minimum bid price requirement.
BFRIThe company reported $6.5 million in revenue and net income of $3.5 million for the quarter ended March 31, 2026, and it still states substantial doubt about going concern.
HCWBGRI Bio reported approximately $11.0 million in cash as of March 31, 2026, and added analyses from its Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis.
GRICell Source, an OTC Pink company, signed a 10-Q on May 14, 2026 for the quarter ended March 31, 2025. It reports $1,240 of cash, a going-concern warning, and notes past due, while it prepares a Nasdaq uplisting.
CLCSThe earlier program bought back shares at an average price of $24.36 for $102.3 million. Zymeworks had about 73.0 million common shares outstanding as of May 13, 2026.
ZYMEAprea said its $30 million private placement closed on March 31, 2026, and reported $46.5 million in cash at March 31, 2026, with runway into the first quarter of 2028. The company also described two partial responses in its Phase 1 trial of APR-1051.
APREAvenue Capital Management II, L.P. is the lender under a term loan facility signed January 7, 2026. The first $15.0 million tranche funded after closing.
SPRBAptevo says its RAINIER trial of mipletamig remains on track for Phase 2 dose selection by year end, and that a $60 million standby equity purchase agreement extends its access to capital.
APVOEquillium said cash and cash equivalents were $61.3 million at March 31, 2026, following a $35 million private placement with RA Capital Management completed in March 2026.
EQThe Swiss unit added two peer-reviewed papers, began enrolling in a U.S. validation study with Labcorp and kept expanding sales in Europe. The release does not report quarterly revenue or cash.
ONCODermata Therapeutics said its at-the-market facility produced $2.0 million of net proceeds in the first quarter of 2026. Cash was $6.9 million at March 31, 2026, and the company expects its resources to fund operations into the first quarter of 2027.
DRMAWhitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing.
WHWKThe notes carry no interest and convert at about $138.94 a share, a 30% premium to the May 12 price. Mirum swapped $237.2 million of 4% notes due 2029 for cash and shares.
MIRMThe company said its cash should fund operations into 2027, including completion of the dose escalation part of the BDC-4182 study. It expects initial clinical data in the third quarter of 2026.
BOLTThe royalty company reported net income from continuing operations of $103 thousand and cash of $8.4 million as of March 31, 2026, and said it still evaluates strategic alternatives.
TXMDMirum plans to sell $600.0 million of convertible senior notes due 2032, with an option for up to $90.0 million more. Part of the proceeds would go toward exchanges of its 2029 notes.
MIRMThe facility refinances Aquestive's existing debt. It starts with $55.0 million at signing and adds tranches tied to FDA approval and sales milestones.
AQSTCollegium paid about $650 million in cash for AZSTARYS, using about $350 million of cash on hand and a $300 million delayed draw term loan. Two senior executives are leaving, and the company may pay up to $135 million more if AZSTARYS hits milestones.
COLLCollegium paid about $650 million in cash for AZSTARYS, using $350 million of its own cash and a $300 million loan draw. Corium Therapeutics may receive up to $135 million more if milestones are met.
COLLThe 0.50% notes would lift convertible principal to $619.9 million but cut the coupon. Travere said it would spend about $350.9 million to repurchase part of the older debt.
TVTXThe company sold $250 million of 1.75% notes due 2032 and shares at $17.00 ahead of its first approval. It used part of the money to pay off about $55.1 million of term debt.
VRDNA late-breaking abstract on the obesity candidate DA-1726 was accepted for a poster at the EASL Congress 2026 in Barcelona, scheduled for May 27, 2026.
MTVACash was $4.6 million at March 31, 2026, and Adial says it can fund operating expenses into the second half of 2026 on its committed development plans.
ADILThe company agreed with all Series C holders to reset the conversion price to $0.1636 per share, the market price at signing.
MEHAAurinia said on May 11, 2026 that it completed its acquisition of Kezar Life Sciences. Holders received $6.955 in cash plus one contingent value right per share, after a tender offer in which 5,927,580 Kezar shares, about 80.24% of those outstanding, were validly tendered.
AUPHArriVent BioPharma, Inc. filed a prospectus supplement on May 11, 2026 under its existing sales agreement with Jefferies LLC. The last reported sale price was $29.50 per share on May 8, 2026.
AVBPNasdaq staff said on May 7, 2026 that SciSparc now meets the $2,500,000 stockholders' equity standard, but the letter is conditional. Delisting is possible if the company's next periodic report does not show compliance.
SPRCKiora ended the first quarter with $13.9 million in cash and short-term investments. It raised an additional $5.0 million in gross proceeds from a strategic equity investment after quarter end.
KPRXNektar will sell up to $150 million of stock through Guggenheim Securities and H.C. Wainwright at a 3.0% commission. The company used $208.5 million in operations in 2025, and its Phase 3 spending is set to rise.
NKTRPTC reported first quarter 2026 total revenue of $273 million and a net loss of $2.8 million, and raised full-year product revenue guidance to $750 to $850 million.
PTCTQuoin said an FDA Type C meeting indicated a single Phase 3 study may be sufficient for U.S. approval of QRX003, and reported approximately $14 million in cash as of March 31, 2026.
QNRXCash stood at $14.1 million on March 31, 2026, which the company says covers operations through the first quarter of 2027.
REVBOragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years.
OGENSIGYAn institutional investor will fund up to $3.5 million in two tranches. The first note carries 7% interest, matures in eighteen months and converts at a price that cannot fall below $0.50.
GELSCapricor Therapeutics filed a complaint in New Jersey seeking to rescind its January 24, 2022 distribution agreement and asking for a preliminary injunction. The FDA target action date for Deramiocel is August 22, 2026.
CAPROperating expenses fell to $31.0 million from $46.2 million, but revenue fell by $27.3 million and the net loss was approximately $27.0 million.
ARCTLeerink Partners LLC and Cantor Fitzgerald & Co. are the sales agents. About $58.5 million of ADSs had already been sold, leaving $341,478,784 of capacity after the supplement.
GPCRFirst-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases.
TGTXInMed reported a net loss of $3.0 million for the quarter ended March 31, 2026, and cash, cash equivalents and short-term investments of $5.2 million, as it winds down its commercial operations.
INMAptevo says mipletamig data from 31 evaluable frontline AML patients show continued activity, and that the RAINIER trial has entered its final dose-optimization stage.
APVOViridian's $250,000,000 offering of 1.75% convertible senior notes due 2032 includes the full $25.0 million over-allotment option. A concurrent sale of 7,352,942 shares was priced at $17.00 a share.
VRDNCitius Oncology signed a warrant inducement worth about $11.5 million and a loan of up to $25.0 million with Avenue. Existing warrants are repriced to $0.90, and the new warrants and conversion rights add to the share count.
CTORCitius Oncology signed a loan of up to $25 million with an Avenue Capital fund and expects about $11.5 million gross from a warrant exercise. Only $10 million of the loan funds at closing, and the new warrants cannot be exercised until stockholders approve the shares.
CTORInflaRx N.V. sold 75,000,000 ordinary shares in an underwritten offering led by Guggenheim Securities. The offering closed on May 7, 2026.
IFRXThe company reported cash of $14.4 million at March 31, 2026, a runway into Q1 2027, and FDA general agreement on a pivotal Phase 3 design for VCN-01.
TOVXCash and cash equivalents were $50.8 million at March 31, 2026. The company received $14.2 million of at-the-market proceeds after the quarter ended.
QTTBThe company reported a GAAP net loss of $125.4 million for the quarter, including a $109.4 million non-cash warrant charge, and said the first patient was screened in March.
NERVApimeds named Sungjoon Chae Co-Chief Executive Officer on May 4, 2026 on a stockholder's nomination. The Form 8-K, dated May 5, 2026, describes his background as an architect and urban designer.
APUSTravere plans to sell $400 million of convertible senior notes due 2032, with an option for up to $60 million more. It intends to use part of the proceeds to repurchase 2029 notes for cash.
TVTXKartik Krishnan, M.D., Ph.D., became chief medical officer on May 1, 2026, and will oversee clinical development and medical strategy for PAS-004.
KTTALexicon signed a loan of up to $100 million from Hercules in three tranches. The first $55 million was funded at closing, and Hercules receives warrants at $1.59 a share.
LXRXCNS Pharmaceuticals priced a private placement of common stock at $2.30 per share and pre-funded warrants at $2.299, for approximately $22.5 million gross. Most of the shares are pre-funded warrants for 9,143,479 shares. Closing is expected May 5, 2026. A director resigned and a new one was named.
CNSPLisata and Kuva Labs signed an amendment and waiver on May 3, 2026 that moves the tender offer start from April 13, 2026 to May 29, 2026. Kuva will pay up to $1.1 million of Lisata's expenses until the offer starts, and the offer is $5.00 in cash plus a $1.00 contingent value right.
LSTAGyre closed its merger with Cullgen on May 4, 2026. Cullgen holders get Gyre common and Series B preferred stock, and Cullgen's former CEO Ying Luo becomes Gyre's CEO.
GYRECandid terminated its merger agreement with Rallybio on May 3, 2026, and entered into a Permitted Alternative Agreement with UCB S.A. Rallybio intends to withdraw its Form S-4 registration statement.
RLYBThe merger is backed by an $11 million private placement that Shuttle expected to close on May 4, 2026.
SHPHVeradermics closed an underwritten sale of 3,843,790 shares at $100.00 and a $30.0 million private placement of pre-funded warrants on May 1. Its pivotal hair-loss trials are still running against $70.0 million of annual losses.
MANECue Biopharma agreed to pay a $15.0 million upfront for rights to Ascendant-221, an anti-IgE antibody still in a Phase 2 study run by the licensor's affiliate, and to issue pre-funded warrants for up to 551,724 shares. Milestones could reach $676.5 million, and the company's own release cites a current going concern determination.
CUEThe offering totals $254,880,000 before fees, and Seaport expects net proceeds of about $233.9 million. Entities affiliated with General Atlantic, a holder of more than 5% of the stock, have indicated interest in up to $50 million of shares, which is not binding.
SPTXA proxy supplement corrects a typographical error that showed a 1-for-50 maximum on the proxy card and notice before the May 28, 2026 annual meeting.
ENVBThe company says the first cohort of its Phase 1b norovirus challenge study is fully enrolled, with prevention and treatment cohorts to follow.
COCPThe 10% note matures in twelve months and is sold to YA II PN, LTD. for $5,760,000. It comes with a warrant for 2,158,274 shares at $1.1824 a share.
PDSBThe amendment raises the subscription amount so that $10,000,000 of capacity remains for future convertible promissory notes.
CMNDPerrigo (NYSE: PRGO) received €305.6 million at closing and may get up to €27.0 million more over three years. The company says net proceeds will be used primarily to reduce debt.
PRGOAddex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business.
ADXNThe offering totals $300,000,006 before fees. The shares have been approved for listing on the Nasdaq Global Select Market as AVLN.
AVLNDEK:Rockwell Medical's proxy asks holders to approve a reverse split at a virtual meeting on June 12, 2026. Approval needs a majority of the votes cast, and the company's 2025 net loss was $5.3 million.
RMTIThe company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date.
TLSAThe company says it lacks operational and financial data for its subsidiary The Social Proxy Ltd., which is in liquidation proceedings.
XTLBCorMedix wants stockholders to ratify earlier changes to its Series E and Series C-3 preferred stock, and to let preferred holders alone approve future changes to those terms.
CRMDThe company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date.
MENSAfter an interim efficacy analysis, the Data Monitoring Committee recommended stopping the Phase 3 HyBryte trial for futility, and Soligenix says it has approximately $5.9 million of cash.
SNGXNasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until October 19, 2026 to cure, while its auditor has flagged going-concern doubt and its parent funds most operations.
CTORAvalo can pay $5.125 million in cash or stock within 90 days instead of $15 million owed when a Phase 3 trial doses its first patient. If it does not, the milestone amount becomes $12.75 million.
AVTXNasdaq's notice dated April 27, 2026 says the ordinary shares closed at $1.00 or more for 10 consecutive business days. The matter is closed.
IFRXInMed agreed to amend the exercise prices on preferred investment options held by Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC to $0.80 per share.
INMClovis Davis Pharmaceuticals will lead distribution, promotion, marketing and sales of SOLOSEC in the territory. The release is dated April 27, 2026.
EVFMThe April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent.
SCNXLigand will pay about $739 million in equity value for XOMA Royalty, plus a contingent value right tied to litigation. The deal needs a XOMA Royalty stockholder vote and is expected to close in the third quarter of 2026.
LGNDOrganon agreed on April 26, 2026 to be bought by Sun Pharma for $14.00 a share in cash, a 103% premium to an April 9 close set before a media report. The company's enterprise value is $11.75 billion, and it carries $8.6 billion of debt.
OGNJosh Epstein joined the board on April 23, 2026 and chairs its Nominating and Corporate Governance Committee. The 8-K says neither resignation involved a disagreement with management.
ONCOTelomir acquired 100% of TELI on April 22, 2026 and now holds the global rights to Telomir-1. Bayshore Trust contributed $1 million at closing and entered an option to pay up to $4 million more if milestones are met.
TELOCitius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern.
CTXRCTORThe company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning.
LABTAmneal will pay $375 million in cash and issue 28,942,108 shares to buy Kashiv BioSciences, and some sellers are affiliates of the Amneal Group. Up to $350 million more depends on US regulatory milestones for Kashiv products.
AMRXNYSE Regulation told Apimeds Pharmaceuticals US on April 17, 2026 that it had not filed its 2025 annual report on time. The company has until October 15, 2026 to file, its stock carries a ".LF" tag, and a trading halt that began April 2 is still in effect.
APUSAltimmune sold 64,250,000 shares at $3.00 with a warrant for each share, against a last reported sale price of $3.47 on April 22, 2026.
ALTCue Biopharma's 1-for-30 reverse split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. The company says it is meant to restore compliance with Nasdaq's minimum bid price, and its filing still carries a going-concern determination.
CUEGazelle Parent, Inc. filed the registration statement on April 22, 2026. Galera has agreed to sell Series C preferred stock for about $350.0 million, less certain Obsidian financing proceeds, before the mergers close.
OBXThe agreements dated April 21, 2026 cover 17,500,000 shares at $0.04 per share, and the offering closed the same day. The filing names no underwriter or placement agent.
HEPACASI Pharmaceuticals filed a Form NT 20-F on April 21, 2026, saying its annual report on Form 20-F for 2025 will be late because its U.S. GAAP financial statements are not yet available. It expects that report to say there remains substantial doubt about its ability to continue as a going concern.
CASIFSILV Fund Ltd. replaces Point72 Associates, LLC for 531,670 shares. The resale prospectus still covers up to 39,425,806 shares, against 49,542,691 outstanding on February 28, 2026.
ORKAEli Lilly gave notice on April 16, 2026 that it is terminating its license for ocadusertib, a RIPK1 inhibitor, effective June 15, 2026. Rigel expects to regain full rights and does not expect future milestones or royalties under the agreement.
RIGLLeerink Partners, Guggenheim Securities and Oppenheimer & Co. are joint book-running managers, with Jones and Craig-Hallum as co-managers.
SPRBSemnur ended a private placement agreement with JW Capital Securities Limited and a share purchase agreement with Biconomy PTE. Ltd. Neither agreement had produced any issued shares.
SMNRFirst Tracks Biotherapeutics began trading on Nasdaq as AnaptysBio completed the spin-off. The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks.
TRAXDaré issued 20,000 Investor Units at $5.00 each, with one Series A Convertible Preferred share and two warrants per unit. The offering is for up to 4,854,000 units, and the company's auditor has raised going concern doubt.
DAREThe notes mature in 2027 and carry 12% interest. They can convert into common stock at 75% of the lowest trading price in the prior ten trading days, and only after an event of default.
IGCAnaptysBio completed the spin-off of First Tracks Biotherapeutics on April 20, 2026, one share for every share held on April 6. AnaptysBio keeps the royalty business and gives a range of $140-$145 million for its net cash, while the press release calls the spin-off taxable and cites an EBIT margin it does not reconcile to GAAP.
ANABKailera Therapeutics (Nasdaq: KLRA) sold 44,921,875 shares in its initial public offering, including the underwriters' full option. A restated charter set up a classified board and exclusive forum rules.
KLRAShareholders received one First Tracks share for each AnaptysBio share held on April 6, 2026. AnaptysBio now manages two royalty collaborations and starts with about $140-$145 million in net cash.
ANABTRAXAN2 Therapeutics filed an $80,000,000 prospectus supplement dated April 20, 2026 for sales through Jefferies LLC, which will be deemed an underwriter, earns up to 3.0% of gross proceeds and is under no obligation to sell any set amount.
ANTXThe company was spun off from AnaptysBio, Inc. on April 20, 2026. It says it has a two-year cash runway.
TRAXA poster on April 20, 2026 will report tumor response, biomarker and subgroup analyses from the VIRAGE Phase 2b trial of VCN-01.
TOVXEmergent drew a $150 million term loan with OrbiMed as administrative agent and repaid its prior credit agreement. Interest is Term SOFR plus 6.25%, with a 3.00% floor, and the loan matures as late as April 16, 2031. The asset-based revolver falls from $100 million to $50 million.
EBSThe Credit Agreement also provides a $75 million delayed draw term loan, available for 24 months. Interest is Term SOFR plus 6.25% per annum, with a 3.00% floor.
EBSThe offering totals $625,000,000 before fees. Existing stockholders have indicated interest in buying up to approximately $225 million of shares.
KLRAHenry H. Du, a certified public accountant and interim chief financial officer of Alpha Cognition, fills the board seat left by the resignation of Jon Kuwahara.
EMMAACOGThe result reflects a non-cash increase of approximately $365.4 million in the fair value of the company's GMP Biotechnology investment, partly offset by a tax provision.
OTLCThe company agreed to sell 2,222,223 shares at $2.25 per share with warrants, for about $5 million upfront, with H.C. Wainwright & Co. as placement agent.
ENVBAcurx agreed to sell 816,068 shares at $3.03 and pre-funded warrants for 9,017 shares, plus Series H warrants at $2.78 in a concurrent private placement. H.C. Wainwright & Co., LLC is the placement agent, and the 10-K says existing resources will not fund operations for at least 12 months.
ACXPShareholders approved raising authorized common stock from 200,000,000 to 400,000,000 shares, against 130,105,177 shares outstanding at the March 13, 2026 record date.
ALTTrevi sold 11,600,000 shares at $13.00 each, about $150 million, below the $14.54 last sale on April 16, 2026. Its two pivotal Phase 3 trials for Haduvio are not due to report until the second half of 2027 and the first half of 2028.
TRVITraws says a $10 million upfront private placement, with up to $50 million more in warrants, supports operations into the first quarter of 2027, including a planned challenge trial of tivoxavir marboxil.
TRAWMustang Bio's common stock closed below $1.00 for 30 consecutive business days, and the company has until October 12, 2026 to regain compliance with the Nasdaq minimum bid price rule.
MBIOWave Life Sciences said on April 15, 2026 that its board approved moving the parent company from Singapore to Delaware. Shares would be exchanged one for one, and the company expects the change in mid-2026, subject to shareholder and Singapore High Court approval.
WVETelix raised its convertible notes offering from US$550 million to US$600 million and will use most of the money to buy back its 2029 convertible bonds. The reference price for the conversion terms was set at an 8.0 per cent discount to the closing share price.
TLXThe first patient in the Phase IIa trial of ONP-002 was dosed at Mackay Hospital in Australia, the first site activated, with two more Australian sites expected to activate in the second quarter.
OGENThe April 13, 2026 agreement provides $225,000 and a pro-rata bonus of $30,625, plus six months of COBRA reimbursement. Dr. Lbiati also left the board that day.
HEPACue Biopharma holders approved a reverse split at a ratio between 1-for-30 and 1-for-50. The board will pick the ratio and the timing without another stockholder vote, and the filing does not say why the split is wanted.
CUEThe Fourth Amendment, dated April 10, 2026, makes the notes payable in full at the earliest of three events. It bars prepayment for six months without Adjuvant's consent.
EVFMSeaport Therapeutics filed its Form S-1 on April 10, 2026 with the share count and price range still blank. The filing shows a 2025 net loss of $74,881 thousand and a stockholders' deficit of $92,545 thousand.
SPTXA special meeting on share issuance for warrants did not convene because too few shares were present, and the company will call another meeting.
TOVXNasdaq says Alaunos does not meet its $2,500,000 minimum for stockholders' equity, and the company plans to submit a compliance plan.
TCRTThe April 2, 2026 letter cites Listing Rule 5450(b)(3)(A) and revenue of FibroGen International held for sale. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance.
KYNBGossamer Bio (Nasdaq: GOSS) says its stock did not maintain a $1.00 minimum bid price for 30 consecutive business days. It has 180 calendar days to regain compliance and may be eligible for an additional 180 days.
GOSSAN2 Therapeutics set up an $80 million at-the-market sales program with Jefferies LLC on April 9, 2026 and ended an earlier agreement with TD Securities, against a 2025 net loss of $35.2 million and cash used in operations of $29.8 million.
ANTXEnsysce Biosciences sold 2,000 shares of Series B preferred stock for $2 million on April 6, 2026, to 3i, LP. The deal comes with warrants for up to 8,727,273 common shares, all at $0.55, and the stated value of the preferred stock was raised from $1,100 to $1,200 a share.
ENSCAvalyn Pharma Inc. filed a Form S-1 on April 8, 2026. The cover leaves the share count and price range blank.
AVLNPhio set up an at-the-market program that lets it sell up to $6,360,000 of common stock through H.C. Wainwright & Co., LLC, with a 3.0% commission. The size is capped because its public float is only $19,080,217, and its auditors have raised a going concern doubt.
PHIOThe compensation committee approved restricted stock awards on April 7, 2026 for Cary Claiborne, Vinay Shah, Tony Goodman and other directors, vesting on the first anniversary or on a change of control.
ADILThe board notified Alexander Arrow, MD, on March 31, 2026, that his employment will be terminated effective April 30, 2026. The filing gives no reason for the decision.
PTIXNasdaq confirmed that Artelo Biosciences has regained compliance with its equity and annual meeting rules. The company is now subject to a one-year panel monitor.
ARTLSupernus agreed on April 1, 2026 to buy the NV-5138 assets from Navitor. The price is an obligation to complete one Phase 2b study plus milestone payments of up to $350 million, and Supernus may stop pursuing the milestones if it judges the study unsuccessful.
SUPNKiora Pharmaceuticals, Inc. closed the deal with Perceptive Advisors and ADAR1 Capital Management on April 6, 2026, with $5.0 million in upfront funding. Up to $19 million more could come if milestone-based warrants are exercised.
KPRXThe company bought the UK manufacturer from a seller controlled by its chief executive. Payment is due in installments over two years.
NWBOThe company says 2025 revenue rose 4.1% and its net loss was $5.98 million, which it attributes partly to a $1.75 million impairment charge, and it expects cost cuts of $2 million to $3 million in 2026.
SBFMEnsysce Biosciences said director Curtis Rosebraugh resigned effective April 1, 2026, and that he had served on the Nominating and Corporate Governance Committee.
ENSCNYSE American says Matinas BioPharma is out of compliance with three stockholders' equity standards, with equity of $4.83 million at December 31, 2025, and a plan due by May 2, 2026.
MTNBLisata and Kuva Labs agreed on April 2, 2026 to move the tender offer start from April 3 to April 13, 2026, or a later agreed date. The offer pays $5.00 in cash plus a $1.00 contingent right, and Lisata's 10-K says its $16.0 million in cash does not cover twelve months of spending.
LSTAAn Aurinia subsidiary will buy Kezar Life Sciences for $6.955 in cash per share plus a CVR, but the offer depends on Kezar holding at least $50.0 million of net cash at closing. The deal is expected to close in the second quarter of 2026.
AUPHThe notice cites a stockholders' deficit of approximately $55 million as of December 31, 2025. AEON keeps its listing and has until August 3, 2026 to regain compliance.
AEONThe Equity Distribution Agreement is dated March 23, 2026. Piper Sandler's commission is 3.0% of the gross sales price per share, and the prospectus says the $4.07 share price is below net tangible book value per share.
AARDKiora said Eric J. Daniels, M.D., MBA, will leave his role as Chief Development Officer on April 17, 2026, and that the company has started a search for a successor. The company's ABACUS-2 and KLARITY trials continue.
KPRXThe oral antiviral candidate gains earlier FDA contact and a possible path to Priority Review, Cocrystal said in an April 2, 2026 release.
COCPAdagene Inc. priced 18,666,000 American depositary shares at $3.75 for about $70.0 million gross, below the $4.61 last sale price on April 1. Leerink Partners LLC and LifeSci Capital LLC are joint book-running managers, and cash stood at $74.5 million at the end of 2025.
ADAGCyclerion and private Korsana Biosciences signed a merger agreement on April 1, 2026. A concurrent private financing of approximately $380 million is expected to fund Korsana's operations into 2029.
KRSAChina Pharma says it will file its 2025 annual report within fifteen calendar days after March 31, 2026. Its estimates show revenue of $4.1 million and a net loss of about $3.19 million, and its auditors have raised going-concern doubt before.
CPHIApollomics signed a $2.0 million unsecured note with its chairman and chief executive, Hung-Wen (Howard) Chen, on March 30, 2026, at 0% interest, which converts into equity at a 20% discount if the company later raises at least $10.0 million.
APLMTherapeuticsMD filed a Form 12b-25 notice on April 1, 2026 after a printer error left the predecessor auditor's report out of its 2025 annual report. The company reported a 2025 net loss of $569,000 and year-end cash of $7.5 million.
TXMDGreenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss.
GLSIZenas BioPharma closed a $200 million offering of 2.50% convertible senior notes due 2032, with net proceeds of about $193.7 million and Jefferies, Evercore, Citigroup and Guggenheim as representatives. Its 10-K reports substantial doubt about going concern.
ZBIOGeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors.
GOVXOramed Pharmaceuticals closed the sale of its Oratech subsidiary to Lifeward Ltd. on March 25, 2026, for 1,250,363 Lifeward ordinary shares, pre-funded warrants, warrants and a 4% revenue share on ReWalk products. The same day it bought $9,000,000 of Lifeward convertible notes, and Lifeward carries a going-concern warning of its own.
ORMPTraws Pharma filed a Form NT 10-K on March 31, 2026, saying it has not yet signed any financing and needs time to assess how a deal would affect its going-concern evaluation. The notice also gives unaudited 2025 net income of about $9.2 million, driven by a $26.7 million warrant accounting gain.
TRAWSunshine Biopharma filed a Form 12b-25 on March 31, 2026 for its 10-K for the year ended December 31, 2025. It cites time constraints and says it will file no later than fifteen days after the original due date. Its 2024 net loss was $5,134,116.
SBFMTransCode blames the complexity of accounting for its October 2025 deal with DEFJ, LLC, including a roughly $25 million Series B preferred placement. It expects to file within the extension period.
RNAZUnder an asset purchase agreement dated March 30, 2026, SCYNEXIS acquired Poxel's AMP kinase activator assets, including PXL-770, now SCY-770, and received a worldwide license.
SCYXThe company cites issues tied to its Advent BioServices acquisition, including differences between UK GAAP and US GAAP. The notice gives no date for the annual report.
NWBOSilo filed an 8-K covering an asset purchase from Many Ads Inc. paid for with 2,100,000 shares of common stock. The filing names no underwriter or placement agent.
SILONasdaq told InMed on March 27, 2026 that its shares closed below $1.00 for 30 consecutive trading days. The company has 180 calendar days to regain compliance and keeps trading as INM.
INMOrdinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b).
KZIAOnKure Therapeutics, Inc. is selling 26,713,636 shares and pre-funded warrants for 9,430,959 shares to institutional accredited investors. AI Biotechnology LLC is lead investor and gets a board nominee right.
OKURAnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs.
ANABTRAXKailera Therapeutics, Inc. filed a Form S-1 on March 27, 2026. The cover leaves the share count and price range blank.
KLRAQuantum BioPharma reports $11.3 million in cash and digital assets at the filing date and says cash lasts beyond January 2028. Its annual report shows year-end cash of $1.9 million, and the release does not split out the digital assets.
QNTMThe 2025 financing closed in two parts before the IPO. Holders tied to board members were among the buyers, the proxy shows.
MPLTUpstream Bio signed a sales agreement with Leerink Partners LLC on March 26, 2026 that lets it sell up to $150,000,000 of common stock on the Nasdaq market. Leerink may earn a commission of up to 3.0% of gross proceeds, and cash used in operations rose to $133.3 million in 2025.
UPBNkarta set up a $100 million at-the-market program with Stifel on March 25, 2026, with commissions of up to 3%. Its 2025 net loss was $104.1 million, and its operating cash use was $88.7 million.
NKTXAll five resolutions passed at the March 24, 2026 annual meeting, including a share reclassification and a share consolidation.
ZYBTFive buyers including Yun Yao and Sino Lion Ventures Limited bought preferred stock that could convert into 108,936,000 shares. The board appointed Junyi Dai chairman and chief executive officer, and four directors resigned on March 18, 2026.
INDPCytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%.
CYDYGilead agreed to buy Ouro Medicines for $1,675 million in cash plus up to $500 million in milestones. Galapagos said it would pay 50% of the upfront cost under proposed terms, and no agreement between the two companies had been signed.
LKFTTurn Therapeutics signed a term loan of up to $25.0 million with Avenue Venture Opportunities Fund II, L.P. It bears interest of at least 12.25%, is secured on the company's assets, and only $7.0 million is committed up front.
TTRXAardvark Therapeutics, Inc. signed an equity distribution agreement with Piper Sandler & Co. on March 23, 2026 and filed a Form S-3 shelf registration the same day. The company paused its main Phase 3 trial in February 2026 after cardiac observations in a healthy volunteer study.
AARDNasdaq staff says Ernexa's stock failed to maintain a $1.00 minimum bid price for 30 consecutive business days, and that the company is not eligible for a 180-calendar day compliance period because of a reverse stock split in the past year. The company plans to request a hearing.
ERNAThe change has the same effect as a one-for-four reverse ADS split. The ordinary shares are not affected.
XTLBNasdaq told Skye Bioscience (Nasdaq: SKYE) its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and says it will consider its options.
SKYEThe March 19, 2026 release recalls an August 2025 ADS ratio change that worked as a one-for-four reverse ADS split.
CMMBThe board lifted the program from $10 million. The company had repurchased approximately $2.6 million of stock through March 17, 2026.
NAGENuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size.
NCNAThe change, aimed at Nasdaq's $1.00 minimum bid price, is expected on or about April 6, 2026. Holders must exchange five old ADRs for one new one, and the company says it cannot guarantee the change will work.
BDRXStoke's shelf includes a $150,000,000 at-the-market program with Cantor Fitzgerald, which can be paid up to 3.0% of gross proceeds in commissions. The stock's last reported sale price was $33.96 on March 16, 2026.
STOKThe ADSs held a closing bid of $1.00 or more for at least 10 consecutive business days, reached on March 13, 2026. The company is now compliant with applicable listing standards.
PPBTTalphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing.
TLPHAmphastar's board raised its buyback by $50 million on March 12, 2026, to offset dilution from equity compensation, while 2025 net income fell to $98.1 million and cash from operations dropped.
AMPHCytomX priced 45,990,567 shares and pre-funded warrants for 1,179,245 more at $5.300 a share, below the $5.45 last reported sale price on March 17, 2026. Its lead clinical data are interim, and the prospectus gives no patient count or response rate.
CTMXThe deal settles a Delaware lawsuit. Zevra says it repaid its $63 million term loan in full before signing.
ZVRACorvus had sold no shares under its $100,000,000 Jefferies program and had suspended it in January. The amendment doubles the ceiling to $200,000,000, with Jefferies paid up to 3.0% of gross proceeds.
CRVSNeuroThera would issue 56,600,000 of its own shares, valued at approximately $9,459,954.20, plus up to $2,500,000 in earn-out payments. The release does not say what the issuance would do to SciSparc's approximately 75% stake in NeuroThera.
SPRCNTLXNasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences.
YARWThe sale came a day after phase 3 X-TOLE2 results. Xenon ended March with $1.34 billion in cash and says it funds operations into 2029.
XENEThe company is selling 8,245,611 shares and pre-funded warrants for up to 5,789,493 shares to institutional investors. Leerink Partners is the exclusive placement agent, and closing is expected March 10, 2026.
ANTXSepterna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain.
SEPNRelmada agreed to sell 29,474,569 shares and pre-funded warrants for up to 4,210,527 shares to institutional and accredited investors. It announced 12-month Phase 2 data for NDV-01 the same day, where the 12-month response rate rests on 25 patients.
RLMDLongeveron told Nasdaq on March 4, 2026 that it was temporarily out of compliance after director Richard Kender resigned from its audit committee. The company had $19.2 million of cash at December 31, 2024, and its annual report projected that cash would last only into the fourth quarter of 2025.
LGVNDianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel.
DNTHKorro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028.
KRROGenentech elected to terminate the agreement for convenience. Xencor says it expected the move.
XNCRInMed's board approved exiting BayMedica's sales on March 4, 2026. The company calls BayMedica its only revenue-generating business, expects about $550,000 in severance costs and about $120,000 in other spending, and its annual report already carries a going-concern warning.
INMEupraxia Pharmaceuticals Inc. sold 7,607,145 common shares at US$7.00 each, plus pre-funded warrants for 1,428,571 shares. The material change date is February 20, 2026.
EPRXNurix raised its Piper Sandler at-the-market program to $413.65 million, of which $113.65 million has already been sold. Its fiscal 2025 net loss was $264.5 million and cash used in operations was $249.5 million.
NRIXContineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding.
CTNMMediWound ended 2025 with $53.6 million in cash, cash equivalents and deposits after a $30.0 million registered direct offering. Its net loss narrowed to $23.9 million mainly because of warrant revaluation, while revenue fell to $17.0 million.
MDWDRegen Biopharma issued 77,849,847 common shares between February 4 and February 27, 2026 to settle convertible debt and fees. The company had 212,318,424 shares outstanding on March 3, 2026, and its pipeline has not yet entered a clinical trial.
RGBPModerna agrees to pay a $950.0 million noncontingent lump sum and may owe a further $1.3 billion depending on a Federal Circuit appeal on 28 U.S.C. §1498. Arbutus is entitled to 20% of proceeds after litigation costs, or, if less, tiered low single-digit royalties.
ABUSChina Pharma's subsidiary Helpson agreed on February 26, 2026 to buy a sublingual tablet patent for $6.93 million, paid in 12,600,000 unregistered shares at $0.55 each. The company has a going-concern warning in its latest annual report.
CPHIOn March 1, 2026 the audit committee concluded the quarterly reports contained an error: Greenshoe Rights from a May 2025 private placement required liability classification. GT Biopharma (Nasdaq: GTBP) will file Forms 10-Q/A.
GTBPGyre Therapeutics agreed to buy privately held Cullgen in an all-stock deal valued at about $300 million, issuing common stock and Series B convertible preferred. Until stockholders approve the conversion, Gyre may not issue more than 19.99% of its stock, and Cullgen's lead drug has completed only a Phase 1 trial.
GYREZymeworks sold 30% of its future Ziihera royalties to a subsidiary that borrowed $250 million from Royalty Pharma. The loan costs about $481 million by its 2042 maturity, and it is secured by the subsidiary's assets.
ZYMEThe February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test.
ACRVAnebulo's March 2, 2026 Form 15 puts its SEC reporting duties to an end and gives 71 holders of record for its common stock, while the company's last reported cash figure was $9.0 million at December 31, 2025.
ANEBBelite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end.
BLTEThe sales agreement pays TD Securities (USA) LLC up to 3.0% of gross proceeds. Geron's stock last sold at $1.65 on February 26, 2026, and the company's 2025 net loss was $83.5 million.
GERNSionna Therapeutics signed a sales agreement with Leerink Partners LLC on March 2, 2026 for up to $250,000,000 of common stock sold at the market. Leerink's commission is up to 3.0% of the gross sales price per share.
SIONNasdaq says the stock closed below $1.00 for 30 consecutive business days and that its market value of listed securities stayed below $35 million. The company has until August 25, 2026 on both, and its auditor has raised going-concern doubt.
JUNSStockholders approved conversion of preferred stock that, once converted, would give David Lazar 111.0 million common shares, about 96.4% of the fully diluted common stock. They also approved up to two reverse stock splits and authorized shares rising to 1,000,000,000.
INDPAtrium Therapeutics became independent on February 26, 2026, when Avidity Biosciences distributed all of its shares at one Atrium share for every ten Avidity shares. Atrium began trading on Nasdaq as RNA on February 27, and it signed an amended license and a transition services agreement with Avidity the same day.
RNAAltamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lists 48 holders of record, and the company's last business description, from April 2025, still calls its lead programs preclinical.
CYTOFThe offering totals $400,000,000 before costs, with net proceeds estimated at $368.8 million. The prospectus keeps the going-concern warning and says no pivotal trial has finished.
GENBThe audit report says XORTX must finance its research or postpone it. The statements show an accumulated deficit of $23,824,557 at December 31, 2025.
XRTXAfter an enterprise-wide strategic review, Viatris committed to restructuring that it expects to cut its global workforce by up to approximately 10%. It expects potential savings of between $600 million and $700 million.
VTRSLipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration.
LPCNAvidity holders of record on February 12, 2026 would receive Atrium shares, but the distribution depends on Avidity's merger with Novartis and is taxable to holders. Avidity may instead sell Atrium to a third party, in which case no distribution would occur.
RNALargest stockholder Deerfield and some directors indicated interest in buying. The priced offering is 20,000,000 shares at $5.00, or $94,000,000 to the company before expenses.
LRMRBicara priced 7,175,000 shares at $16.00 and pre-funded warrants for 2,200,000 more, with underwriting discounts of $9,000,000 on a total of $149,999,780.
BCAXMoonLake drew $25.0 million under a Hercules loan totaling $500.0 million across six tranches. Most of the tranches still to come depend on Phase 3 results and FDA action for its lead drug, sonelokimab, and the company's 81% response figure comes from 26 patients with no comparison arm reported.
MLTXCyprium, a majority-owned Fortress Biotech subsidiary, agreed on February 22, 2026 to sell a priority review voucher for $205 million in cash at closing. Fortress also amended its Oaktree credit agreement, with about $29.5 million outstanding.
FBIOThe February 18, 2026 amendment sets the change-of-control payment to HCR at $150 million or $200 million and revises a buyout option. HCR received warrants at $3.8130 per share.
ADCTThe company lowered its expected cell therapy restructuring cash costs to €125 to €175 million. It expects to be a lean organization of about 35-40 employees by the end of 2026.
LKFTOric Pharmaceuticals, Inc. has sold 13,478,432 shares under the program for gross proceeds of approximately $139.7 million. The new supplement replaces the one from March 2024.
ORICPurchasers paid $3.39 per share for 7,374,632 non-voting convertible preferred shares. Conversion into common stock depends on stockholder approval at the 2026 annual meeting. Preliminary cash was $45 million at year end.
IRDShareholders gave Psyence's board authority to consolidate the common shares at a ratio of up to 250:1, but the board has not set a ratio or timing, and the company says a consolidation may never happen.
PBMSensei Biotherapeutics closed its acquisition of Faeth Therapeutics on February 17, 2026, and agreed the same day to sell about $200 million of Series B preferred stock. The new investors would hold 54.3% of the company on an as-converted basis, and the lead drug's headline response rate comes from 15 patients.
FTHAtossa Therapeutics received a Nasdaq letter on February 17, 2026 saying it regained the $1.00 minimum closing bid price. The stock met the test on February 13, 2026, the last trading day before the extended deadline, after a February 2025 notice and an extension granted in August 2025.
ATOSMereo BioPharma's American Depositary Shares failed to hold a $1.00 minimum bid price for 30 consecutive business days, and Nasdaq gave the company until August 17, 2026 to regain compliance. The company's 2024 annual report shows a net loss of $43.3 million and $69.8 million of cash.
MREOGeoVax sold 402,000 shares and pre-funded warrants for up to 30,902 shares, plus Series A-1 and A-2 warrants in a concurrent private placement. H.C. Wainwright & Co., LLC was placement agent.
GOVXAnebulo filed a Form 25 on February 17, 2026 to withdraw its common stock from Nasdaq as a voluntary withdrawal, while its lead drug candidate remains at an early stage and its cash fell in the second half of 2025.
ANEBNasdaq told Citius Pharmaceuticals on February 9, 2026 that its stock had closed below $1.00 for 30 consecutive business days, and the company has until August 10, 2026 to regain compliance. The same filing reports $3.9 million in first-quarter revenue from LYMPHIR, against $7.7 million in cash.
CTXRWerewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330.
HOWLEvommune's $125 million private placement was followed by a failed atopic dermatitis trial; the company says its 2026 raise brought net proceeds of $117.2 million.
EVMNNasdaq staff decided on February 6, 2026 to delist Lunai Bioworks, saying a reverse stock split in September 2025 bars the company from the usual 180-day cure period. The company has asked for a hearing, which pauses a February 18 trading suspension.
LNAINasdaq told Vistagen on Feb 3, 2026, that its stock had closed below $1.00 for 30 consecutive business days. The company has until Aug 3, 2026, to regain compliance, and its last annual report carried a going-concern warning.
VTGNAnebulo's board approved leaving Nasdaq and ending SEC reporting, with a Form 25 due about February 17, 2026 and a Form 15 about February 27, while its lead drug candidate is still in early clinical work.
ANEBVeradermics closed its initial public offering of 15,077,647 shares at $17.00 a share on February 5, 2026. The underwriters later exercised in full their option on 2,261,647 more shares.
MANELB Pharmaceuticals agreed to sell 3,306,571 shares and pre-funded warrants for up to 1,417,107 shares to institutional investors. It plans to use the proceeds for a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes.
LBRXThe S-1 leaves the share count and price range blank. Management and the auditor say cash will not last twelve months, which raises going-concern doubt.
GENBAmneal Pharmaceuticals LLC cut the interest margin on its term loans by 50 basis points in an amendment dated February 2, 2026, with JPMorgan Chase Bank, N.A. as administrative agent. The company estimates annual cash interest savings of about $11 million, and the loans still mature on August 1, 2032.
AMRXPerspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. Piper Sandler & Co. is one of five joint book-running managers, and Hogan Lovells US LLP is counsel to the company.
CATXPolaryx began trading on Nasdaq on February 2, 2026 without an underwriter, and the company received no money from the listing.
PLYXALX Oncology priced 76,979,112 shares and pre-funded warrants for 18,574,120 more, at $1.57 a share, after a year of failed or dropped combination trials and a narrower focus on its CD47 drug evorpacept.
ALXOBGM Group Ltd. says it cannot file its annual report on Form 20-F for the year ended September 30, 2025 on time. It is still finishing the consolidation and acquisition accounting for its purchase of YX Management Company Limited.
BGMThe senior notes due 2034 priced at par and will sit in escrow until the deal closes. BioMarin also completed syndication of a $2 billion term loan B.
BMRNAprea expects gross proceeds of approximately $5.6 million from selling 6,288,857 shares, or pre-funded warrants, with common warrants for the same number of shares at $0.765. Maxim Group LLC is placement agent for a 7% fee. Closing is expected January 30, 2026.
APREAltimmune is selling 12,397,920 shares at $4.40 each, plus pre-funded warrants for 4,647,534 shares, to one investor, with Titan Partners Group LLC as sole placement agent.
ALTAs amended, the loan agreement provides for up to $105 million of term loans, and the added draws depend on FDA approval of MOLBREEVI for aPAP. Two covenant compliance dates move to April 1, 2027 and September 30, 2027.
SVRAThe company amended its November 4, 2024 note purchase agreement to reflect that Indivior U.S. now reports the financials. The board carries over, and a 2026 equity plan reserves 17,500,000 shares.
INDVLarimar agreed with Blue Owl Healthcare Opportunities IV Public Investments LP to swap 2,500,000 common shares for 250,000 Series A convertible preferred shares. Each preferred share converts into 10 common shares, and closing is expected January 23, 2026.
LRMREach share of Series A convertible preferred stock converts into 10 shares of common stock, subject to certain limitations. The exchange was expected to close on January 23, 2026.
LRMRBioAge Labs priced 5.9 million shares with Goldman Sachs, Piper Sandler and Citigroup nine days after new phase 1 data on BGE-102, its brain-penetrant NLRP3 inhibitor.
BIOAAEON Biopharma exchanged its senior secured convertible notes held by Daewoong for new shares, pre-funded warrants and a smaller $1,500,000 note after stockholders approved the deal on January 21, 2026. The swap adds dilution, and the second closing of its private placement is still pending.
AEONNasdaq's staff found only conditional compliance with the $2.5 million equity rule after a December 2025 deficiency notice. The company's auditors had already raised going-concern doubt in its 2024 annual report.
GRINasdaq said NRX Pharmaceuticals is out of compliance because it did not hold an annual meeting within twelve months of fiscal year end. The company set the 2025 Annual Meeting for March 23, 2026.
NRXPTiziana Life Sciences Ltd sold 7,040,000 ordinary shares to senior management and existing shareholders without a placement agent. Each share came with a warrant at $1.50.
TLSAThe notes due 2033 carry a 45% conversion premium. Underwriters later took the full option, and BridgeBio bought back about 1.1 million shares alongside the sale.
BBIOCell Source closed $1,875,000 of original issue discount convertible notes for $1,500,000 in gross proceeds. The notes convert at 90% of a recent low price, and buyers also received warrants at $.40.
CLCSBriaCell Therapeutics sold 5.4 million units at $5.59, each with a five-year warrant struck at $6.93. The best-efforts deal closed Jan. 15.
BCTXPolaryx's 1-for-4 reverse split took effect on January 12, 2026, ahead of a Nasdaq direct listing that raised no money for the company.
PLYXThe AI-driven antibody company sold shares and pre-funded warrants at $2.35 in a private placement. It says the cash runs into calendar 2028 and that first human trials of IBIO-610 start in early 2027.
IBIOGenelux sold 6,666,667 shares at $3.00 through Lucid Capital Markets, raising about $20.0 million gross. The oncolytic virus developer is running a phase 3 trial of Olvi-Vec in platinum-resistant ovarian cancer, and its China partner Newsoara holds the rights there.
GNLXThe radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size.
AKTSLLYBMYMRKAlumis sold 17.65 million shares at $17 after two phase 3 trials of its oral TYK2 inhibitor envudeucitinib met all endpoints. A prospectus had flagged going-concern doubt before the deal.
ALMSPropanc Biopharma received a Nasdaq notice that its stock has been below the $1.00 minimum bid price, and it has until June 30, 2026 to regain compliance. Its latest annual report showed cash of $12,088 at June 30, 2025.
PPCBArrowhead Pharmaceuticals raised the notes from $500,000,000 to $625,000,000 while selling common stock at the same time. The notes rank behind $254.9 million of secured borrowing.
ARWRPhathom priced 6,875,000 shares at $16.00 plus pre-funded warrants for 1,250,078 shares, for a public offering of $129,999,998. Its cash fell from $297.3 million at the end of 2024 to a preliminary $130 million at the end of 2025, and the company expects operating profit only in the second half of 2026, excluding stock-based compensation.
PHATPraxis Precision Medicines sold 2.2 million shares to fund launch plans for two Breakthrough-designated drugs. Net proceeds later came to $621.2 million.
PRAXNasdaq approved Immunic's move from the Global Select Market to the Capital Market, with trading there from January 7, 2026. The company now has until June 22, 2026 to regain compliance with the $1.00 minimum bid price and has told Nasdaq it would seek a reverse stock split if necessary.
IMUXThe December 31, 2025 warrant went to Paramora Holding LLC at $23.01 per share under an October 7, 2025 option agreement with Paragon Therapeutics. The board named Sherwin Sattarzadeh Chief Operating Officer.
DMRAThe registered direct offering is expected to bring in about $234,000 before expenses. IGC Pharma says it will use the money for working capital and general corporate purposes.
IGCNasdaq said on December 31, 2025 that the company missed the $1.00 minimum bid price and gets no grace period. Suspension is set for January 9, 2026 unless it appeals by January 7, 2026.
DCOYNasdaq staff plans to delist FibroBiologics after its stock did not regain the $1.00 minimum bid price by December 29, 2025. The company will ask for a hearing and has asked stockholders to approve a reverse split of 1 for 5 to 1 for 30.
FBLGThe exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share.
ELDNThe January 2, 2026 filing covers the company's common shares. It relies on the SEC rule for a voluntary withdrawal by the issuer.
HELPCommon stock authorized rises from 1,700,000,000 to 2,600,000,000 shares. The company filed the amendment in Delaware on December 30, 2025.
NWBOClimb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment.
CLYMThe five-year facility has a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver, with Truist Bank as administrative agent. Collegium used the initial loan to repay its previous term loan in full, including its prepayment premium, which the filing does not size.
COLLThe at-the-market sales agreement names Cantor Fitzgerald, Wells Fargo Securities and William Blair. As of December 22, 2025, the company had sold 1,179,201 shares under it for about $12 million.
ARCTThe $980 million facility matures in 2030 and includes a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver. The initial term loan repaid about $581 million owed to Pharmakon, so it brought no new cash at closing.
COLLSilo Pharma did not regain the $1.00 minimum bid price by December 24, 2025, and Nasdaq granted it a second 180-day period to June 22, 2026. The company has told Nasdaq it may use a reverse stock split to cure the deficiency, and its annual report shows an accumulated deficit of $15,264,691.
SILOCassava and Chief Financial Officer Eric J. Schoen accepted a mediator's recommendation to settle the consolidated securities class action for $31.25 million. Remi Barbier and Lindsay Burns did not sign the term sheet but would receive releases once the court approves.
FLNAAnebulo's board dropped a planned reverse split and will instead tender for up to 300,000 shares at $3.50, to keep its holder count below 300 for a go-private plan, while its lead drug rests on a Phase 2 study in healthy volunteers.
ANEBApollomics reports a $4,398 thousand shareholders' deficit at June 30, 2025, after cash fell to $2,094 thousand from $9,766 thousand at year-end and the six months produced a $12,536 thousand loss.
APLMBiodexa priced 157,000 units and 2,891,781 pre-funded units at $3.28 each, with two Series L warrants per unit. The last reported sale price of the ADSs was $6.50 on December 16, 2025.
BDRXLarimar Therapeutics agreed to swap 2,500,000 common shares held by a Blue Owl fund for 250,000 Series A convertible preferred shares, each convertible into 10 common shares. The filing calls the preferred "toothless," and the holder can raise its conversion blocker to 19.99%.
LRMRNYSE American accepted Azitra's plan to restore its $4.0 million minimum stockholders' equity and set April 1, 2027 as the deadline. The stock stays listed while the plan runs, but the company's 2024 annual report carried a going-concern warning.
AZTRCadrenal will sell 207,374 shares at $10.85 plus unregistered warrants for up to 414,748 shares at $10.60, for expected gross proceeds of about $2.2 million. H.C. Wainwright & Co., LLC is exclusive placement agent.
CVKDLexaria sold 2,661,600 shares at $1.315 in a registered direct offering and placed matching warrants at $1.19, for about $3.5 million gross. H.C. Wainwright & Co., LLC was placement agent. Its annual report says the company has substantial doubt about continuing as a going concern.
LEXXGeron Corporation estimates about $18 million in restructuring charges, mostly severance and benefits, and expects the workforce reduction to be substantially complete in the first quarter of 2026.
GERNThe company estimates about $18 million in restructuring charges, mostly severance and benefits, hitting results in the fourth quarter of 2025 and the first quarter of 2026.
GERNTherapeuticsMD stockholders approved raising authorized common stock to 640,000,000 shares at the December 15, 2025 annual meeting. The company had 11,574,362 shares outstanding at the record date, and the increase drew 548,884 votes against.
TXMDThe 10-K reports GEM bought 1,235,200 shares for about $4.07 million in 2025 under an $85.0 million agreement. The company has since drawn a $7.0 million term loan and flagged going-concern doubt.
TTRXImmunome said on December 15, 2025 that it planned a $400 million stock offering, and priced it the next day at $21.50 a share.
IMNMThe preliminary filing leaves the size and price blank. There is no minimum amount, so the company may sell fewer shares than offered.
TLSAClimb Bio agreed on December 11, 2025 to take back 20,440,000 shares from an entity affiliated with RA Capital in exchange for a pre-funded warrant. After the exchange, RA Capital and its affiliates will hold about 23.0% of the voting power, and the filing describes no cash payment to the company.
CLYMTivic Health Systems bought the manufacturing and development assets of Scorpius Holdings at a public auction, paying $16,253,147.10 in cash funded by a senior secured convertible note sold to 3i. The note converts at a fixed price and at a discount to market, which can add shares.
VBIOAddex Therapeutics amended its at-the-market agreement with H.C. Wainwright and filed a prospectus supplement for up to $3,300,000 of ADSs. The company reported CHF 2.2 million of cash at September 30, 2025 and says it covers expenses through mid-June 2026.
ADXNThe First Amendment lets Dyne draw a $50.0 million tranche from Hercules Capital. Up to $75.0 million more depends on milestones, and the loan matures July 1, 2030 at prime plus 2.45% with a 7.50% floor.
DYNThe $150.0 million offering priced on December 10, 2025 at $13.50 a share and was upsized to $175.0 million. Its lead drug data come from 12 patients in one dose cohort, and the dose comparison rests on six.
FULCWave Life Sciences filed a preliminary prospectus supplement on December 8, 2025 for a $250,000,000 offering. The pricing that followed on December 9 raised the deal to about $350 million at $19.00 per ordinary share.
WVECrescent agreed to sell 13,795,685 ordinary shares at $13.41 for about $185.0 million. Two license deals with Kelun-Biotech require Crescent to pay $80.0 million within 30 days of signing, while Kelun-Biotech pays it $20.0 million in the same period.
CBIONasdaq told GRI Bio on November 26, 2025 that it does not meet the $2,500,000 stockholders' equity requirement for the Capital Market. The company has until January 10, 2026 to submit a compliance plan, and its annual report already carried a going-concern warning.
GRIThe deal has no common warrant coverage but includes prefunded warrants. Kazia expects net proceeds of approximately $46.5 million and says its cash runway would extend into the second half of 2028.
KZIAOmeros got $240.0 million upfront and may earn up to $510 million in development and approval milestones and $1.3 billion in sales milestones. About $72.6 million retired its credit agreement and the board approved a buyback of up to $100.0 million.
OMERQ32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027.
QTTBAKBANasdaq told GT Biopharma on November 20, 2025 that its stock had closed below $1 for 30 consecutive business days. The company has until May 19, 2026 to regain compliance, and its last annual report carried a going-concern warning alongside a $13.2 million net loss.
GTBPNasdaq told Akari Therapeutics on November 24, 2025 that its American Depositary Shares had closed below $1.00 for 30 consecutive business days. The company has until May 25, 2026 to regain compliance, and its 2024 annual report carries a going-concern warning.
AKTXMetaVia Inc. (Nasdaq: MTVA) was granted more time to regain compliance after its stock closed below $1.00 for 30 consecutive trading days. It says a reverse stock split is an option.
MTVANasdaq's staff ruled that Artelo had not completed the capital raise it promised to fix its equity shortfall. Trading continues pending a hearing panel appeal, and the company's last annual report carried going-concern doubt.
ARTLCumberland's amended Pinnacle Bank line has up to $15 million available, a right to request $10 million more, and a maturity of October 1, 2027. The filing does not say how much is drawn.
CPIXVerrica agreed to sell common stock, pre-funded warrants and Series C warrants for about $50 million, and will use $35.0 million to settle its OrbiMed credit agreement. The company says cash will last into mid-2027.
VRCAAnaptysBio's Verified Complaint of Nov 20, 2025 names Tesaro, Inc. and its parent GlaxoSmithKline and alleges breaches of the Jemperli collaboration. Tesaro sued AnaptysBio the same day, and the parties have agreed to ask for an expedited schedule.
ANABNasdaq staff issued a delisting determination against Moleculin Biotech's common stock for failing the $2.5 million stockholders' equity rule. The company said it will ask a hearing panel to stay any suspension, and its last annual report showed $4.3 million of cash and a going-concern warning.
MBRXAbbott agreed on November 20, 2025 to buy Exact Sciences for $105 per share in cash, an equity value the companies put at about $21 billion. Abbott's commitment letter provides up to $20 billion of bridge loans, and the companies expect the deal to close in the second quarter of 2026, subject to a shareholder vote and antitrust review.
ABTHarrow paid about $4.3 million in cash to close its purchase of Melt Pharmaceuticals on Nov 17, 2025. The contingent milestone payments are unchanged, and the MELT-300 sedation drug still needs an NDA, which the company plans for the first half of 2027.
HROWCogent Biosciences closed a $230,000,000 offering of 1.625% convertible notes due 2031 on November 18, 2025, including the full over-allotment option. The 8-K names no underwriters, and the company's 2024 annual report showed operating cash use of $207.8 million that year.
COGTBristol Myers Squibb amended its cash tender offers for its own notes after the November 17, 2025 early tender deadline. It cut the Pool 1 cap from $4,000,000,000 and raised the Pool 2 cap from $3,000,000,000, and it set early settlement for November 20. Accepted notes will be cancelled and retired.
BMYNasdaq told Soligenix on November 18, 2025 that the matter is closed. The company reported stockholders' equity of $7,597,976 for the quarter ended September 30, 2025, against a $2,500,000 requirement.
SNGXShuttle reported stockholders' equity of $1,394,161 against Nasdaq's $2,500,000 minimum. Nasdaq staff will keep monitoring, and delisting is possible if compliance is not shown in the next periodic report.
SHPHThe best efforts sale would pair each ADS with a Series L warrant whose exercise price resets after issue. The company says it will likely receive no additional cash when those warrants are exercised.
BDRXHoli Hemp LLC sold equipment, inventory and operating assets for an agreed fair value of about $2.7 million, but the consideration was supply rights and a contingent payout, with no cash. The pro forma statements show a non-cash gain of $1,051 thousand that narrows a reported quarterly loss to $548 thousand.
IGCThe company sold 1,970,000 shares at $1.68 per share and pre-funded warrants for up to 1,601,429 shares to one investor, and issued Series A and Series B warrants in a concurrent private placement.
NNVCHoli Hemp LLC completed the disposition on September 29, 2025. IGC Pharma filed pro forma financial statements showing a $1,051 thousand gain.
IGCThe at-the-market supplement lets Cantor Fitzgerald sell up to $50,000,000 of stock for up to 3.0% in commissions. The company's lead drug failed its Phase 3 Alzheimer's study, and its share price closed at $3.11.
FLNAKorro Bio cut about 34% of its workforce on November 12, 2025, paused its Novo Nordisk collaboration for 12 months, and said the moves extend its cash into the second half of 2027. Its chief medical officer also resigned, and its lead RNA editing candidate fell short of the protein levels the company had projected.
KRROArcturus blamed a technical transmission error for missing the deadline on its September 30, 2025 quarterly report. The notice gives no results, and the company's 2024 annual report shows cash use rising sharply.
ARCTAnnexon priced 25,096,153 shares at $2.60 for about $75 million on November 12, 2025, with pre-funded warrants for up to 3,750,000 more shares, and its two lead programs are still in late-stage trials.
ANNXArcturus says a technical transmission error caused it to miss the 5:30 PM Eastern deadline on November 10, 2025 for its quarterly report. Its commercial product is KOSTAIVE, a COVID-19 vaccine sold in Japan.
ARCTThe RNA editing company ended the third quarter of 2025 with $102.5 million in cash and securities. Its AATD drug candidate KRRO-110 did not reach projected protein levels.
KRROGalecto completed its acquisition of Damora Therapeutics on November 10, 2025. A concurrent private placement of Series C preferred stock for approximately $285 million is expected to close November 12.
DMRALyell Immunopharma agreed to pay $40 million in cash and issue 1.9 million shares for exclusive rights to LYL273, a CAR T candidate for colorectal cancer that has been tested in 12 patients. The deal also carries more shares, large milestone payments and tiered royalties, and the company says its cash lasts into 2027 once it closes.
LYELEvommune sold 9,375,000 shares at $16.00 in its New York Stock Exchange listing, with a 30-day option on 1,406,250 more. Its most advanced drug's efficacy data come from a small Phase 2 study in a different condition than the one it is pursuing.
EVMNOnly $3,000,000 was paid at closing on November 6, 2025. The rest of the $10,000,000 maximum depends on a $1,000,000 payment and up to $6 million in sales milestones, and Xepi had no sales in 2024.
BFRIThe amendment raises term loan availability from $100.0 million to $125.0 million and extends the interest-only period to 30 months. Altimmune held $210.8 million in cash, cash equivalents and short-term investments at September 30, 2025.
ALTHolders exercised existing warrants, most at a reduced $2.05 per share, in return for new Series A Warrants. Phio expects total gross proceeds of approximately $13.4 million before fees.
PHIOPrelude Therapeutics gave Incyte an option on its preclinical JAK2V617F JH2 inhibitor program for a $35 million cash payment, plus a $25 million stock purchase. Exercising the option would cost Incyte $100 million, and the company is pausing a separate SMARCA2 degrader program.
PRLDJefferies LLC is the sales agent for up to $100,000,000 of common stock. A second Jefferies program, dated January 18, 2023, may still sell up to approximately $80.0 million.
ARDXCytoDyn can sell up to $30 million of common stock to Yorkville Advisors Global over 36 months, at its own discretion and with no warrants attached. The release names no placement agent or counsel, and the annual report says the company will pursue non-dilutive financing in addition to traditional fundraising.
CYDYThe company expects to file its annual report for the year ended June 30, 2025 within the fifteen-day grace period.
GELSThe company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date.
KZIALunai Bioworks received a Nasdaq notice that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days. It has until April 27, 2026 to regain compliance, and the company says the notice has no immediate effect on trading.
LNAISavara priced 23,809,524 shares at $4.20, below the $4.41 last sale price, and pre-funded warrants for 7,142,857 more. Jefferies, Piper Sandler and Guggenheim Securities are joint book-running managers, and Polsinelli PC is the company's counsel.
SVRAMapLight Therapeutics closed its initial public offering at $17.00 a share, and the underwriters exercised their option for more shares in full. Its lead drug has no Phase 2 results yet.
MPLTGSBiofrontera Inc. closed its purchase of U.S. rights to Ameluz and RhodoLED from its former parent on October 24, 2025, paying an earnout of 12% or 15% of Ameluz revenue. The same day it closed a $2.5 million second tranche of Series C preferred, and the company says that closing and the deal together keep it above Nasdaq's equity requirement.
BFRINasdaq said Enveric's stock closed below $1.00 for 30 consecutive trading days and the company has no compliance period. It plans to request a hearing and will split its shares 1-for-12 on October 28, 2025.
ENVBVivo Capital LLC led the deal, which brings $80 million upfront in Series A preferred stock. The rest comes from two warrant tranches, and the larger one is tied to a Phase 3 roluperidone trial meeting its primary endpoint.
NERVAlkermes offers $18.50 a share in cash, plus a CVR that pays only if two conditions are met by December 31, 2028. The deal is funded with cash and a JPMorgan bridge loan, and it has not closed.
ALKSNYSE American told Oragenics on October 20, 2025 that it again meets stockholders' equity standards. The company also paid Ladenburg Thalmann $700,000 to settle a dispute over a $2,500,000 fee claim.
OGENKeros Therapeutics, Inc. offers to buy back its stock for cash, for up to $194.4 million in total. The Schedule TO was filed October 20, 2025.
KROSMedicus Pharma (Nasdaq: MDCX) sold shares in eight transactions between September 8 and October 16, 2025 for approximate aggregate consideration of $2,526,364. It used part to prepay a Yorkville debenture.
MDCXNasdaq says Aspire's shares face delisting for missing the $50,000,000 market value rule and the $1.00 bid price rule. The company paid $20,000 to request a hearing, and its 2024 audit carried going-concern doubt.
ASBPA Nasdaq Hearings Panel granted HCW Biologics (Nasdaq: HCWB) continued listing on October 13, 2025. The company must show compliance with the Equity Rule by December 31, 2025 and with all other rules by February 16, 2026.
HCWBThe plan was amended by the board on October 15, 2025 and is filed as an exhibit. It is built around Nasdaq's inducement-grant exemption from shareholder approval.
KURAQuoin sold ADSs and pre-funded warrants with four series of warrants whose cash exercise depends on FDA and trial events that the filings do not report as having happened. Maxim Group LLC was the exclusive placement agent, and director Dennis Langer took part.
QNRXKeros Therapeutics agreed on October 15, 2025 to buy 10,176,595 shares from two investors for about $181 million at $17.75 each, and plans a tender offer for up to $194 million at the same price. Two directors resigned under the Pontifax agreement, and the company's preliminary cash figure of about $693.5 million is unaudited.
KROSThe repurchases are part of a $375 million capital return program. Keros also plans to share 25% of certain net cash from its Takeda license with stockholders.
KROSKaryopharm closed a recapitalization on October 10, 2025 that borrowed $12.5 million under its term loan, issued $15.0 million of 9.00% notes due 2028 and $103.5 million of 9.00% notes due 2029, and exchanged $100.978 million of older notes. Lenders also waived specified defaults under the loan.
KPTIHolders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026.
CLRBHolders exercised warrants for 1,048,094 shares at $5.25 and received new warrants at $6.00. Cellectar says cash should last into the third quarter of 2026.
CLRBCanaccord Genuity is sole bookrunner. Xenetic plans to use net proceeds for working capital and general corporate purposes.
XBIOThe shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025.
ALZNThe twelve-month program starts October 15, 2025. The company says it represents approximately 5% of the 46,154,188 common shares outstanding.
HYFTThe deals combine new loans and notes, payment deferrals, debt-for-equity exchanges and a private placement of about $8.75 million. Karyopharm expects about $36 million of gross proceeds and a cash runway into the second quarter of 2026.
KPTIAfter the deal, CK Life Sciences would hold about 91% of TransCode on a fully diluted basis, and existing holders about 9%. Converting the preferred stock needs stockholder approval where Nasdaq rules apply, and up to $95 million in milestones may go to CK Life Sciences.
RNAZInstitutional investors are buying 502,181 shares at $68.00 and pre-funded warrants for 233,144 more, for expected gross proceeds of about $50.0 million. The 8-K contains no clinical data for tralesinidase alfa, the program Spruce plans to file in the first quarter of 2026.
SPRBZenas gains global rights to the BTK inhibitor outside oncology plus two early autoimmune drugs. It also registered an at-the-market program for up to $200,000,000 of stock with Jefferies.
ZBIONasdaq granted Adicet Bio an additional 180 calendar days. The stock moves from the Nasdaq Global Market to the Nasdaq Capital Market on October 9, 2025.
ACETJade Biosciences agreed to a PIPE financing of about $135 million at $9.14 per share, with Jefferies, TD Cowen, Stifel and Wedbush named as placement agents, and says its cash will fund operations into the first half of 2028.
JBIOBiomea Fusion is issuing 11,195,121 shares and 1,000,000 pre-funded warrants under an October 6, 2025 prospectus supplement, for $24,999,898 before discounts. Jefferies is book-running manager and H.C. Wainwright & Co., LLC is lead manager.
BMEASalarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The figure is preliminary, and Nasdaq has not yet confirmed compliance.
DCOYThe death of director Dr. Alon Lazarus on September 30, 2025 left Werewolf's audit committee with two members, one short of Nasdaq's three-member minimum. The company plans to appoint an independent director at its earliest opportunity.
HOWLThe Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security.
ZVSAOvid Therapeutics agreed to a private placement of convertible preferred stock and warrants with initial gross proceeds of about $80.8 million and up to $175.1 million in total. The preferred cannot convert until stockholders approve more shares, and the same day the company reported Phase 1 data from 68 healthy volunteers, with the CEO among the investors.
OVIDXilio moved its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market after missing the $1.00 minimum bid price. The move does not cure the bid price problem, and the company's March annual report carried a going-concern warning.
XLONYSE American told Azitra on October 1, 2025 that its stockholders' equity of $2.2 million is below the $4.0 million required. The company has until October 31, 2025 to submit a plan, with compliance due by April 1, 2027. Its 2024 annual report carried a going-concern warning.
AZTRNYSE American says Azitra is below its $4 million stockholders' equity standard, and the company has until October 31, 2025 to file a plan to restore compliance.
AZTRInstitutional investors bought 7,813 shares of Series E convertible preferred stock and warrants for 2,025,223 common shares. The preferred converts at $3.8576.
ONCONasdaq approved the transfer from the Global Select Market effective October 6, 2025. Xilio now has until March 30, 2026 to regain compliance with the minimum bid price rule.
XLOBolt will cut about 20 employees, roughly 50% of its workforce, with pre-tax charges of $1.5 million to $2.0 million. The company says the cut extends its cash runway into 2027. Initial BDC-4182 clinical data, now expected in the third quarter of 2026, will come later after a protocol change.
BOLTTheriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024.
TOVXOxford Finance says an event of default under a Material Adverse Change clause is continuing and has accelerated all obligations under the 2021 loan agreement. The notice says interest began accruing at the Default Rate, and that $29.1 million is now payable.
KALAJaguar agreed to sell 161,583 shares and 479,442 pre-funded warrants at $1.56 to Brown Stone Capital Limited. Two days later it issued 286,532 shares to cut a royalty balance by $600,000.
JAGXEdesa and the Government of Canada amended a contribution agreement worth up to CAD $23 million ($17 million USD) in partially repayable funding. Repayment would begin only if the company earns gross revenue.
EDSAR.F. Lafferty & Co., Inc. is the sole book-running manager. The filing also cuts the company's at-the-market program to $0 after it sold all the remaining stock under it.
ARTLThe preliminary filing left price and share count blank. The final prospectus supplement, dated September 30, 2025, priced 6,500,000 shares at $10.00, with $61,100,000 going to the company before expenses.
ENTASKNY contributed $5 million in marketable securities to MIRA as a closing condition. MIRA says it believes it has regained compliance with Nasdaq's $2,500,000 equity rule, but the filing gives no share count for the deal.
MIRAKALA BIO will stop developing KPI-012 and its stem cell secretome platform, cut approximately 19 employees and talk with its secured lender while it explores strategic options.
KALABon Natural Life's unaudited interim statements for the six months to March 31, 2025, filed in a Form 6-K on September 29, 2025, reflect a 1-for-25 share consolidation and net proceeds of $10,543,805 from a public offering of Class A ordinary shares. Cash rose from $80,466 to $8,894,053 over the period.
BONJourney Medical's $25.0 million SWK term loan now matures June 27, 2028. Principal repayments start in February 2026 unless trailing revenue tops $60.0 million at December 31, 2025.
DERMANI mandatorily converted the last 20,000 preferred shares into 482,320 common shares on September 26, 2025. The filing reports no cash proceeds, and no preferred shares remain outstanding.
ANIPNasdaq notified Longeveron (LGVN) on September 22, 2025 that its Class A common stock missed the $1.00 minimum bid price. The notice does not cause immediate delisting; a second 180-day period may be available.
LGVNThe company has until March 23, 2026 to bring its Class A common stock back above the threshold. The notice has no immediate effect on its listing.
LGVNBetween September 17 and September 25, 2025, 696 shares of Series B Convertible Preferred Stock converted into common stock. Alzamend had 3,439,861 common shares outstanding as of September 25, 2025.
ALZNCuranex paid $408,537.32 on two notes held by its secretary, Dian Ying Jing, the wife of its chief executive. The payments came on September 23 and 24, 2025, well before the notes matured in 2027.
CURXuniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130.
QUREImmuneering is selling 18,959,914 shares at $9.23 and expects about $164.1 million in net proceeds, plus about $23.3 million from a Sanofi unit. The company's 2024 audit report carried a going-concern paragraph.
IMRXPepGen priced 31,250,000 shares at $3.200 for gross proceeds of $100,000,000, a price above the $2.66 close the filings report for September 24, 2025. The company says the proceeds plus its existing cash will not be enough to finish development of any product candidate.
PEPGAllarity agreed to sell 1,562,500 shares at $1.60 each, or pre-funded warrants, to one investor, closing September 23, 2025. The investor may buy $7.5 million more: within 90 days per the 8-K, 60 days per the purchase agreement.
ALLRCytokinetics issued $750.0 million of 1.75% convertible senior notes due 2031 on September 19, 2025, and expects to spend about $402.5 million of the net proceeds on the cash side of exchanges for its 2027 notes. The notes convert at about $68.42 a share. Neither the 8-K nor the release gives the company's cash balance.
CYTKThe buyer gets 1,562,500 shares or pre-funded warrants at $1.60 and can add $7.5 million more within 90 days, at a price set by Nasdaq's minimum-price rule.
ALLRMBX Biosciences filed an S-1 on September 22, 2025 for 10,000,000 shares. The deal priced on September 24 at $18.00 for 11,108,055 shares and closed on September 26 with net proceeds of about $187.5 million.
MBXThe company is selling 10,933,405 shares at $15.00 and pre-funded warrants for 1,066,666 more. Closing was expected on or about September 19, 2025.
ORKAEquillium's public float of about $93.7 million lifts it above Form S-3 sales limits. The company had sold $0.96 million of stock under the program so far, against the $21,950,000 covered by the earlier prospectus.
EQIGC Pharma, Inc. set the amount under a $60,000,000 at-the-market sales agreement with A.G.P./Alliance Global Partners. The cap follows a rule that limits small companies to one-third of their public float.
IGCThe size is capped by SEC limits for companies with a public float under $75,000,000. Longeveron's stock last sold at $0.77 on September 18, 2025.
LGVNNasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice.
PRLDThe offering covers 5,555,560 shares or equivalents with matching five-year warrants. Soligenix also cut the exercise price on 1,162,064 older warrants to $1.35.
SNGXThe 8% debenture matures in twelve months and refinances about $1.7 million of earlier Yorkville debentures. Medicus expects net proceeds of approximately $5.7 million, and the lender can require repayment from part of any equity raise.
MDCXNasdaq told ZyVersa it would announce the delisting on September 18, 2025. The shares have traded on the OTCQB Venture Market since July 28, 2025.
ZVSAArvinas said on September 17, 2025 that it will cut its workforce by a further 15%, mainly in vepdegestrant commercialization roles, and that it will seek a third party to take over the drug with Pfizer. The same day its board authorized a buyback of up to $100 million, and the filing does not give the cash balance on which that depends.
ARVNThe company and Pfizer have agreed to out-license vepdegestrant commercialization rights and have begun looking for a partner. Arvinas expects about $4.5 million in workforce costs.
ARVNNasdaq accepted Neuphoria's plan on September 10, 2025, after a July 18, 2025 notice that it had not held an annual meeting. The company has until December 29, 2025 and says it will file its Form 10-K on or before September 29, 2025.
NEUPNasdaq told Ovid on September 11, 2025 that it again meets the $1.00 minimum bid price, but the company's notice does not say how it got back above that level.
OVIDRelmada Therapeutics said on September 16, 2025 that Nasdaq confirmed in a September 15 notice that it has regained compliance with the $1.00 minimum bid price. The stock stays on the Nasdaq Capital Market under RLMD, but the company's lead drug failed in late 2024.
RLMDHolders of 13,065,000 Class H warrants agreed to exercise at $2.20 per share and receive 13,065,000 new Class I warrants in a private placement. Roth Capital Partners advised.
REVBRevelation Biosciences said on September 11, 2025 that holders will exercise warrants for up to 4,355,000 shares at $2.20 each, about $9.6 million in gross proceeds. In return they receive new Class I warrants for up to 13,065,000 shares, which cannot be exercised until stockholders approve them.
REVBBenitec's Audit Committee found share-based compensation expense was understated in the quarters ended December 31, 2024 and March 31, 2025. The company expects to file its 2025 annual report on time.
BNTCNasdaq told the company on September 11, 2025 that its stock closed below $1.00 for 30 consecutive business days. It has until March 10, 2026 to regain compliance, and the Nasdaq Capital Market listing is unchanged for now.
YARWTraws Pharma paid $2,350,000 in cash, in full, for assets tied to a pyrrolidine antiviral compound held by Viriom. The seller's executive chairman is Traws's own chief operating officer, and its 2024 annual report carries a going-concern warning.
TRAWThe company agreed to sell 2,764,710 shares at $1.70 each, with warrants for up to 5,529,420 shares at $1.50 that could add approximately $8.3 million if fully exercised for cash. H.C. Wainwright & Co. is the placement agent.
COCPDominari Securities bought 562,500 more shares at the $4.00 IPO price. Total gross proceeds from the offering reached $17,250,000.
CURXThe offering totals $285,000,000, and the shares are approved for listing on Nasdaq under LBRX. Proceeds to the company are $265,050,000 before expenses, and the company's lead drug has a Phase 3 trial still ahead.
LBRXNRx's subsidiary HOPE Therapeutics closed its purchase of Dura Medical, which runs two Florida clinics. The 8-K gives no purchase price, and part of the consideration is paid in later earn-outs and in interests that convert into HOPE shares.
NRXPTraws Pharma paid $2,350,000 in cash for intellectual property and other assets from Viriom, a company tied to its chief operating officer. The board and audit committee approved the deal and called the price fair and reasonable.
TRAWVYNE Therapeutics, now Yarrow Bioscience, has until March 10, 2026 to lift its closing bid price back to at least $1.00 per share.
YARWBHC Lyon accepted 19,984,767 DURECT shares and merged into DURECT on September 11, 2025. Holders get $1.75 per share in cash plus a contingent value right that pays only if net sales milestones are reached.
BHCFour investors who could defer their purchases until December 31, 2025 agreed to buy now. In return, TuHURA extended warrants on 1.5 million shares to December 31, 2030.
HURASELLAS says an institutional investor will exercise January 2025 warrants for 19,685,040 shares, bringing about $23.6 million gross. The investor gets new unregistered warrants for the same number of shares at $1.88, so the dilution continues.
SLSAnixa Biosciences filed a $200,000,000 replacement shelf on September 10, 2025, with a $100,000,000 sales program through Cantor Fitzgerald & Co., because its current shelf expires on September 19, 2025 and its clinical programs are still in early trials.
ANIXLeerink Partners is lead placement agent for the $50 million upfront, with Piper Sandler & Co., Cantor Fitzgerald and Wedbush & Co. as co-placement agents. The second $50 million depends on milestones, including clearance to start a trial of CMP-SYNGAP-01.
CAMPShares sold at $0.55 each. Investors other than CorMedix agreed to buy about $12 million more if the NEPHRO CRRT study meets its primary endpoint and the stock clears a price test.
TLPHActuate Therapeutics priced 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds, below the $8.24 last sale price. Lucid Capital Markets is the sole underwriter, and the prospectus says the company's current liabilities exceeded its assets at June 30, 2025.
ACTURein received net proceeds of $0.95 million from the $1.0 million second advance on September 8, 2025. Yorkville buys each advance at 95% of face value, charges 8% interest and can require repayment in stock.
RNTXAbivax reported a first-half net loss of EUR 100.8 million and negative shareholders' equity of EUR 48.3 million at June 30, 2025, before a July US offering and several note conversions. The company now says its cash lasts into the fourth quarter of 2027.
ABVXThe $8.8 million combines an August registered direct offering with at-the-market sales since July 1, 2025. The company says none of it carried warrants, repricing or variable-rate terms, but the filing gives no share count, price or investor names.
NRXPPharvaris agreed to file a resale shelf registration within 30 calendar days for General Atlantic PH B.V., and the investor decides when to sell, how and at what price. The company may postpone the shelf only once in any twelve months, and the filing does not say how many shares the investor holds.
PHVSRapport priced 9,615,385 shares at $26.00 the day after reporting Phase 2a epilepsy data for RAP-219, with net proceeds of about $234.7 million. The data came from 30 treated patients and were tested against fixed null rates, not a placebo group.
RAPPFibroGen used part of the proceeds to repay about $81 million of Morgan Stanley Tactical Value term loans. Pro forma total equity turns positive only with minority interests counted, while the stockholders' deficit attributable to FibroGen remains.
KYNBThe company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance.
NCNAThe company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged.
ACIUNasdaq notified the company on August 29, 2025. Its shares closed at $1.00 or more for at least 10 consecutive business days.
EQPrecigen entered a five-year senior secured loan agreement with funds managed by Pharmakon Advisors. A $25.0 million delayed draw tranche is available until June 29, 2027, and the loans mature September 3, 2030.
PGENAdial Pharmaceuticals has until March 2, 2026 to hold its shares at $1.00 or more for ten consecutive business days. Its 10-K for 2024 said current cash would not cover the next twelve months, and its accumulated deficit reached $82.0 million.
ADILNasdaq told Celularity on September 2, 2025 that it complies with Listing Rule 5250(c)(1) again, after the company filed its Form 10-Q reports for the periods ended March 31 and June 30, 2025.
CELUNasdaq told Ironwood on August 29, 2025 that the matter is closed. The company had received a deficiency notice on May 28, 2025.
IRWDMedicus closed its Antev deal on August 29, 2025 and could owe up to approximately $65 million more on milestones. It also sold 250,000 shares to Yorkville for approximately $490,535 and added Patrick J. Mahaffy to its board.
MDCXCorMedix paid $260 million in cash and $40 million in common shares to Melinta's owners. A contingent payment agreement adds up to $25 million tied to a rezafungin approval by June 30, 2029.
CRMDNasdaq gave Context Therapeutics until February 23, 2026 to regain compliance with the $1.00 minimum bid price rule. The company says it may need a reverse stock split and cannot promise it will regain compliance.
CNTXZenas BioPharma sold Royalty Pharma a share of future obexelimab revenue for up to $300 million. It received $75 million at closing, and the other three $75 million payments depend on a Phase 3 milestone and two FDA approvals. The company says the cash lasts into the first quarter of 2027.
ZBIORPRXThe new deadline is February 23, 2026. The company says a reverse stock split is an option if needed, and it gives no assurance it will regain compliance by then.
CNTXvTv Therapeutics agreed on August 29, 2025 to sell 5,243,732 units for expected gross proceeds of about $80 million before offering expenses. Each unit carries a warrant exercisable at $22.71, and the placement was expected to close initially on September 3, 2025.
VTVTRoyalty Pharma will pay $75 million upfront for a 5.5% royalty on worldwide net sales of obexelimab, with three more $75 million payments tied to milestones.
ZBIORPRXNasdaq says Enveric does not meet the $2,500,000 minimum stockholders' equity requirement. The company reported stockholders' equity of $2,184,769 in its latest 10-Q and has until October 10, 2025 to file a compliance plan.
ENVBNasdaq's deficiency letter came after the company reported stockholders' equity of $2,184,769 at June 30, 2025, below the $2,500,000 minimum for the Nasdaq Capital Market. Enveric has until October 10, 2025 to submit a plan to regain compliance.
ENVBHolders will exercise warrants for 16,216,216 shares at $0.37. They get new Series F warrants for 64,864,864 shares at $0.55, pending shareholder approval.
MBRXThe August filing assumed $2.22 per ADS. The September 4 pricing set a combined $1.00 with short-term warrants, for about $6 million of gross proceeds before fees.
PPBTRallybio moved its listing to the Nasdaq Capital Market on August 29, 2025 after missing its first bid-price deadline. It received 180 more days, to February 23, 2026, to bring its stock back to at least $1.00.
RLYBNasdaq says Xilio reported stockholders' equity of $7,069,000 at June 30, 2025, below the $10.0 million minimum for the Global Select Market. The company has until October 6, 2025 to submit a plan, and it remains out of compliance with the $1.00 minimum bid price rule.
XLOImunon (Nasdaq: IMNN) says the Nasdaq Hearings Panel notified it on August 27, 2025 that it meets the $1.00 minimum closing bid price. The stock will continue trading on the Nasdaq Capital Market.
IMNNJourney Medical signed an at-the-market sales agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC for up to 3,750,000 shares. It ended an older B. Riley program under which it had sold 4,121,318 shares.
DERMThe Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent 15% stock dividend.
IMNNCuranex closed its initial public offering of 3,750,000 shares at $4.00 a share on August 27, 2025. Dominari Securities led the underwriters, and the proceeds are earmarked for Phyto-N, a lead drug candidate for ulcerative colitis.
CURXThe FDA accepted the GTx-104 application on August 22, 2025, with an April 23, 2026 target date. Warrants from the September 2023 private placement, at $3.003 each, expire on the earlier of the 60th day after acceptance or September 25, 2028.
GRCEA Nasdaq letter received August 26, 2025 says Veru has regained compliance with the $1.00 minimum bid price rule and that the matter is closed. Nasdaq first wrote to the company about the bid price on August 29, 2024.
VERUIndivior says its Action Agenda initiative brings headcount reductions and real estate consolidations. It expects $27 million to $35 million of the charges to be cash and is exploring strategic alternatives for OPVEE and its non-U.S. business.
INDVBriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange.
BCTBCTXPiper Sandler & Co. and Cantor Fitzgerald & Co. are the agents under an August 25, 2025 equity distribution agreement. The company's latest annual report shows cash used in operations of CAD 1.9 million for fiscal 2024.
DRUGEvofem's sixth amendment to its Aditxt merger agreement adds a new Series G-1 preferred stock to the deal and caps dissenting shares. Common holders share a total of $1,800,000, and the proxy says no fairness opinion was sought.
EVFMShattuck says the placement could fund operations into 2029 if all warrants are exercised. Two new directors join the board, including OrbiMed's Mona Ashiya, and four directors leave.
STTKIRONNasdaq staff told Dermata on August 22, 2025 that the company again meets the $1.00 minimum bid price, which closes the matter. The company needed a hearing panel's exception to reach that point, and its 8-K gives no cash figure.
DRMASarepta would swap about $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due 2030, about $123.3 million in cash and new shares. It also agreed to a $20.0 million private placement, with J. Wood Capital Advisors LLC as financial advisor and subscriber.
SRPTThe new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed.
ATOSEnanta Pharmaceuticals says it sued Pfizer Inc. and certain of its subsidiaries in the Unified Patent Court on Aug 20, 2025, alleging infringement of a European patent through Paxlovid sales. The claim is untested, and no hearing date is given.
ENTANasdaq says Genprex's equity of $1,391,195 is below the $2.5 million minimum, adding a second basis for delisting to an unresolved bid price failure. A hearing request has stayed any delisting for now.
GNPXPro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients.
NBPNasdaq says HCW Biologics was out of compliance with its equity rule on June 30, 2025. The shares would be suspended on August 28 unless the company asks for a hearing by August 26.
HCWBUnicycive said a securities class action was filed in the Northern District of California against the company and certain of its officers, who are not named. The suit concerns statements about its oxylanthanum carbonate application. The company calls the claims meritless.
UNCYStockholders' equity of $1,391,195 at June 30, 2025 is below the $2.5 million minimum. Genprex has asked for a Nasdaq Hearings Panel hearing, which pauses any delisting while the process runs.
GNPXPropanc sold 1,000,000 shares at $4.00 each, while its prospectus carries a going-concern warning and reports $50,760 of cash on March 31, 2025. The stock left the OTC Pink market for the Nasdaq Capital Market.
PPCBThe company says it needs more time to review its financial statements after recent changes in management. It expects to file its Form 10-Q within the five calendar day period under Rule 12b-25.
CINGOS Therapies could not file its quarterly report for the period ended June 30, 2025 by its August 14, 2025 due date. Its last annual report carried an auditor's going concern warning and showed $5,533,527 of cash at the end of 2024.
OSTXHeron's board adopted a Tax Benefit Preservation Plan on August 13, 2025. A holder that reaches 4.99% without board approval would trigger rights, and the company says it had about $1.37 billion of U.S. federal NOLs at December 31, 2024.
HRTXCingulate filed a late-filing notice for its report on the quarter ended June 30, 2025. It expects to file within the five-day extension period.
CINGHCW Biologics says it needs more time to finish its June quarter 10-Q and expects to file within the five-day grace period. The notice gives no revenue, loss or cash figures.
HCWBThe plan, effective August 14, 2025, aims to deter any investor or group from reaching 4.99% of the common stock. The release gives no current taxable income, net loss or cash figure.
HRTXOS Therapies says it needs more time to finish its financial statement close for the quarter ended June 30, 2025, and expects to file within the five-day extension.
OSTXSol-Gel's second-quarter report shows $24.2 million in cash and securities at June 30, 2025, and net income of $11.6 million that came mostly from a one-time $16 million sale of U.S. product rights. The company's largest pipeline asset still has no results until the fourth quarter of 2026.
SLGLSoligenix reported stockholders' equity of $1,828,951 at June 30, 2025 and has until September 29, 2025 to submit a plan to regain compliance with the Nasdaq minimum.
SNGXThe company says $0.4 million of milestone payments to Sarborg Limited were booked as research and development expense but should have been an acquired diagnostic asset. It plans to amend its first-quarter Form 10-Q.
CDTAllarity says its auditors have not finished reviewing the quarter. It expects to file within five calendar days of the due date and does not anticipate a significant change in results from a year earlier.
ALLRNRx Pharmaceuticals (Nasdaq: NRXP) told the SEC it needs more time to compile information for its June 30, 2025 quarterly report. It expects to file within five calendar days of the due date.
NRXPThe company filed a late-filing notice on August 14, 2025 for its report on the quarter ended June 30, 2025. It expects to file within the extension period, but its auditors had not finished their review.
ALLRApimeds says it cannot file its quarterly report for the period ended June 30, 2025 on time and expects to file within the five-day extension. Its lead drug, Apitox, rests on a prior Phase III trial that the company's own filing describes in conflicting terms.
APUSAquestive sold 21,250,000 shares at $4.00 through Leerink Partners, Cantor and Oppenheimer, a day after agreeing to a conditional $75 million revenue-interest deal with an affiliate of RTW Investments. Anaphylm's approval is a condition of that deal.
AQSTJupiter said it needs more time to complete the presentation and review of its financial statements. It expects to file within five calendar days of the deadline and says it anticipates no significant change in results.
JUNSNRx told the SEC it will miss the regular deadline for its June quarter report and needs more time to compile information. It expects to file within the form's five-day grace period, and the notice gives no figures.
NRXPNeOnc needs more time to review non-cash expense charges tied to previously granted restricted stock units. It expects to file within five days.
NTHIThe company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date.
OCEAProtagenic Therapeutics said on August 14, 2025 that it cannot file its June quarter report on time, because its board approved a restructuring to a virtual operating model on August 8. The company expects to file by August 19, 2025, and the notice gives no cost or cash estimate for the restructuring.
PTIXDenali Capital filed a Form 12b-25 notice on August 14, 2025 saying it cannot file its June 30, 2025 quarterly report on time, because it is still completing its financial statements. The notice says the report will come no later than the fifth calendar day after the due date.
SMNRBridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025.
BBOTThe Open Market Sale Agreement with Jefferies is dated June 23, 2023. Enliven's common stock is listed on the Nasdaq Global Select Market.
ELVNProMIS filed a $50,000,000 base shelf on Form S-3 and an at-the-market agreement with H.C. Wainwright & Co. for up to $17,988,524 of common shares, at a commission of up to 3.0%. The stock closed at $0.628 on August 11, 2025, and the supplement does not explain its float figures.
PMNCorMedix closed a $150,000,000 private placement of 4.00% convertible senior notes due 2030 on August 12, 2025. Each $1,000 of principal converts into 74.2515 common shares at the initial rate, and U.S. Bank Trust Company is trustee under the new indenture.
CRMDORIC expects a one-time cost of approximately $1.9 million for the workforce reduction. The company says cash and investments should fund its revised operating plan into 2H 2028, helped by $244 million in gross proceeds.
ORICThe 4.00% notes were sold in a private placement. The initial conversion rate is 74.2515 shares of common stock per $1,000 principal amount.
CRMDDiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance.
DMACThe company ended discovery research to focus on ORIC-944 and enozertinib. It does not expect to use its at-the-market facility for the foreseeable future.
ORICVeru's 1-for-10 reverse stock split took effect at 11:59 p.m. Central time on August 8, 2025, and the stock trades split-adjusted from August 11. The 8-K gives no reason for the split and no pre-split share count.
VERUVerrica's 1-for-10 reverse stock split took effect at the close of trading on July 24, 2025, cutting issued shares from 92,650,404 to 9,265,034. Second-quarter net income of $0.2 million depended on an $8.0 million Torii milestone.
VRCAThinkEquity was sole underwriter for 5,620,000 units and 380,000 pre-funded units. Warrants carry a $2.50 exercise price and trade as BIVIW; BioVie plans to use the money for working capital.
BIVINet proceeds were about $15.2 million after fees and expenses. The company plans to start a Phase IIa concussion trial in Q3 2025.
OGENBioVie priced 6,000,000 units, including pre-funded units, at $2.00 each for about $12 million. ThinkEquity is sole book-running manager, and the prospectus says the financial statements raise substantial doubt about the company's ability to continue as a going concern.
BIVIFibroBiologics received a Nasdaq notice that its market value of listed securities is below the $35.0 million minimum. It has until February 2, 2026 to close at or above that level for ten business days, and the 8-K gives no current market value or remedy.
FBLGNasdaq has given Processa until February 2, 2026 to bring its share price back to at least $1, a second 180-day period. The company says it will consider a reverse stock split, and the filing gives no recent share price to show how far it is from the threshold.
PCSAFormer Censa securityholders holding about 90% of its equity gave up 8% to 12% net sales payments on sepiapterin. PTC will owe milestone payments of about $90.0 million each if sales reach set thresholds.
PTCTProcessa says the private placement closed August 6, 2025, with LifeSci Capital LLC as exclusive placement agent. The company also says it is evaluating corporate cryptocurrency treasury strategies.
PCSACorMedix said it will buy Melinta Therapeutics, with closing targeted as early as September 1, 2025. The company's August 7 release gives no price, no financing and no adviser for the deal.
CRMDPTC paid about $225.0 million in cash to former Censa holders who gave up their share of sepiapterin sales, and it is still obligated to make five milestone payments of about $90.0 million each. The filing does not say what the rights were worth.
PTCTHelix says about $120 million remains in trust after redemptions, and that a $261 million private placement led by Cormorant Asset Management would bring the merger with BBOT to about $382 million gross.
BBOTOncotelic's $560,000 note converts at a fixed $0.07 per share and carries 10% interest, and a separate equity purchase agreement with the same lender could add up to $25 million of stock sales.
OTLCBon Natural Life says Nasdaq has closed its bid price matter after the Hearings Panel decision, but the company stays under a one-year Discretionary Panel Monitor. The Nasdaq confirmation came on July 29, 2025, and the company reported it in a Form 6-K dated August 4, 2025.
BONNasdaq's board declined to review a May 15, 2025 Listing Council decision, making it Nasdaq's final action. The company's chief financial officer and a director have also resigned.
OCEAExicure said it met Listing Rule 5250(c)(1) as of July 1, 2025, after filing its Form 10-Q for the quarter ended March 31, 2025.
XCURAlzamend Neuro (Nasdaq: ALZN) issued 243,429 common shares between July 23 and July 30, 2025 on conversion of Series B Convertible Preferred Stock. It had 3,139,861 common shares outstanding on July 30.
ALZNGeoVax's closing bid price was below $1.00 for 30 consecutive business days, according to a July 31, 2025 deficiency letter. The first deadline is January 27, 2026, and a second 180-day period is possible.
GOVXThe company has until January 26, 2026 to regain compliance. Its shares keep trading on The Nasdaq Capital Market under the symbol IBIO for now.
IBIOQuazar Investment would buy 1.4 million shares and fund trials and infrastructure in the UAE and MENA region. Closing still depends on a capital formation round.
NTHISupernus completed its acquisition of Sage Therapeutics on July 31, 2025 after a tender offer, paying $8.50 in cash per share plus a contingent value right worth up to $3.50. The filing puts the cash consideration at about $561 million, and says no CVR payment is assured.
SUPNThe Form F-4 for Veraxa Biotech Holding AG is dated July 16, 2025 and covers the business combination with Voyager Acquisition Corp. under an agreement dated April 22, 2025. The date of Voyager's shareholder meeting is still blank.
VRXAPropanc Biopharma sold a $112,350 convertible note to 1800 Diagonal Lending LLC for $107,000. The note bears 22% interest, matures April 30, 2026 and converts at a 25% discount after 180 days, in a stock its last annual report says was quoted at $0.0003.
PPCBMerck expects to eliminate certain positions in sales, administrative and research and development organizations and expects annual savings of approximately $1.7 billion, substantially realized by the end of 2027.
MRKRevenue was $24.5 million in both fiscal 2025 and fiscal 2024, and the net loss widened to $30.2 million from $26.1 million. The release gives no date for the regained Nasdaq compliance.
HYFTCingulate reported on July 25, 2025 that it issued common stock in three transactions with a lender, in exchange for part of the debt it owes, at $4.18 to $4.79 a share. The filing also covers a 7,538-share issuance to a service provider and a 30,000-share officer option grant. It names no bank or placement agent.
CINGThe Israeli company may sell American depositary shares from time to time and is not obligated to sell any. LifeSci Capital will earn a 3.0% commission.
CMMBCytoDyn filed a Form S-3 shelf that would let it offer up to $100,000,000 of stock, warrants, subscription rights and units. The stock is quoted on the OTCQB, where it closed at $0.29 on July 24, 2025, and the shelf cannot be used until it takes effect.
CYDYLyell's private placement starts with about $50 million at $13.32 per share. A second $50 million at $25.61 per share depends on a milestone within 12 months.
LYELPolar Asset Management Partners is buying 5,365,853 shares at a premium of approximately 14% to the closing price on the agreement date. Closing was expected on or about July 28, 2025.
OMERProcessa filed a new prospectus supplement that lets it sell up to $5,239,073 of stock through its at-the-market program with A.G.P./Alliance Global Partners. Its shares closed at $0.2497 on July 22, 2025, down from $0.40 on June 11, 2025, the date its public float was measured.
PCSAIncannex had already sold about $63,469,250 of stock under the program. A week later it said it has no plans to use the full capacity in the near term.
IXHLRocket says the plan, approved by its board on June 18, 2025, aims to extend its operational runway into the second quarter of 2027. The company expects about $3.5 million in charges in the second half of 2025, against a 2024 operating cash outflow of $209.7 million.
RCKTAdicet's board approved a cut of about 30% of its workforce on July 22, 2025 and ended its ADI-270 cancer program. The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024.
ACETScilex will pay a $1,500,000 option fee in two installments. If the buyback is completed and paid in full, the maturity of the Tranche A Note moves to March 31, 2026.
ORMPDiaMedica will sell 8,606,426 common shares at $3.50 each, for expected gross proceeds of $30.1 million before fees. The 8-K names no placement agent, and the company used $22,076 thousand in operations in 2024 while its equity fell to $40,718 thousand.
DMACAbeona Therapeutics lowered the rate on its senior secured term loan from 13.5% to a fixed 11.75% and gave the Avenue lenders warrants for up to 16,474 shares at $6.07. Its 2024 net loss was $63.7 million, and its 10-K says $98.1 million in year-end cash and investments, plus later at-the-market proceeds, covers at least 12 months from issuance.
ABEONeuphoria Therapeutics received a Nasdaq notice that it did not hold an annual meeting within a year of its June 30, 2024 fiscal year end. It has until September 1, 2025 to submit a plan, and its annual report for that year carries a going-concern warning with cash that, combined with an ATM facility, is expected to fund work into late in the first quarter of fiscal 2026.
NEUPThe Nasdaq Stock Market LLC filed a Form 25-NSE on July 18, 2025, to remove Avenue Therapeutics common stock from listing and registration.
ATXI60 Degrees Pharmaceuticals priced 2,631,578 shares at $1.90 with warrants. About $5 million comes in up front, and the short-term warrants could bring in about $5 million more only if fully exercised for cash.
SXTPGain agreed to sell 4,501,640 shares and warrants for 2,250,820 shares at $3.11 per set through Newbridge Securities. It expects net proceeds of approximately $6.3 million, with closing expected on or about July 17, 2025.
GANXThe company's American Depositary Shares closed at $1.00 or more for 10 straight business days, ending a deficiency first flagged on March 24, 2025.
CNTBThe deal gives the company rights tied to the antibody in its lead drug candidate, givastomig, and removes royalties owed on it. The efficacy figure behind the program is early and comes from a dose escalation study of 17 patients.
NBPCell Source's July 16, 2025 Form 15 checked the rule for suspending reporting duties. Its later filing list shows more reports, and in January 2026 the company said it was preparing a Nasdaq uplist.
CLCSThe stock closed at $1.00 or higher for 10 consecutive business days from June 27, 2025 to July 11, 2025. Nasdaq considers the matter closed.
INDPOnconetix holders would keep 10% of the combined company. Closing was expected in the fourth quarter of 2025, subject to regulatory, stockholder and third-party approvals.
ONCOThe panel granted the exception on July 11, 2025, so Imunon can regain compliance with the $1.00 minimum bid price and the stockholders' equity requirement. Stockholders also approved 2,000,000 more plan shares, bringing the plan's limit to 3,970,000.
IMNNMaloneBailey said recurring losses and a net capital deficiency raise substantial doubt. Stockholders' equity fell to $2,857 thousand from $11,752 thousand.
ARTLThe shell company says the registration statement for its merger with BBOT is effective and set a shareholder meeting for August 4, 2025, but the release gives no deal value or minimum cash figure.
BBOTBBIONasdaq Stock Market LLC filed a Form 25 notification dated July 11, 2025 to strike Bio-Path Holdings' common stock from listing and registration. The notice cites Exchange Act Rule 12d2-2(b), which covers removals the exchange initiates, and it does not give the reason.
BPTHThe amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under the agreement so far.
NBPRani Therapeutics filed a resale prospectus on July 11, 2025 covering up to 13,160,172 Class A shares issuable on exercise of a Series D warrant. The company says it will receive no proceeds from the resale itself.
RANIDenali Capital deposited $874.78 into its trust account to extend its deadline by one month, to August 11, 2025. The blank-check company's units, shares and warrants now trade on the Pink market and the OTCQB, and it remains a shell company that depends on monthly extensions.
SMNRPacira is shutting down its 45-liter EXPAREL suite in San Diego and cutting 71 employees, about 8% of its workforce. It expects $2.4 million to $2.8 million of cash charges in the third quarter and about $13 million a year in lower operating expenses.
PCRXNasdaq confirmed on July 9, 2025 that Jupiter's stock held an average closing price of at least $1.00 over 13 days. The company's last annual report still carries a going concern warning.
JUNSPacira is closing its 45-liter EXPAREL manufacturing system and cutting about 70 Technical Operations jobs, and the employee note it filed says the larger 200-liter process in San Diego and Swindon now supplies the product.
PCRXNasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025.
FTHThe new $10 million line covers spending through June 2026, and $81 million of earlier borrowings from the same investor now mature September 30, 2026. The lead drug's NAVIGATE composite endpoint did not reach statistical significance.
GALTNasus Pharma seeks to list 1,000,000 shares on NYSE American at $10.00 to $12.00. Its prospectus says current cash will not fund planned operations, which raises substantial doubt about going concern, and its epinephrine Phase 2 study included 12 patients.
NSRXRecursion issued 1,457,952 of its shares to Rallybio's selling subsidiary. Rallybio could receive more shares, development milestone payments and low single digit royalties later.
RLYBRallybio sold its 50% interest in the ENPP1 joint venture to a Recursion subsidiary on July 8, 2025. It received 1,457,952 Recursion shares for an initial $7,500,000, and it could receive $12,500,000 more in stock if milestones are met.
RLYBNasdaq confirmed on July 7, 2025 that Unicycive's shares had averaged at least $1.00 after a 1:10 reverse stock split took effect on June 20, 2025. The release does not say what the FDA has done on the company's lead candidate, which had a PDUFA date of June 28, 2025.
UNCYThe July 3, 2025 credit agreement is a $300.0 million senior secured revolver maturing July 3, 2030, and Pacira used part of it to repay its term loan A without prepayment penalties or fees. Wells Fargo Bank is administrative agent, and Wells Fargo Securities, Citizens Bank and Truist Securities are joint bookrunners and lead arrangers.
PCRXThe board approved the program on July 1, 2025. It runs through December 31, 2026 and will be funded from existing cash on hand, but the 8-K gives no cash balance to measure that against.
COLLPacira signed a $300.0 million senior secured revolving credit facility with Wells Fargo as administrative agent, and used part of it to repay its 2023 term loan A. The filing does not say how much was drawn.
PCRXProMIS now has until December 29, 2025 to lift its share price to at least $1.00. It said it may effect a reverse stock split if necessary.
PMNNasdaq notified Silo Pharma on June 27, 2025 that its common stock has not met the $1.00 minimum bid price. The company has until December 24, 2025 to regain compliance, and may consider a reverse stock split if needed.
SILOThinkEquity LLC will earn a 3.0% commission on shares sold. Lantern's public float was $46,607,112 as of July 3, 2025, which limits sales to one-third of that float in any 12-month period while the float stays below $75 million.
LTRNLexicon gets until December 30, 2025 to regain the $1 minimum bid price and moves to the Nasdaq Capital Market on July 7, 2025, with a reverse split on the table if needed.
LXRXNasdaq told Silo Pharma on June 27, 2025 that its common stock fell below the $1.00 minimum bid price, based on closing bids from May 14 to June 26. The company has until December 24, 2025 to regain compliance and says it may consider a reverse stock split.
SILOThe net loss widened to $3.3 million as third-party sales fell. Cash rose to $47,272,851, mainly because of a $15,000,000 share issue and related-party borrowings.
UPCAlaunos told Nasdaq on July 2, 2025 that its audit committee falls short of Listing Rule 5605(c). The shortfall came after chief executive Dale Curtis Hogue, Jr. resigned and director Holger Weis took over as CEO and left the committee. The company plans to use a 180-day grace period.
TCRTOragenics closed a registered offering of 660,000 Series H preferred shares and warrants on July 2, 2025, for about $16.5 million gross. The preferred converts at $2.50 a share, the conversion price has no floor, and Dawson James Securities took 7.00% of gross proceeds as placement agent.
OGENAbeona received gross proceeds of $155 million on June 27, 2025. The company says unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million as of June 30, 2025.
ABEOThe sale closed on June 27, 2025. Abeona says cash and investments were about $225 million as of June 30, 2025, a figure it labels unaudited, and the release again does not name the buyer.
ABEOEach unit carried one share and two warrants exercisable at $0.65. Estimated net proceeds are $5,582,557.50, and the lead program is a COVID-19 vaccine whose key comparison trial is still ahead.
GOVXTuHURA closed its merger with Kineta on June 30, 2025, issuing about 2,868,169 shares at closing, with about 1,129,885 more due after six months, subject to adjustment. The deal adds the antibody TBS-2025, for which the press release reports tolerability and receptor occupancy but no efficacy results.
HURAAptevo says about $15.9 million of gross equity raised in the June quarter puts it back above Nasdaq's $2.5 million stockholders' equity minimum. The figure is the company's own belief, and it was still awaiting formal confirmation from Nasdaq.
APVOThe company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake.
BFRIEach Kineta share converts into 0.185298 TuHURA shares, or 2,868,169 shares in total, with 1,129,885 more due after six months. The release gives no cash balance or loss figure.
HURAA single institutional investor is buying 1,952,363 shares or pre-funded warrants plus options on the same number of shares. H.C. Wainwright is placement agent.
INMAntev shareholders would receive about 17% of Medicus common shares, plus up to US$65 million in contingent payments tied to FDA milestones. Antev's lead drug missed a secondary endpoint in an earlier Phase 2a trial, and Medicus carries going-concern doubt.
MDCXThe company has until December 24, 2025 to regain compliance. The notice has no immediate effect on its listing on The Nasdaq Global Select Market.
IMUXThe company has until December 22, 2025 to regain compliance. It may qualify for a second 180-day period and is considering its options.
KTTAThe stock closed below $1.00 for 30 straight business days. The company may consider a reverse stock split to regain compliance.
MBRXNasdaq told Nektar on June 24, 2025 that it met the minimum bid rule after a $1.00 closing bid held for 10 consecutive business days. The 8-K gives no share price or financial figures, and the company's pipeline is still in mid-stage trials.
NKTRThe warrant holders net exercised in full after Zymeworks removed a 19.99% ownership cap. Shares outstanding rose to 74,844,505.
ZYMEMarcum LLP resigned as Cell Source's auditor on June 26, 2025, after CBIZ CPAs took over its attest practice. Marcum's reports on 2022 and 2023 carried a going-concern paragraph.
CLCSThe deal pairs each share with a $7.00 warrant and is expected to bring in approximately $4.7 million in gross proceeds. Bios 2024 Co-Invest, LP, a current stockholder, is among the purchasers, and the filing says Bios would be deemed to own about 49.9% of the company.
ACTUSCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.
SCYXRani Therapeutics received a Nasdaq notice on June 20, 2025 that its Class A shares had a closing bid price below $1.00 for 30 consecutive business days. Its deadline to regain compliance is December 17, 2025, and the notice gives no closing price.
RANISCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.
SCYXLipella's common stock was quoted on the OTC Pink Market under LIPO as of June 19, 2025. Nasdaq objected to securities paid to a placement agent and advisor.
LIPOAmarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually.
AMRNAmarin is licensing Vazkepa in Europe to Recordati for a $25 million upfront payment and starting a restructuring that targets about $70 million in cost savings over the next 12 months, while the release gives no loss or cash-flow figures.
AMRNAmendment No. 6 to Aytu's loan and security agreement moves both maturities to June 12, 2029 and raises the term loan principal to $13.0 million. The new advance carries SOFR plus 5.50%.
AYTUImpact BioMedical agreed on June 21, 2025 to a reverse merger with Dr Ashleys, after which Impact holders would own 4.80% of the combined company. Closing needs shareholder approval, an effective registration statement and NYSE American listing approvals.
IBOThe combined company would trade on the NYSE American as Dr Ashleys Limited. The deal needs Impact BioMedical shareholder approval.
IBOAN2 Therapeutics swapped 2,500,000 and 300,000 common shares for pre-funded warrants held by Coastlands Capital Partners LP on June 17 and June 19, 2025, and the 8-K reports no cash to the company from either exchange.
ANTXThe NYSE accepted Annovis Bio's plan to regain compliance with its market capitalization and stockholders' equity standards, giving the company 18 months from a March 26, 2025 notice, quarterly progress reports and a warning that trading could still be suspended.
ANVSTheriva Biologics filed to sell up to $2,534,352 of stock through A.G.P./Alliance Global Partners, under a cap set by its public float. Its auditor's report carries a going-concern paragraph, and the main survival result in its lead trial has a p-value of 0.0546.
TOVXCrescent Biopharma completed its merger with GlycoMimetics, and the combined company began trading as CBIO on June 16, 2025. The $200 million financing includes $37.5 million of converted notes. GlycoMimetics's own 2024 10-K had raised going-concern doubt.
CBIOProthena expects $16 to $20 million in severance and related charges from the workforce reduction. Its Chief Regulatory Officer and Chief People Officer will leave effective August 1, 2025.
PRTAReShape says sales under its at-the-market program and a June 9 offering have lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The company says that does not guarantee it will stay listed.
HINDJyong Biotech, a Taiwan-based drug developer, priced 2,666,667 shares at $7.50 with Joseph Stone Capital, LLC as sole underwriter. Its lead candidate failed its primary endpoint in a pivotal U.S. trial, its auditor has raised going-concern doubt, and a Chinese court judgment puts about USD 19.4 million at stake.
MENSProthena will cut about 63% of its workforce after ending birtamimab, and expects $16 to $20 million in charges, mostly cash. The 8-K gives no headcount, cash balance or savings figure.
PRTANextCure agreed to pay Hainan Simcere Zaiming $17 million, including a $12 million upfront payment, for rights to a Phase 1 antibody drug conjugate. A Zaiming affiliate agreed to buy 4,063,633 shares for $2.0 million, and the company now says its cash lasts into mid-2026, not the second half of 2026 that its March 6 annual report gave.
NXTCAptevo filed to sell up to 1,709,401 shares with five common warrants each and signed a $25.0 million equity line with Yorkville. Its auditor's report carries a going concern paragraph, and cash was $2,139 thousand at March 31, 2025.
APVOAn 8-K filed June 13, 2025 reports the sale. Certain insiders had agreed in April to buy up to $10,000,000 of stock at $3.25 per share in the private placement.
RZLTNasdaq extended Equillium's deadline to December 8, 2025. The company says it will consider options including a reverse stock split, and its stock keeps trading on the Nasdaq Capital Market as "EQ".
EQThe transfer from the Nasdaq Global Market is part of the company's effort to meet Nasdaq continued listing requirements. Shares would keep trading as IXHL.
IXHLADC Therapeutics approved a restructuring on June 11, 2025 that closes its U.K. research facility and cuts about 30% of its global workforce. The same day it agreed to a $100 million private placement priced at $3.53 per share.
ADCTA Nasdaq panel accepted Spruce Biosciences' appeal, but the stock returns to the Capital Market only if it meets the minimum bid price by August 5, 2025. Trading had been suspended on April 29, 2025, and the 10-K carries a going-concern warning.
SPRBNasdaq notified the company on June 11, 2025. Its American Depositary Shares will stay listed and traded on Nasdaq.
NBPSpruce's shares have traded over the counter since a Nasdaq suspension on April 29, 2025. The Hearings Panel accepted the company's appeal on June 9, 2025, but the stock returns to the Nasdaq Capital Market only if it meets the bid price requirement by August 5, 2025.
SPRBTempest sold 405,000 shares and prefunded warrants for 334,000 shares to one institutional investor at $6.25 each, for about $4.1 million net. The company's cash estimate runs only into the second quarter of 2026, and it is exploring strategic alternatives.
TPSTCogent drew $50 million of a term loan facility of up to $400 million from SLR credit funds on June 11, 2025. Most of the rest depends on pivotal trial results and a launch the company expects in 2026, and the debt falls due in 2030.
COGTSalarius cut its relative valuation in the Decoy merger from $4.6 million to $2.31 million, so its legacy holders would keep 7.6% of the combined company instead of 14.1%. The 8-K blames "substantial deterioration" in its share price.
DCOYTonix set up two ways to sell new stock on June 11, 2025: up to $150.0 million through A.G.P./Alliance Global Partners and up to $75.0 million to Lincoln Park Capital Fund. Its lead drug has an FDA decision date of August 15, 2025.
TNXPAytu paid Fabre-Kramer a $3,000,000 upfront on June 5, 2025 for U.S. rights to EXXUA and owes a second $3,000,000 tied to sales timing. Royalties start at 28% of net sales, and the annual report shows an accumulated deficit of $320.0 million.
AYTUBolt Biotherapeutics filed a one-for-twenty reverse stock split on June 6, 2025, with split-adjusted trading set for June 9. The 8-K gives no reason for the split, and the company's 2024 annual report already said there was substantial doubt about its ability to continue as a going concern.
BOLTAytu agreed to pay a $3,000,000 upfront for U.S. rights to EXXUA, with further payments and royalties of 28% to 39% of net sales that depend on sales.
AYTUBolt Biotherapeutics filed a Certificate of Amendment on June 6, 2025 to effect a one-for-twenty reverse stock split. Split-adjusted trading on the Nasdaq Capital Market under the existing ticker BOLT was scheduled to begin June 9, 2025, under a new CUSIP number.
BOLTCommon stock authorized rises from 200,000,000 shares. The vote was 85,825,060 for and 11,001,501 against, and the 8-K gives no reason for the larger share count.
TNGXCheckpoint Therapeutics became a wholly owned Sun Pharma subsidiary on May 30, 2025. Fortress may also get up to $4.8 million through CVRs and a 2.5% royalty on certain net sales.
FBIOHolders of warrants for 8,301,322 shares agreed to exercise at a reduced price of $0.3041 per share. Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025.
CLRBTalphera (TLPH) moved its listing to The Nasdaq Capital Market on May 30, 2025 and received an additional 180 days to regain the $1.00 minimum bid price. It has told Nasdaq it will use a reverse stock split, if necessary.
TLPHLupin Limited gets a license to launch a generic WAKIX no earlier than January 2030, or July 2030 with pediatric exclusivity, and the Delaware case will be dismissed.
HRMYAvalo ended an earlier $50.0 million sales agreement with Oppenheimer. Its stock last sold at $3.72 on May 29, 2025.
AVTXFortress Biotech says it will receive about $28.0 million in cash from the sale of Checkpoint Therapeutics to Sun Pharma, with up to $4.8 million more if a milestone is met. The gain on deconsolidation is an accounting figure, and pro forma cash is lower than reported.
FBIOTalphera moved its stock to the Nasdaq Capital Market on May 30, 2025 to qualify. It told Nasdaq it would do a reverse stock split if necessary.
TLPHThe note carries interest of up to 12.5% and matures on June 3, 2028. Elicio expects the cash to fund operations into the first quarter of 2026.
ELTXNektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split, and a June 6 amendment raised authorized shares to 390,000,000.
NKTRNasdaq said Ironwood's Class A stock closed below $1.00 for 30 consecutive business days. The company has until November 24, 2025 to regain compliance, and the letter has no immediate effect on its listing.
IRWDAlto may owe up to $71,500,000 in milestone payments, payable in cash or restricted stock, and says its cash is still expected to fund operations into 2028.
ANROBon Natural Life's board approved a share repurchase of up to $1.0 million of its Class A ordinary shares, to be bought in the open market by TradeUp Securities as exclusive agent. The company says it is not obliged to buy any particular number of shares and may suspend the program at any time.
BONActuate Therapeutics filed a corporate overview dated May 31, 2025 that repeats its going-concern warning and says it needs capital to fund operations beyond the second quarter of fiscal 2025. The deck's survival figures are draft, unaudited data, and its progression-free survival result is not statistically significant.
ACTUAdagene Inc. filed a prospectus supplement for an at-the-market program of up to US$100 million of American depositary shares, sold through Leerink Partners. The filing repeats the warning that its auditor is in mainland China, where trading in its ADSs could be barred.
ADAGAdlai Nortye's Phase III BURAN trial of buparlisib missed its overall survival endpoint, the company is dropping the drug, and it plans to cut staff "to preserve cash," with the release giving no survival figures.
ANLMaxim Group LLC is the exclusive sales agent for up to $9,700,000 of stock, for a 3.0% commission. Two days earlier, Nasdaq had determined to delist ReShape, whose stockholders' equity was $1.2 million at March 31, 2025.
HINDThe company's stock closed below $1.00 for 30 consecutive business days. It may be eligible for a second period of 180 calendar days.
MTVAB. Riley Securities and Alliance Global Partners will act as sales agents for a 3% commission. The stock's last reported sale price was $1.10 on May 27, 2025.
RVPHKeros's board approved a plan on May 28, 2025 to cut its overall workforce by about 45%, with about $3.2 million in severance charges and up to about $0.4 million in retention costs. The cuts follow the January 2025 early termination of the PAH trial over pericardial effusion events, though the company held $559.9 million in cash at the end of 2024.
KROSHeadcount will fall to 85 full-time employees, with average annualized savings of about $17 million. The strategic alternatives review is still under way.
KROSORIC Pharmaceuticals agreed to sell about 19.2 million shares or pre-funded warrants at $6.50 in a private placement with roughly $125 million in gross proceeds. The company says the cash funds operations into the second half of 2027, a runway tied to a Phase 3 readout it has not yet reported.
ORICMAIA Biotechnology (NYSE American: MAIA) expects gross proceeds of approximately $695,000 from shares sold at $1.50 with warrants at $1.71. A director is among the buyers, and closing is expected May 29, 2025.
MAIANasdaq closed the matter on May 27, 2025, after the stock closed at $1.00 or above for 10 consecutive trading days. The annual report put the lead programs in Phase 1, and the 8-K gives no cash figures.
CTMXImmunic began an underwritten warrant offering on May 28, 2025 and set final terms on May 30: $0.7499 a unit, $64,991,334 in total. Leerink Partners is sole bookrunner.
IMUXMindMed named Brandi L. Roberts chief financial officer effective June 2, 2025, with inducement awards of an option on 500,000 shares and 125,000 performance share units. The awards sit outside the company's equity plans, and the lead drug's pivotal trials have not yet reported.
DFTXA new purchaser joined the Series L 10% Convertible Preferred deal, which now carries an aggregate purchase price of $5,950,000.00. Buyers also hold greenshoe rights for up to $21,616,514 more.
GTBPThe U.S. District Court for the District of Maryland granted preliminary approval on May 9, 2025 to a settlement of shareholder derivative suits against current and former Emergent directors and officers. The settlement provides a $15 million payment to the company from insurance and governance reforms, and final approval is set for August 6, 2025.
EBSThe May 22, 2025 letter cites Nasdaq Listing Rule 5550(b)(1). Artelo has until July 7, 2025 to submit a plan to regain compliance, and the stock stays listed in the meantime.
ARTLBoundless Bio will drop current BBI-355 trial arms and test BBI-355 with BBI-825. The cut is expected to cost about $1.2 million. Cash and short-term investments were $138.3 million on March 31, 2025, with runway expected into the first half of 2028.
BOLDBiofrontera reported stockholders' equity of $469,000 at March 31, 2025, far below the $2,500,000 Nasdaq requires. It has 45 calendar days to submit a plan to regain compliance.
BFRIThe minimum stockholders' equity requirement is $2.5 million. Q32 Bio has 45 calendar days to submit a plan to regain compliance.
QTTBNasdaq flagged the missing quarterly report on May 20, 2025 as another basis for delisting, ahead of a Panel hearing set for May 27, 2025. Onconetix also issued a promissory note to Keystone Capital Partners for a $250,000.00 purchase price.
ONCOAptevo reported a stockholders' deficit of $1,473,000 against a $2,500,000 minimum. It also filed an at-the-market prospectus supplement for up to $3,015,515 of stock, and it set a 1-for-20 reverse stock split for May 23, 2025.
APVONasdaq confirmed on May 22, 2025 that the bid price deficiency matter is closed. The stock closed at $1.00 or more for 13 consecutive business days.
SLGLAlumis Inc. says the merger closed May 21, 2025, making ACELYRIN a wholly owned subsidiary. Alumis says its cash runway now extends into 2027, and Lynn Tetrault joined its board.
ALMSTelomir sold 1 million restricted shares at $3.00 each to The Bayshore Trust, an entity affiliated with its largest shareholder. The price is 18% above the $2.54 closing price on the day of signing, and an earlier insider purchase in December 2024 was made at $7.00 a share.
TELOThe closing release uses 0.4814 shares per ACELYRIN share, while the merger agreement and Alumis's annual report set 0.4274, and the release does not explain the gap.
ALMSA Nasdaq Hearings Panel has decided to delist Petros, with trading suspended at the open on May 22, 2025, on four grounds that include equity and bid-price rules and concern over the February 2025 public offering. Petros will ask the Listing Council to review the decision.
PTPIRani Therapeutics cut the exercise price of two outstanding warrants from $3.08 and $3.00 to $0.65 so an existing institutional investor would exercise them, for gross proceeds of about $4.3 million before advisory fees. The investor also receives a new Series D warrant for up to 13,160,172 shares.
RANIA federal court in Delaware ruled for Acadia on infringement and validity of the '721 patent against Aurobindo and MSN entities. The company also signed a lease of 12 years and two months for new Princeton offices.
ACADRoyalty Pharma Holdings Ltd also assumed a $380 million term loan facility. The 8-K reports a loan amendment with Bank of America, N.A., an exchange agreement and amended articles of association.
RPRXPhytanix Bio holders would own about 65% of the combined company before financing, on a fully diluted basis, and their preferred stock and warrants need Nasdaq stockholder approval before they can convert or be exercised. The release's count of six drug candidates includes five preclinical assets.
PTIXChina SXT sold 10,000,000 shares with two warrants each for a combined $0.51 a share. The warrant exercise price resets to $0.24 on the seventh day, and the warrants could cover up to 100,000,000 shares. No placement agent or underwriter was used.
SXTCDermata said on May 16, 2025 that Nasdaq's staff has confirmed it regained compliance with the stockholders' equity requirement, but a bid price notice says its securities will be suspended on May 23, 2025 unless it requests a hearing by May 21. The company plans to request one.
DRMAThe company says it needs more time to compile its financial statements for the quarter ended March 31, 2025, including to reflect the May 9, 2025 reverse stock split.
HINDExicure told the SEC on May 15, 2025 that it cannot file its quarterly report for the period ended March 31, 2025 on time, because it has not finished the accounting for its acquisition of GPCR Therapeutics USA, Inc. The company expects to file within the five-day extension that Rule 12b-25 allows, and it says the acquisition will make the quarter's results hard to compare with last year.
XCURPulmatrix said the SEC declared effective the registration statement for its proposed merger with Cullgen, which it expects to close in June 2025. It plans to divest PUR3100 and its other assets as part of the deal. Its cash was $7.7 million on March 31, 2025.
PULMThe one-for-one exchange also means Omeros no longer has to make a $20.0 million term loan prepayment. Separately, it agreed to convert $10 million of the old notes into common stock.
OMERThe company filed a late-filing notice for its quarterly report for the three months ended March 31, 2025. Its lead candidate, GLSI-100, is in a Phase III trial that is still expanding.
GLSIEach unit carries two warrants exercisable at $7.45, and Maxim Group was sole placement agent. The prospectus carries going-concern doubt and a Nasdaq compliance warning.
HCWBHepion says it is still compiling information for its March quarter 10-Q and expects to file within five calendar days. The notice previews research and development spending of $22,235, down from $2.5 million.
HEPAReShape says a reverse stock split on May 9, 2025 is one reason its March quarter 10-Q needs more time. It expects to file within the five-day extension and says it does not expect a significant change in results.
HINDNeuphoria said it needs more time to compile supporting documents and let its auditor finish its review. It expects to file within the five-day extension period.
NEUPPulmatrix says the SEC has declared effective its Form S-4 for the Cullgen merger, and expects a June 2025 close while it seeks buyers for its own assets. It had $7.7 million of cash at March 31, 2025, which it says lasts through the anticipated closing.
PULMTivic reported $669,000 of cash at March 31, 2025 and a $1.5 million net loss for the quarter. It then lined up a $25 million equity line and a purchase agreement for up to $8.4 million of securities.
VBIOThe company said it needs more time on the purchase price allocation for GPCR Therapeutics USA, Inc. It expects results to change significantly from the March 31, 2024 quarter.
XCURMetaVia sold 9,479,345 shares at $0.71 each and pre-funded warrants for 4,605,162 shares. Ladenburg Thalmann was the exclusive placement agent, for a cash fee of 9.0% of gross proceeds.
MTVAJade Biosciences (Nasdaq: JBIO) reported a net loss of $38,169 thousand and cash of $49,929 thousand for the quarter ended March 31, 2025, a period that ended before the merger and pre-closing financing closed April 28.
JBIOCitius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price.
CTORCTXRThe company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31.
CTXRCTORAerovate Therapeutics took the Jade Biosciences name when the deal closed on April 28, 2025. Pre-merger Jade's management team runs the combined company.
JBIOInvestors are buying 9,479,345 shares at $0.71 and 4,605,162 pre-funded warrants. Proceeds go mainly to development of obesity candidate DA-1726.
MTVAOncolytics had cash of 15,303 thousand Canadian dollars at March 31, 2025, and said it can fund operations through the third quarter of 2025.
ONCYThe term loan has four tranches and matures June 1, 2029. The company reported $150 million in cash, cash equivalents and short-term investments as of March 31, 2025.
ALTThe complaint alleges Liquidia infringes U.S. Patent No. 11,357,782 and seeks to bar Liquidia from commercializing YUTREPIA if approved. Liquidia says the claims mirror a patent that the Patent Trial and Appeal Board held invalid.
LQDAAbeona received the voucher when the FDA approved ZEVASKYN on April 28, 2025. The company says the proceeds give it cash for more than two years of operating expenses, but the release does not name the buyer.
ABEOLeerink Partners earns 3.0% of any gross proceeds, and CervoMed is not obliged to sell any shares. The prospectus supplement notes an auditor going-concern paragraph.
CRVONasdaq's hearings panel decided to delist Hepion after it failed the $1.00 minimum bid price and Nasdaq said it believes the company is a public shell. Trading was set to stop on May 13, 2025, and Hepion expects its shares to quote on the OTC Markets.
HEPAImmunome's cash total includes $161.7 million from a January 2025 financing, and the quarter ended with a $41.6 million net loss. Its lead drug's Phase 3 data are not due until the second half of 2025.
IMNMThe new shelf replaces one that expires on September 12, 2025. Jefferies LLC would earn up to 3.0% on ATM sales, and Tango's stock closed at $1.10 per share on May 8, 2025.
TNGXApimeds is selling 3,375,000 shares at $4.00 for $13.5 million gross and listing on the NYSE American as APUS. Its controlling holder stays above 54%, and the company carries a going-concern paragraph from its auditor.
APUSNuvectis can sell up to $60 million of stock through Leerink. It ended an earlier $40 million program with H.C. Wainwright after selling about $18.6 million under it.
NVCTThe auditor's report cites recurring losses. Management also changed how it accounts for two amendments to a $100.0 million royalty-backed financing.
LQDAKorro Bio began a restructuring on May 7, 2025, cutting about 20% of its workforce and taking one-time charges of about $1.2 million. The company cut costs before its first interim data readout, and its net loss widened in the first quarter.
KRROJefferies LLC is the sales agent under an Open Market Sale Agreement for the $100,000,000 at-the-market portion. The May 7, 2025 filing gives a last reported sale price of $4.36 on May 5, 2025 and does not state a cash balance.
DSGNThe agreement covers up to $20,000,000 of stock, but small-float limits cap current sales at $2,994,080.
KRSAThe combined price of $0.6454 per ADS is set below the $1.10 last sale price on May 5, 2025. Warrant terms and a zero exercise price option on the Series B warrants could issue far more ADSs than the 2,452,935 sold.
NCNATransCode received a Nasdaq notice on May 6, 2025 that its stock would be delisted from the Nasdaq Capital Market unless it appeals. Earlier reverse splits left it with no compliance period, so it must request a hearing by May 13, 2025.
RNAZThe amount is what remains under a $75,000,000 sales agreement with Guggenheim Securities after $25,000,000 was sold earlier. Dilution to new buyers at the May 2 price is $4.05 per share, and the company has recorded net losses in every year since it was founded.
COGTThe bonds of KC Creation Co., Ltd. mature on April 30, 2028 and yield 2.9% a year. KC Creation expects to use the money to buy stocks of other corporations.
XCUREvolus signed term loans of up to $250,000,000 in three tranches, with $150,000,000 advanced at the effective date. The loans carry 3-month SOFR plus 5.0%, with a 3.50% floor, and mature five years after the first tranche. Early repayment carries an exit payment of 2% of principal prepaid.
EOLSPDS Biotechnology sold $22,222,222 of senior secured convertible debentures for $20,000,000 on April 30, 2025, and used about $19 million to repay its Horizon Technology loan. The filing names no placement agent, underwriter, financial adviser or counsel.
PDSBArvinas expects about $10 million in severance and termination costs, mostly in the second quarter of 2025. It and Pfizer removed two planned Phase 3 combination trials from the joint development plan.
ARVNAerovate Therapeutics, whose only drug candidate missed its Phase 2b primary endpoint, closed its merger with Jade Biosciences on April 28, 2025. Aerovate holders kept about 1.4% of the combined company, and the financing includes $95 million of converted notes.
JBIOPliant expects to substantially complete the reduction by the end of the second quarter of 2025, with about $3.6 million in severance and related benefits. The cut follows the discontinuation of its BEACON-IPF Phase 2b trial of bexotegrast.
PLRXAN2 Therapeutics says the Phase 3 portion of its EBO-301 study missed its primary endpoint, and it projects $78.5 million in cash lasting into 2028 while it shifts to Chagas, melioidosis and oncology programs that have no human efficacy data yet.
ANTXThe May 1, 2025 registration statement covered up to 3,246,753 shares at an assumed $1.54. The deal priced on May 6, 2025 at $1.40 for 3,571,428 shares or pre-funded warrants.
KTTAThe company says it needs more time for financial reporting, closing procedures and other disclosure items.
XRTXABVC reported stockholders' equity of $723,959, below the $2,500,000 Nasdaq minimum. It also sold shares to 15 non-U.S. buyers for a little more than $436,000.
ABVCAnnJi will pay Avenue $2.0 million over 90 days, plus possible milestones and a 1.75% royalty.
ATXINasdaq said on April 29, 2025 that Quoin's ADSs closed at $1.00 or more from April 9 to April 28, closing the minimum bid price matter. The company says it has no commercialized product and has generated no revenue to date.
QNRXThe annual report for 2024 also lists dilution risk and the availability of capital for working capital needs.
XTLBThe board approved a strategic plan on April 29, 2025 that expects about $2 million in charges, mostly severance. The company says its cash runway still reaches into the second quarter of 2027.
TRDAPfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program.
PFENasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq.
AMRNEntrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another.
TRDAThe company says it is still compiling information for its annual report for the year ended December 31, 2024.
ZYBTSerina can sell up to $13,270,500 of stock through JonesTrading, which earns up to a 3.0% commission. Its auditor has raised going concern doubt, its lead drug is still preclinical, and the program's size is capped by an SEC float rule.
SERNasdaq sent the company a formal notice of compliance on April 24, 2025. The 8-K does not say how the price was restored, and the lead drug's Phase 3 timeline is subject to funding.
TPSTNasdaq says the stock's bid price was below $1.00 for 30 consecutive business days and, after a recent reverse stock split, no compliance period applies. The company plans to appeal by April 30, 2025.
DCOYNasdaq told Incannex on April 23, 2025 that its shares had closed below $1.00 for 30 consecutive trading days, giving it until October 20, 2025 to regain compliance. Its annual report for the year ended June 30, 2024 carries an auditor's going concern paragraph.
IXHLNasdaq will suspend trading on April 29, 2025, and the company's appeal will not stop it. The company is cutting 55% of staff to focus on a rare-disease therapy it has not yet filed for approval, with going-concern doubt on record.
SPRBVerastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.
VSTMNYSE American accepted AEON Biopharma's plan to regain compliance with three continued listing standards and gave the company until August 3, 2026. The 8-K does not say which financial measures the company missed, and the company's migraine trials failed their primary endpoints.
AEONVerastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.
VSTMThe offering is a best-efforts deal placed by Laidlaw & Company (UK) Ltd. Warrant terms with a zero exercise price option and reset provisions could push the number of ADSs issued far above the 16,049,383 offered.
NCNARezolute will sell 20,786,923 shares at $3.25 and pre-funded warrants for up to 6,905,385 shares, through Guggenheim Securities as representative of the underwriters. Estimated net proceeds are $84.2 million, and insiders separately agreed to buy up to $10,000,000 of stock at the same price.
RZLTPacira BioSciences says its board approved a $300.0 million repurchase program on April 17, 2025, replacing the program announced in May 2024, while EXPAREL still accounts for most of its revenue.
PCRXThe company refinanced its K2 HealthVentures term loans with a $42.0 million first tranche, cut the interest rate and gave lenders the right to convert up to $7.0 million into shares. Up to $120.0 million is available in total, but the filing reports only the first tranche as funded.
DFTXJazz paid $8.55 per share in cash after its tender offer for Chimerix expired on April 17, 2025. Chimerix is now a wholly owned subsidiary of Jazz.
JAZZThe amendment allows up to $120.0 million of term loans, with a $42.0 million first tranche that refinanced existing loans. Interest carries a floor of 10.25%, lenders can convert up to $7.0 million into shares, and the 8-K gives no cash balance or net loss.
DFTXCitius Pharmaceuticals sold one share of a newly designated Series A preferred stock for $100 to Chairman and CEO Leonard Mazur on April 17, 2025. The share carries 1,000,000,000 votes on a proposal to raise authorized common shares from 16,000,000 to 250,000,000, and the board also cut the quorum for stockholder meetings to one-third.
CTXRTempest Therapeutics will cut 21 of its 26 full-time employees as it explores strategic alternatives, with cuts effective April 30, 2025. It expects about $1.5 million in cash costs, mostly severance, and its 2024 10-K said cash of $30.3 million would last at least 12 months.
TPSTOne letter cites the $50,000,000 market value of listed securities rule, with a deadline of October 13, 2025. The other cites the $1.00 minimum bid price rule.
ASBPThe Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going.
AVIRCOYACadrenal can sell up to $2,169,272 of common stock through H.C. Wainwright & Co., LLC, after it has already sold $7,655,240 under the same agreement. The sales are capped by an SEC rule that applies because its public float is under $75 million.
CVKDNasdaq found PainReform complies with Rule 5550(b)(1), but warned that delisting could follow if the next periodic report does not show compliance.
PRFXCara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported.
TVRDOS Therapies says the purchase adds three clinical-stage and eight preclinical listeria-based cancer immunotherapy candidates, but the release gives neither the price nor the terms.
OSTXNasdaq says MIRA's stockholders' equity of $2,199,750 at December 31, 2024 is below the $2.5 million minimum. The company has until May 23, 2025 to submit a plan, and says a pending acquisition would bring a $5 million capital infusion.
MIRAMIRA reported stockholders' equity of $2,199,750 as of December 31, 2024, below the $2.5 million Nasdaq minimum. It has until May 23, 2025 to submit a plan to regain compliance, and its main fix is an acquisition the release says it expects to complete.
MIRAAmendment No. 1, dated April 7, 2025, drops the second merger so Cullgen survives the merger as a wholly owned Pulmatrix subsidiary. It also clarifies the fractional shares provision.
PULMNYSE Regulation said it will start proceedings to delist Palatin Technologies (NYSE American: PTN) after the company did not regain compliance within an 18-month plan period. Palatin intends to appeal.
PTNPulmatrix and Cullgen signed Amendment No. 1 to their merger agreement on April 7, 2025, dropping the planned second merger. The 8-K gives no exchange ratio, share count or valuation, and does not say why the structure changed.
PULMImmunic agreed on April 9, 2025 to sell 5,666,667 shares at $0.90 each for about $5.1 million, with Titan Partners Group LLC as sole placement agent. The company's 2024 annual report carried a going concern doubt and reported $35.7 million in cash at year end.
IMUXEach American Depositary Share will represent twenty ordinary shares instead of one. The company says the aim is to meet Nasdaq's $1.00 minimum bid price.
AMRNNasdaq staff said Denali Capital Acquisition Corp. had not regained compliance with its $50.0 million market value and total assets rules and also failed the public float rule. The blank-check company's securities will be delisted unless it appeals by April 9, 2025.
SMNRZevra received gross proceeds of $150.0 million at the April 1, 2025 closing. The press release puts net cash proceeds at $148.3 million and cash, cash equivalents and investments at approximately $68.7 million on March 31, 2025.
ZVRATraws Pharma raised its at-the-market limit to $7,427,749 under the baby shelf cap, after selling 42,100 shares for about $122,210. The float that sets the cap uses an $8.29 high close, while the stock closed at $1.96 on April 4, 2025.
TRAWW. Thorpe McKenzie retired from the board effective March 27, 2025. XBiotech will run one-member audit and compensation committees for now.
XBITArbutus Biopharma and Genevant Sciences sued Moderna, Inc. and a Moderna affiliate, which the filing does not name, over patents tied to the MRNA-1273 COVID-19 vaccine. On March 31, 2025 the court moved the patent trial from September 24 to September 29, 2025.
ABUSMoonLake's subsidiary, MoonLake Immunotherapeutics AG, borrowed the first tranche on March 31, 2025. Most further tranches depend on trial and FDA milestones, and the facility matures April 1, 2030.
MLTXDogwood says a $19.9 million debt exchange with Conjoint and a sale of about $4.8 million in common stock lifted its stockholders' equity above the $2.5 million minimum. Nasdaq had set a May 14, 2025 deadline, and the release does not include a Nasdaq decision.
DWTXOnconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities.
ONCOReShape Lifesciences filed a Form NT 10-K on April 1, 2025, saying it needs more time to compile information for its 2024 annual report. The notice does not explain the delay, and the company's 2023 annual report set a cost reduction target of about 55.4% for 2024.
HINDCara stockholders approved the share issuance for the merger with Tvardi, a reverse split range of 1-for-2 to 1-for-4, and an increase in authorized shares to 150,000,000.
TVRDLyell expects $3.0 million to $4.0 million in closure and severance costs and net cash use of $175 million - $185 million in 2025. Its Chief Business Officer is also resigning.
LYELBoundless Bio filed a Form S-3 on April 1, 2025 covering up to $400.0 million of securities. The same day it signed an at-the-market sales agreement with Jefferies LLC for up to $14.5 million of common stock, which can start only after the SEC declares the registration effective.
BOLDThe company reported pro forma stockholders' equity of $2.8 million as of March 31, 2025, against a $2.5 million minimum. It also said it meets the market value of publicly held securities rule.
CDTThe company needs more time for the first audit by an accounting firm it retained in September 2024. It estimates a loss from operations of about $1.9 million for 2024.
EMMAThe company says it needs more time on its 2024 financial statements and audit procedures. Its lead drug, REQORSA, has a Phase 2a trial whose enrollment rules changed twice in 2024 and 2025.
GNPXThe company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023.
ONCOThe company cited delays in completing its financial statements. It expects to file within the extension period of up to fifteen calendar days under Rule 12b-25.
VCNXThe company says it is still completing its audit for the year ended December 31, 2024 and expects to file the 10-K within 15 calendar days of the due date. It does not expect a significant change in results.
ABVCThe company says it cannot file its 2024 annual report on time and expects to use the 15-day extension. Research and development expenses rose to $12,952,029, and the Phase IIb data behind its lead trial carry unresolved record gaps.
GLSIMatinas said it needs more time to review its financial statements for the year ended December 31, 2024 and plans to file its Form 10-K within the fifteen calendar day extension. It does not anticipate a significant change in results of operations.
MTNBThe company says it needs additional time to complete its financial statements for the period ended December 31, 2024. It checked the box for filing within the fifteenth calendar day after the due date.
SBFMAspire Biopharma told the SEC on March 31, 2025 that it needs more time to finish its 2024 financial statements. The notice gives no reason beyond that, and its narrative refers to a 10-Q deadline that does not match the annual report it is about.
ASBPRein Therapeutics, formerly Aileron, filed a late-filing notice for its 2024 annual report and expects an impairment loss of about $37.0 million tied to a delay in developing LTI-01. The charge is non-cash, but the company's 2023 annual report already carried a going-concern warning.
RNTXABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period.
ABVCThe company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension.
AKTXThe company said it could not file by April 15, 2025, the original due date, because it needs more time for its financial statements.
ASBPThe company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period.
BIXTCelularity expects 2024 revenue of $54.2 million and a loss from operations of $37.3 million, figures it says are still under review.
CELUNasdaq told CNS Pharmaceuticals on March 31, 2025 that it meets the $1.00 bid price rule. For one year, a new lapse leads to a delisting determination, with no compliance plan or extra time.
CNSPThe board approved the Share Repurchase Program on March 31, 2025. The 8-K says the full terms are in a press release attached as Exhibit 99.1, and the 8-K body gives none of them.
EBSThe company needs more time to complete the review of its financial statements and plans to file within the fifteen calendar day extension.
MTNBThe company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year.
OTLCTransCode said it needs time to account for a registered direct offering that closed on March 25, 2025. It expects to file within the Rule 12b-25 extension period.
RNAZThe impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impairment assessment.
RNTXThe company said it needs more time to finalize its financial statements and audit. It plans to file within the fifteen-day extension.
RVPHThe Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results.
SBFMThe company said it could not compile all the information for its financial statements in time. It expects to file within the fifteen-day grace period.
SKVISpruce expects cash to be insufficient to fund research and development for at least 12 months without new financing. It expects collaboration revenue to fall about 50%.
SPRBSavara told Evercore it is ending a $100.0 million at-the-market sales agreement, effective April 2, 2025. The company says it owes no termination penalty and has sold no shares under the agreement since December 31, 2024.
SVRAAcurx Pharmaceuticals received a Nasdaq letter saying it no longer meets the $2,500,000 stockholders' equity minimum for the Capital Market. The company must submit a plan to regain compliance by May 9, 2025, and the notice rests on its 2024 annual report.
ACXPThe company says it is still compiling information for the report. It expects to file no later than the fifteenth calendar day after the due date.
CLCSDermata agreed with holders of warrants for 4,834,470 shares to exercise at a reduced $1.284 a share, for about $6.2 million before fees. In return they receive new Series A and Series B warrants for up to 4,980,806 and 4,688,134 shares.
DRMAThe company expects to file within the 15-day extension period after its accounting staff finalizes the statements.
KAPAFibroGen, now Kyntra Bio, and Fortis Therapeutics amended their evaluation agreement and option and merger agreement, moving the option exercise deadline.
KYNBThe shares come from Series B and Series C preferred stock and placement agent warrants tied to its private offerings. On April 4, 2025 Lipella added an at-the-market program of up to $2,641,881.
LIPOThe NYSE says Annovis's 30-day average market capitalization was approximately $37.9 million and its stockholders' equity was $9.3 million, both under the $50 million floor. The company's 10-K already carries a going-concern warning and says its cash lasts into the fourth quarter of 2025.
ANVSIronwood (Nasdaq: IRWD) has until May 20, 2025, to submit a plan to regain compliance with Nasdaq's timely filing rule and says it plans to file the 2024 Form 10-K as soon as practicable.
IRWDNkarta is cutting 53 positions, about 34% of its staff, at an expected cost of $5.5 million to $6.5 million. It says its $380.5 million of cash and investments can fund operations into 2029, while the first clinical data from its lead program are not due until the second half of 2025.
NKTXRelmada Therapeutics agreed on March 24, 2025 to license NDV-01 from Trigone Pharma for a $3,500,000 upfront fee and 3,017,420 restricted shares, which the press release says is 10% of its outstanding stock. Milestones can reach $200 million, and from 2026 Relmada must spend at least $5,000,000 a year on the drug.
RLMDKAKEN INVESTMENTS INC. paid $102.4 million in cash at closing on March 25, 2025, after purchase price adjustments, for 100% of the stock of Aadi Subsidiary, Inc.
WHWKSavara drew the first $30 million of a loan of up to $200 million from a group led by Hercules Capital, and used it to repay its Silicon Valley Bank term loan. Later draws depend on FDA approval of MOLBREEVI, a revenue milestone or lender approval.
SVRABenitec Biopharma is issuing 2,043,000 shares and 300,000 pre-funded warrants at $13.00 a share. The prospectus says 900,000 of the shares go directly to Averill funds that are affiliates of Suvretta Capital, while the pricing release names Suvretta Capital itself.
BNTCThe smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far.
MAIANkarta is cutting 34% of its workforce and freezing some hires, and it says $380.5 million in cash will fund operations into 2029. Its release reports no efficacy data for NKX019, and the trials enroll small groups.
NKTXThe buyer paid the cash on closing after purchase price adjustments. The deal was signed on December 19, 2024 under the company's former name, Aadi Bioscience.
WHWKDermata reported stockholders' equity of about $1.6 million against the $2.5 million Nasdaq minimum. It must regain compliance or submit a plan by May 9, 2025.
DRMAJupiter Neurosciences received a Nasdaq letter on March 21, 2025 saying its stock fails the $1.00 minimum bid price rule. The company has until September 17, 2025 to regain compliance.
JUNSThe sales agent earns up to 3.0% of gross sales. Climb Bio reported $212.5 million of cash and securities at year end and expects to fund operations through 2027.
CLYMNet proceeds are about $9.1 million. The auditor has raised going-concern doubt, and preliminary year-end cash was $30.9 million.
GNLXThe prospectus puts gross proceeds at $4,999,878 and says auditors have raised going-concern doubt. Cash covers operations into the third quarter of 2025 with the money.
GRINeOnc's prospectus registers 2,101,313 shares for resale in a Nasdaq direct listing, and the company gets none of the proceeds. Its financial advisor RBW Capital Partners is also the placement agent for a $10 million private placement, and the auditor's report carries a going concern paragraph.
NTHITransCode is selling 10,250,000 shares and warrants at $0.98 per share and warrant, through ThinkEquity LLC as exclusive placement agent, for a total offering price of $10,045,000 before fees. The prospectus shows an immediate dilution of $0.72 per share to new investors, and the auditor's report carries a going concern paragraph.
RNAZThe Nasdaq-listed company sold shares, warrants and pre-funded warrants through Craig-Hallum for gross proceeds of approximately $20.0 million. Its CEO and board chairman bought in a separate private placement.
IRDThe company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025.
CNSPAn amendment with TD Cowen cuts the program to $100 million, and the 8-K gives no reason for the cut. The new supplement shows immediate dilution of $3.78 per share at the $4.44 reference price.
FHTXBausch Health's subsidiary launched a $4.0 billion offering of senior secured notes due 2032, and the parent began syndicating new secured credit facilities. The proceeds would retire 2025 and 2027 debt, but the filing gives no interest rate on the new notes or the term loan.
BHCAkebia priced 25,000,000 shares at $2.00 for gross proceeds of $50.0 million, below the $2.84 last sale price the final prospectus cites for March 19, 2025. The company estimates net proceeds of about $46.5 million and reports an accumulated deficit of $1,678,360 thousand.
AKBAMinerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital.
NERVMilestone amended its Jefferies sales agreement to allow up to $75,000,000 of new common shares, within a $77,800,000 total that includes about $2.8 million already sold. Jefferies can earn up to 3.0% commission, and the shares closed at $2.41 on March 17, 2025.
MISTHarrow says it needs more time for accounting analyses and its internal controls evaluation. It expects no changes to preliminary 2024 results, including revenues of between $198 million and $200 million.
HROWFibroGen did not regain compliance by March 11, 2025 and appealed a Nasdaq delisting decision on March 14, 2025. The delisting is stayed pending a Hearings Panel ruling.
KYNBThe company failed to meet Nasdaq's $2,500,000 stockholders' equity rule by the panel's deadline. Trading moves to the OTC Markets under the ATXI symbol.
ATXIThe two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Phase 1.
ENTXOPKThe Rochester, New York company filed the notice on March 17, 2025. It covers its common stock, par value $0.0001 per share.
VCNXGelteq cannot sell to Lincoln Park until a resale registration statement is declared effective. The agreement caps issuance at 1,881,328 shares unless shareholders approve more or the average price reaches $1.29.
GELSThe requirement was met on March 12, 2025 after a notice dated January 29, 2025. Nasdaq considers the matter closed.
TLSAPliant's board adopted a limited-duration rights plan on March 12, 2025, citing recent accumulations of its common stock. The rights trigger at 10% ownership, or 20% for certain passive investors, and expire on March 11, 2026.
PLRXPliant's board adopted a one-year stockholder rights plan, and the company's trigger is a 10% stake bought without board approval. The release cites unspecified "recent accumulations" of stock and does not name who was buying, less than two weeks after its annual report disclosed the discontinuation of its lead Phase 2b trial.
PLRXRallybio cut its at-the-market stock program from $100,000,000 to $9,550,000 on March 13, 2025. The company says it has sold no shares under the agreement, and the cut follows an SEC rule that limits sales for companies with a public float below $75.0 million.
RLYBShuttle Pharmaceuticals priced 19,166,667 shares, or pre-funded warrants, at $0.30 per share for gross proceeds expected to be about $5.75 million. WestPark Capital, Inc. is the sole book-runner on a firm commitment basis.
SHPHEterna Therapeutics (now Ernexa Therapeutics, Nasdaq: ERNA) received $1,500,000 on March 11, 2025, under a promissory note with 5.0% interest that matures no later than June 15, 2025.
ERNADogwood will cancel its loans from Conjoint Inc., a subsidiary of its largest shareholder, for 284.2638 shares of Series A-1 preferred stock convertible into 10,000 common shares each.
DWTXThe secured term loan matures on March 12, 2026. Armata also pushed back the maturity of three earlier Innoviva credit agreements to the same date.
ARMPINVAViking Therapeutics' Irish subsidiary agreed on March 10, 2025 to make prepayments to CordenPharma for supply of its obesity candidate VK2735. The 8-K puts the prepayments at $90.0 million through 2028, and the press release gives a $150 million total. This is money Viking pays out, not money it raises, and neither document gives a cash balance against which to test it.
VKTXThe blank-check company's annual report says it must liquidate if it does not close its deal with BridgeBio Oncology by February 14, 2026, and that doubt over its ability to continue is substantial.
BBOTLeerink Partners will earn 3.0% of gross proceeds on any sales. The stock last sold at $0.8449 on March 10, 2025.
XLOAcurx Pharmaceuticals sold 2,150,000 shares and pre-funded warrants for 595,000 more at about $0.40 each, and added private warrants for up to 8,235,000 shares. The price is far below the $1.015 the company got in a January offering, and a Nasdaq bid-price notice arrived on February 24, 2025.
ACXPCheckpoint Therapeutics, the majority-controlled unit of Fortress Biotech, agreed to be bought by Sun Pharma for $4.10 in cash per share plus a contingent value right of up to $0.70. Fortress has agreed to vote in favor and will receive a 2.5% royalty.
FBIONasdaq told Adial Pharmaceuticals on March 5, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until September 1, 2025 to regain compliance, and its annual report carries a going-concern warning.
ADILThe company will not receive any proceeds from sales by the stockholder. The shares were acquired under a stock purchase agreement dated November 25, 2024.
ARWRNuvation Bio's automatic shelf lets it sell up to $200,000,000 of common stock through Jefferies LLC as sales agent, at up to 3.0% of gross proceeds. The stock last sold at $1.82 on March 4, 2025, and the company's lead drug is still waiting on an FDA decision.
NUVBRTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials.
TENXALX Oncology's board approved a cut of about 30% of staff on Feb 28, 2025, and eliminates its president and chief scientific officer role. The company estimates about $2.2 million in severance and benefits for a lead drug that has not completed a pivotal trial.
ALXOThe Avenue Venture Opportunities Fund II loan matures September 1, 2028 and carries a warrant for 641,163 shares at $2.32. CalciMedica says the first tranche extends its cash runway to the middle of 2026.
CALCJazz Pharmaceuticals agreed to buy Chimerix for $8.55 a share in cash, about $935 million in total, through a tender offer. The main asset, dordaviprone, is still awaiting an FDA decision, and Chimerix owes Jazz a $35 million fee in some cases if it accepts a rival offer.
JAZZAadi Bioscience closed a private placement of about $100 million on March 4, 2025, selling 21,592,000 shares at $2.40 and pre-funded warrants for 20,076,500 more shares. The company says the money, with the FYARRO sale, should fund operations into 2028.
WHWKThe company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so.
IBIOIronwood said it expects its internal control over financial reporting to be ineffective as of December 31, 2024. It plans to file within the 15-day grace period.
IRWDAerovate filed a Jade communication on March 3, 2025, under their October 30, 2024 merger agreement. The combined company is expected to trade on Nasdaq as JBIO.
JBIOA federal judge in Washington denied Liquidia's summary judgment motion on February 27, 2025, upholding the FDA's three-year exclusivity for United Therapeutics' Tyvaso DPI. The exclusivity still ends May 23, 2025, and a related cross claim remains pending.
LQDAMustang Bio received the $1.0 million purchase price from escrow on February 25, 2025. It expects about $2.0 million in cash savings on the lease over the next 24 months and has moved its headquarters to Waltham.
MBIOAbCellera's common shares last sold at $2.92 per share on February 26, 2025. The prospectus sets no dollar amount for the offerings and names no bank or agent.
ABCLAltimmune's $400 million shelf would also carry a $150 million share sales program, with Leerink Partners, Piper Sandler and Stifel as sales agents. The filing itself sells no shares.
ALTCrescent Biopharma said on February 24, 2025 that it still expects its reverse merger with GlycoMimetics to close in the second quarter of 2025. The merger filing says the deal depends on a financing transaction and on GlycoMimetics stockholder approval.
CBIOThe company expects about $2.0 million in lease savings over 24 months. It has moved its headquarters to Waltham, Massachusetts.
MBIOShuttle paid Alto Opportunity Master Fund $75,000 under an amendment signed February 26, 2025. The holder gave up its right to buy up to $10 million of additional notes and warrants, and waived its right to join a contemplated registered offering.
SHPHThe company expects the sale to close within 30 to 45 days, subject to customary conditions including a Hart-Scott-Rodino waiting period.
ZVRANasdaq said CytomX stock did not hold a $1.00 minimum bid for 30 consecutive business days. The company has 180 calendar days to regain compliance, and the notice has no immediate effect on its listing.
CTMXKiniksa has incurred about $19 million in expenses from ending the Sjögren's trial and expects $14 million to $17 million more. It reported $243.6 million in cash, cash equivalents and short-term investments and no debt, and its 2024 net loss was $43.2 million.
KNSARallybio's closing bid price was below $1.00 for 30 consecutive business days. It may be eligible for another 180-day period if it applies to move its listing to the Nasdaq Capital Market.
RLYBMAIA Biotechnology agreed on February 24, 2025 to sell 894,300 shares at $1.50 each, with warrants at $1.85, to accredited investors and certain directors. Combined gross proceeds are expected to be about $1.43 million, and the company's 2023 annual report carried a going-concern warning.
MAIAThe company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on the report.
UPCNasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until August 20, 2025 to cure, and a second 180-day period is possible.
ATOSBofA Securities will sell shares as agent for a commission of up to 3.0%. The stock last sold at $0.7724 before the filing.
KYNBUroGen paid for IconOVir Bio's ICVB-1042 candidate with shares tied to a $4.0 million price, a possible $15.0 million sales milestone and a low single-digit royalty. Entities tied to UroGen's board chair hold IconOVir notes.
URGNThe later date applies only if none of the company's 1.5% convertible notes due May 24, 2026 remain outstanding. Otherwise the loan comes due earlier.
HRTXPharming's subsidiary now controls 92.70 percent of Abliva through its SEK 0.45 cash offer, and it has extended the acceptance period to March 6, 2025 for holders who have not yet tendered. Pharming plans a compulsory acquisition of the rest and a delisting from Nasdaq Stockholm.
PHARMPHARThe deal covers the product candidate ICVB-1042. A director's affiliates hold IconOVir notes that may entitle them to about 28.3% of the purchase price.
URGNNasdaq's staff found on February 12, 2025 that Conduit Pharmaceuticals had not met two market value requirements within the 180-day grace period. The next day the company repaid the last $926,149 of a senior secured note to Nirland Limited, which it says was meant to help with the Nasdaq deficiencies.
CDTThe notes mature in 2028, 2030, 2035 and 2055. AbbVie plans to use the money and cash on hand to repay 2025 senior notes, and the sale is expected to close February 26, 2025.
ABBVPetros is selling about 40,000,000 shares, or pre-funded warrants in their place, at $0.24 for about $9.6 million gross. Dawson James Securities, Inc. is the placement agent, paid 8% of the gross proceeds, and the warrants cannot be exercised until stockholders approve them.
PTPIThe drug-delivery company is acquiring an AI solar analytics platform from BladeRanger Ltd. BladeRanger would receive 178,769 ordinary shares plus four sets of warrants, and the release gives no price or valuation for the business.
PRFXThe sales agreement with H.C. Wainwright still limits what it can sell now to $5,800,000, because of a cap tied to its public float.
CPIXCitius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes.
CTXRCTORXencor's audit committee concluded that a 2023 royalty deal with OMERS Life Sciences should be debt, not deferred income, and the company says its 2023 operating cash flow was overstated by $163.0 million. It also found tax misstatements. The company says cash and marketable debt securities are not affected.
XNCRNasdaq says Ovid's average closing bid price was below $1.00 for 31 consecutive trading days. The company has 180 calendar days to regain compliance and says its Nasdaq listing is unaffected for now.
OVIDNasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00.
BCTBCTXEdesa sold 834 Series B-1 preferred shares at $10,000 each and 3,468,746 common shares at $1.92. A Velan Capital analyst joined its board.
EDSANasdaq says Genprex does not meet the $1.00 minimum bid price, based on the last 30 consecutive business days. Separately, Nasdaq extended the company's deadline on the stockholders' equity requirement.
GNPXQ32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance.
QTTBGrace Therapeutics expects about $13.8 million in net proceeds from a private placement at $3.395 a share, with TD Securities (USA) LLC as placement agent. The same day, its Phase 3 safety trial of GTx-104 was reported, and the company's own release says the trial was not powered to show efficacy.
GRCEAkebia drew the extended $10.0 million Tranche C loan on February 3, 2025, the last day of its extension. It received $9.3 million net and issued a warrant to a Kreos affiliate for 1,153,846 shares at $1.30 a share.
AKBAAkebia received net proceeds of $9.3 million on February 3, 2025. The warrant has an exercise price of $1.30 per share and runs eight years.
AKBABelite Bio is selling 258,309 ADSs and warrants for the same number of ADSs at $58.07 each through Titan Partners Group LLC. The prospectus says the company has recorded net cash outflows from operations since inception.
BLTEThe warrants can be exercised only after stockholders approve. The offering follows a 1-for-50 reverse stock split on January 15, 2025.
MBIOFBIOThe offering totals $190,588,194, and the stock is approved to list on Nasdaq under SION. Proceeds to the company are $177,247,020 before expenses.
SION60 Degrees Pharmaceuticals sold 1,503,500 shares at $0.715 each in a registered direct offering that closed Feb 6, 2025. H.C. Wainwright was the placement agent, and the company reports about $908,627 of net proceeds, with matching warrants at $0.59.
SXTPACELYRIN holders would receive 0.4274 Alumis shares for each share and own about 45% of the combined company. The cash figures behind the deal are preliminary and unaudited, and ACELYRIN's lead program is being re-evaluated.
ALMSACELYRIN holders would receive 0.4274 Alumis shares for each share they own, and the $737 million pro forma cash figure rests on preliminary year-end balances.
ALMSBriaCell sold 762,500 common shares at $4.00 each through placement agent ThinkEquity. The $3.05 million in gross proceeds is before fees and expenses, and the agent also received warrants on 38,125 shares.
BCTXAlto Neuroscience filed a $300,000,000 shelf on February 3, 2025 and signed a $75,000,000 at-the-market sales agreement with Leerink Partners LLC, but no sale can start until the SEC declares the shelf effective, and its year-end cash figure is still preliminary.
ANROAnnovis Bio priced 5,250,000 units at $4.00 for $21,000,000 on February 3, 2025, through ThinkEquity as underwriter, with a $1,260,000 discount and warrants exercisable at $5.00, which is 125% of the offering price.
ANVSJefferies is the sales agent. ArriVent's stock last sold at $29.09 per share on January 30, 2025.
AVBPH.C. Wainwright & Co. is the exclusive placement agent for a $3.00 offering of shares and warrants. The auditor's report on the 2023 financial statements already raised substantial doubt about the company's ability to continue as a going concern.
ENVBThe board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027.
ZNTLThe January 21, 2025 agreement sells up to $2,840,000 of shares at $0.20 each, with warrants for 200 percent of each buyer's shares at $1.00. It also sets a penalty of 2.0 percent of the subscription amount for public information failures.
SXTCThe company expects a net loss of about $20.33 million for the year ended September 30, 2024, up from $6.16 million a year earlier.
UPCThe company applied to list on the Nasdaq Global Market. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are the underwriters named on the cover.
AARDUnder the January 15, 2025 agreement, Arvinas Operations owes no rent after the termination date if it clears the space by January 21, 2025.
ARVNThe unsecured notes carry 8% interest and convert into Series D-1 preferred stock at $2.8620 per share. The board also approved the closing of a 2024 financing under which the company had received $1,000,000 in notes.
PVCTAadi Bioscience's preliminary proxy, filed January 21, 2025, asks holders to approve a $100 million cash sale of its FYARRO business to Kaken and a private placement of 21,592,000 shares at $2.40 each. The meeting date is still blank in that filing.
WHWKPhio sold 610,000 shares at $3.00 per share and issued short-term warrants for up to 1,220,000 shares in a concurrent private placement. Net proceeds are approximately $1.6 million, after a placement agent fee of 7.5% plus a 1.0% management fee.
PHIOKairos Pharma (NYSE American: KAPA) sold 2,500,000 pre-funded units, each with a common warrant at $1.40 per share. Boustead Securities and D. Boral Capital were co-placement agents.
KAPASionna Therapeutics filed a preliminary S-1 on January 17, 2025 for an IPO of common stock on the Nasdaq Global Market under SION. The filing leaves the share count, price range and net proceeds blank, and lists Goldman Sachs & Co. LLC, TD Cowen, Stifel and Guggenheim Securities as underwriters without marking a lead.
SIONAlto Neuroscience's January 13, 2025 amendment lifts the maximum term loans from $35.0 million to $75.0 million and moves maturity to January 1, 2029. Only $20.0 million was funded at signing, and about $10 million of that went to refinance the old loan and pay fees.
ANROGain Therapeutics received a Nasdaq deficiency notice on January 8, 2025 over its Market Value of Listed Securities. Nasdaq staff confirmed in writing on January 15 that the company is back in compliance.
GANXThe note purchase agreement allows up to $150.0 million of notes with interest capped at 9.75%. Verastem also sold 1,416,939 shares to Oberland funds at $5.2931 per share and received about $32.3 million in net proceeds from the notes after the Oxford payoff. Its year-end cash figure is unaudited and preliminary.
VSTMiBio sold 240,807 common shares at $2.72 each to its directors and officers, for about $655,000 in gross proceeds, and the placement closed on January 10, 2025. The company says the price was at-the-market.
IBIOOpus Genetics can sell up to $40,000,000 of stock through Leerink Partners, which takes 3.0% of gross proceeds. The company's last reported sale price was $1.42 on January 10, 2025, and the earlier JonesTrading program had sold about $26.4 million of stock.
IRDThe January 6, 2025 letter cites Section 704 of the NYSE American Company Guide. The shares stay listed with a ".BC" indicator, and Matinas says it will hold its annual meeting no later than December 31, 2025.
MTNBIncannex Healthcare received a Nasdaq notice on January 3, 2025 that its market value of listed securities fell below the $50.0 million minimum for the Global Market. It has until July 2, 2025 to regain compliance, and its 2024 annual report carries a going-concern warning with $5.6 million of cash at June 30, 2024.
IXHLEach ADS sells for $4.275 with a warrant to buy another at $5.796. Full cash exercise of the warrants could lift gross proceeds to about $353 million.
CMPSSensei Biotherapeutics told investors on January 7, 2025 that Nasdaq had moved its stock to the Capital Market and given it until July 7, 2025 to lift its share price above $1.00. Its 2023 annual report showed a $34,101 thousand net loss and cash that fell to $13,011 thousand at year end.
FTHThe Nasdaq Hearings Panel kept the stock listed on two conditions: a reverse stock split by January 31, 2025 and a $1.00 close for ten straight trading days by February 14, 2025. The panel confirmed the equity deficiency is cured.
REVBAfter its Phase 3 ReThink-ALZ study of simufilam missed its co-primary endpoints, Cassava is cutting 10 employees, or 33% of its staff, at a one-time cost of about $0.4 million. It reported unaudited cash of about $128.6 million at December 31, 2024.
FLNAAcurx will sell 2,463,058 shares at $1.015 to institutional investors and six insiders, with Series E warrants for the same number of shares at $0.90. H.C. Wainwright & Co. is the exclusive placement agent, and it receives a 7.0% cash fee plus a 1.0% management fee.
ACXPThe Alzheimer's drug developer expects about $0.4 million in one-time costs. The release gives no efficacy numbers for the two Phase 3 studies, and it still plans to report topline results from the one it is discontinuing.
FLNAThe contract manufacturer received $7 million at closing and expects the rest in three tranches over 18 months. It says current capacity supports up to $300 million in annual revenue.
LFCRRenovaro plans to pay for Predictive Oncology with preferred stock in an all-stock deal. The letter of intent sets out the main terms, and the release gives no exchange ratio or value for the shares.
LNAIIt is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing.
ABVCAEON Biopharma priced 40,000,000 units at $0.50 each for about $20.0 million gross, with Aegis Capital Corp. as sole book-running manager. Each unit carries two warrants that cannot be exercised until stockholders approve them, and their exercise price can reset lower.
AEONThe restructuring focuses the company on CX-2051 and its research collaborations. CytomX expects the changes to extend its cash runway into the second quarter of 2026.
CTMXCitius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed.
CTORCTXREton bought the Wilson Disease treatment on December 31, 2024 for $7.0 million at closing plus $0.2 million for inventory. It will also pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of its first U.S. sale.
ETONThe sale closed December 30, 2024. Veru expects about $12.5 million in net proceeds after a $4.2 million change of control payment to SWK Funding LLC, which ended a residual royalty agreement.
VERUVeru closed the sale of its FC2 female condom business on December 30, 2024 for $18.0 million in cash. After a $4.2 million change of control payment to SWK Funding and other fees, it estimates about $12.5 million in proceeds.
VERUiBio agreed to license an anti-myostatin antibody from AstralBio and paid the $750,000 upfront fee in common stock. AstralBio can earn up to $28 million in milestones, and the antibody's data so far are preclinical.
IBIOThe deal covers 1,000,000 common shares at $2.00 each, plus two series of warrants. H.C. Wainwright & Co. is placement agent.
PBMThe company is selling 1,340,603 shares at $6.44 and 3,286 Series I preferred shares at $644.00. It expects the money to fund operations into the first quarter of 2026.
KALAPrecigen agreed to sell 8.00% Series A convertible perpetual preferred stock for anticipated gross proceeds of $79.0 million, with warrants for 52,666,669 shares at $0.75 attached. The company says the money extends its cash runway into 2026, provided the PRGN-2012 launch comes after approval.
PGENThe lender is an entity controlled by Aspire Biopharma's director of investor relations. $184,543.80 had been loaned as of the filing.
ASBPThe notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii).
RGBPThe unit held the legacy AgeX assets. Juvenescence, Serina's largest holder, paid a nominal cash amount on top of assuming the secured debt.
SERThe note carries 9% annual interest and matures in 18 months. Cingulate says the money extends its cash runway into the fourth quarter of 2025.
CINGThe shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024.
CNTXThe underwritten offering and a concurrent private placement are expected to bring net proceeds of about $37.6 million.
MNPRQuoin Pharmaceuticals priced a $6.8 million offering at $0.45 per ADS, below the $0.647 close on December 19. Older warrants were repriced to the same level, and the prospectus sets no minimum amount for the deal to close.
QNRXThe Nasdaq Hearings Panel denied the company's request to stay listed over the $1.00 minimum bid price rule. Shares are to trade as CYTOF, and the company says it plans no reverse stock split.
CYTOFInvestors agreed to buy 1,783,805 shares plus warrants. The warrants need stockholder approval before they can be exercised.
MRKRCara Therapeutics agreed on December 18, 2024 to combine with private Tvardi Therapeutics in an all-stock deal. Pre-merger Cara holders would own about 17.0% of the combined company, and the closing depends on Cara holding at least $18.0 million of net cash.
TVRDThe Supreme Court of New South Wales approved the scheme of arrangement. Neuphoria shares are expected to start trading on Nasdaq as NEUP on December 24, 2024.
NEUPSalarius Pharmaceuticals agreed on December 12, 2024 to let C/M Capital Master Fund, LP purchase up to $10 million of its common stock over 36 months, once a resale registration is effective. The 8-K names no placement agent or counsel, and it gives the company's Nasdaq symbol as SLRX.
DCOYThe shares went to one institutional investor, and the prospectus says no placement agent or underwriter was involved. The prospectus puts the immediate dilution to the buyer at $11.35 per share.
ETONInovio is selling 10,000,000 shares at $3.00 with warrants for 10,000,000 more shares at $3.76. The filing gives net proceeds of about $27.6 million and immediate dilution of $0.19 per share.
INOThe notice, dated December 11, 2024, lists 16 holders of record of its common stock.
NTRRRocket Pharmaceuticals priced 13,200,000 shares at $12.50 on December 10, 2024, below the $13.84 last sale price on December 9. Net proceeds are about $154.8 million before the underwriters' option, and the company's own prospectus says the money will last into the second quarter of 2026.
RCKTJupiter Neurosciences priced a firm commitment IPO of 2,750,000 shares at $4.00, or $11,000,000 gross. Its prospectus carries a going concern warning and an accumulated deficit of $23,903,481 at June 30, 2024.
JUNSKorro Bio's S-3 shelf registers up to $400,000,000 of securities. Its sales agreement with TD Securities (USA) LLC covers up to $100,000,000 of common stock, and the filing gives no cash balance.
KRRONektar sold the Huntsville plant, certain other related manufacturing assets and certain related liabilities to the buyer under an agreement dated November 1, 2024.
NKTROlema is selling 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares. Novartis will supply ribociclib for the planned Phase 3 OPERA-02 trial.
OLMAJefferies LLC is the sales agent for up to $50,000,000 of common stock. Its commission is up to 3.0% of gross proceeds, and a significant part of the business runs through a Chinese subsidiary.
GYREThe letter is non-binding and the release states no price. TuHURA targets a definitive agreement in Q4 2024 and completion of the acquisition in H1 2025.
HURAB. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents.
NAGEPMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program.
PMVPVerrica priced 44,964,045 shares at $0.89 with Series A and B warrants, for a total public offering price of $42,007,776. Entities tied to director Paul B. Manning agreed to buy 22.9 million shares, and the filing carries a going-concern warning.
VRCAJefferies will earn a commission of up to 3.0% on any shares sold. The stock last sold at $1.28 on November 15, 2024.
ATOSAclaris also pointed to a private placement financing announced the same morning and said it maintains its cash runway into 2028. The release gives no license payment terms.
ACRSThe company filed a late-filing notice on November 15, 2024. It plans to file the report no later than 5 days after the original due date.
ADTXThe company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days.
NGNEThe company found that certain warrants and preferred stock issued before 2023 had not been accounted for properly. It estimated cash of $34.3 million at September 30, 2024.
CLRBA separate exhibit carries an audited balance sheet dated February 6, 2024, the company's inception. The auditor's report on it raises going-concern doubt.
ORKARockwell Medical may sell up to $25,000,000 of stock through Cantor Fitzgerald, which takes a commission of up to 3.0%. At the assumed $4.43 price, the filing says new buyers would face an immediate dilution of $3.33 a share.
RMTIThe balance includes net proceeds of a $50 million registered direct offering priced June 14, 2024. Third-quarter net loss was $15.0 million.
MREOAbout 99% of shares present voted in support. Akari targets a close on November 13, 2024 and expects the deal to fix its Nasdaq equity deficiency.
AKTXJefferies will earn up to 3.0% of gross proceeds. The stock last sold at $16.65 before the agreement.
ASMBGeron drew $125 million under a Pharmakon term loan and took $125 million from Royalty Pharma, in a quarter with a $26.4 million net loss. The release gives no royalty rates or loan interest rate.
GERNPalvella said the first patient was dosed in its SELVA Phase 3 trial. Later, Pieris added merger disclosures after nine stockholder demands and two lawsuits alleging disclosure gaps, which the defendants deny.
PVLASCYNEXIS can sell up to $50,000,000 of stock through Cantor Fitzgerald, which earns a 3.0% commission, with the stock at $1.33 on November 5, 2024. Its approved drug is off the market under a recall, and the supplement gives no cash balance.
SCYXAnaptysBio's new shelf replaces one that expires January 11, 2025, and its $100,000,000 sales program with TD Securities (USA) LLC could sell up to 4,819,277 shares at $20.75 each, with immediate dilution of $15.59 per share for new buyers.
ANABNeurogene is selling 1,835,000 shares and pre-funded warrants for up to 2,165,042 shares to a group of healthcare investors.
NGNELyell adds IMPT-314, a CAR T-cell candidate, through the ImmPACT Bio deal. The release gives no purchase price and no cash balance, and says cash will fund operations into 2027.
LYELStockholders approved the share issuances at the annual meeting on October 29, 2024, the same day the placement closed. The company also agreed to register the new shares for resale, and its equity had been below Nasdaq's $2.5 million minimum.
ERNAImmunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement.
IMNM
aibio